<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="100" offset="0" totalResults="1237"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="777" label="Small molecule therapeutic"/><FilterOption id="585" count="607" label="Oral formulation"/><FilterOption id="648" count="510" label="Intravenous formulation"/><FilterOption id="761" count="466" label="Biological therapeutic"/><FilterOption id="740" count="432" label="Infusion"/><FilterOption id="595" count="430" label="Tablet formulation"/><FilterOption id="586" count="300" label="Capsule formulation"/><FilterOption id="746" count="290" label="Solution"/><FilterOption id="751" count="288" label="Film coating"/><FilterOption id="573" count="281" label="Immunoglobulin-G"/><FilterOption id="898" count="249" label="Formulation powder"/><FilterOption id="750" count="218" label="Freeze drying"/><FilterOption id="85" count="209" label="Protein recombinant"/><FilterOption id="647" count="205" label="Subcutaneous formulation"/><FilterOption id="169" count="190" label="Monoclonal antibody humanized"/><FilterOption id="1263" count="143" label="Immuno-oncology"/><FilterOption id="1652" count="107" label="Prodrug"/><FilterOption id="1647" count="102" label="Natural product"/><FilterOption id="168" count="91" label="Monoclonal antibody human"/><FilterOption id="594" count="84" label="Oral suspension formulation"/><FilterOption id="593" count="80" label="Oral liquid formulation"/><FilterOption id="80" count="71" label="Peptide"/><FilterOption id="175" count="68" label="Drug combination"/><FilterOption id="766" count="63" label="Parenteral formulation unspecified"/><FilterOption id="805" count="55" label="Daily dosing"/><FilterOption id="902" count="53" label="Orally disintegrating tablet"/><FilterOption id="166" count="52" label="Chimeric monoclonal antibody"/><FilterOption id="589" count="50" label="Sustained release formulation"/><FilterOption id="180" count="48" label="Antibody fragment"/><FilterOption id="651" count="47" label="Intramuscular formulation"/><FilterOption id="745" count="44" label="Suspension"/><FilterOption id="894" count="39" label="Liquid formulation"/><FilterOption id="743" count="37" label="Granule"/><FilterOption id="667" count="34" label="Peptidomimetic"/><FilterOption id="630" count="34" label="Stereochemistry"/><FilterOption id="171" count="32" label="Monoclonal antibody conjugated"/><FilterOption id="596" count="30" label="Injectable formulation"/><FilterOption id="603" count="30" label="Systemic formulation unspecified"/><FilterOption id="66" count="27" label="Antibiotic"/><FilterOption id="701" count="25" label="Nucleoside synthesis"/><FilterOption id="680" count="24" label="Buccal formulation systemic"/><FilterOption id="852" count="24" label="Intravesical formulation"/><FilterOption id="348" count="23" label="PEGylated formulation"/><FilterOption id="1646" count="22" label="Injectable controlled release formulation"/><FilterOption id="742" count="22" label="Pellet"/><FilterOption id="599" count="21" label="Nanoparticle formulation injectable"/><FilterOption id="660" count="21" label="Oral sustained release formulation"/><FilterOption id="90" count="21" label="Steroid"/><FilterOption id="127" count="20" label="Cell culture"/><FilterOption id="74" count="20" label="Glycoprotein"/><FilterOption id="112" count="19" label="DNA technology"/><FilterOption id="102" count="19" label="Nucleotide and derivatives"/><FilterOption id="84" count="19" label="Protein fusion"/><FilterOption id="128" count="18" label="Cell culture technique"/><FilterOption id="1164" count="17" label="Antibody drug conjugate"/><FilterOption id="641" count="17" label="Controlled release formulation"/><FilterOption id="598" count="17" label="Liposome formulation injectable"/><FilterOption id="723" count="16" label="Drug coating"/><FilterOption id="649" count="16" label="Intraperitoneal formulation"/><FilterOption id="207" count="15" label="Protein conjugated"/><FilterOption id="616" count="12" label="Inhalant formulation"/><FilterOption id="756" count="11" label="Pharmaceutical carrier"/><FilterOption id="611" count="10" label="Dermatological formulation"/><FilterOption id="620" count="9" label="Ophthalmic formulation"/><FilterOption id="776" count="9" label="Oral gel formulation"/><FilterOption id="208" count="9" label="Protein conjugation"/><FilterOption id="558" count="9" label="Transdermal formulation"/><FilterOption id="851" count="8" label="Intradermal formulation"/><FilterOption id="349" count="8" label="Lipid"/><FilterOption id="753" count="8" label="Microparticle formulation"/><FilterOption id="51" count="8" label="Monoclonal antibody"/><FilterOption id="103" count="8" label="Oligonucleotide"/><FilterOption id="569" count="8" label="Oligonucleotide antisense"/><FilterOption id="652" count="7" label="Intra-articular formulation"/><FilterOption id="167" count="7" label="Monoclonal antibody murine"/><FilterOption id="267" count="7" label="Multivalent antibody"/><FilterOption id="662" count="7" label="Quick release formulation"/><FilterOption id="857" count="6" label="Allogenic stem cell therapy"/><FilterOption id="537" count="6" label="Chimeric antibody"/><FilterOption id="1669" count="6" label="Emulsion formulation"/><FilterOption id="731" count="6" label="Imaging"/><FilterOption id="654" count="6" label="Intrathecal formulation"/><FilterOption id="159" count="6" label="Oligosaccharide"/><FilterOption id="724" count="6" label="Radiolabeling"/><FilterOption id="617" count="5" label="Aerosol formulation inhalant"/><FilterOption id="612" count="5" label="Emulsion dermatological"/><FilterOption id="347" count="5" label="Intratumoral formulation"/><FilterOption id="764" count="5" label="Local formulation unspecified"/><FilterOption id="236" count="5" label="Macrolide"/><FilterOption id="170" count="5" label="Multivalent monoclonal antibody"/><FilterOption id="559" count="5" label="Oral controlled release formulation"/><FilterOption id="135" count="5" label="T-lymphocyte"/><FilterOption id="878" count="4" label="Adipose stem cell therapy"/><FilterOption id="216" count="4" label="Antibody conjugated"/><FilterOption id="582" count="4" label="Antibody polyclonal"/><FilterOption id="570" count="4" label="Cell therapy"/><FilterOption id="1247" count="4" label="Chimeric antigen receptor T cell therapy"/><FilterOption id="590" count="4" label="Enteric coated formulation"/><FilterOption id="864" count="4" label="Mesenchymal stem cell therapy"/><FilterOption id="807" count="4" label="Monthly dosing"/></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="3657" count="58" label="Metastatic breast cancer"/><FilterOption id="2399" count="56" label="Adenocarcinoma"/><FilterOption id="1828" count="51" label="Multiple myeloma"/><FilterOption id="159" count="49" label="HIV-1 infection"/><FilterOption id="3665" count="40" label="Metastatic non small cell lung cancer"/><FilterOption id="49" count="38" label="Breast tumor"/><FilterOption id="158" count="37" label="HIV infection"/><FilterOption id="1069" count="36" label="Metastasis"/><FilterOption id="1731" count="30" label="Acute myelogenous leukemia"/><FilterOption id="3257" count="27" label="Stage IV melanoma"/><FilterOption id="3246" count="26" label="Hormone refractory prostate cancer"/><FilterOption id="3658" count="23" label="Metastatic colorectal cancer"/><FilterOption id="307" count="23" label="Squamous cell carcinoma"/><FilterOption id="3713" count="22" label="Advanced solid tumor"/><FilterOption id="1771" count="22" label="Transitional cell carcinoma"/><FilterOption id="4250" count="21" label="Metastatic renal cell carcinoma"/><FilterOption id="1734" count="20" label="Chronic lymphocytic leukemia"/><FilterOption id="84" count="20" label="Crohns disease"/><FilterOption id="337" count="20" label="Ulcerative colitis"/><FilterOption id="1749" count="19" label="Diffuse large B-cell lymphoma"/><FilterOption id="1272" count="18" label="Myelodysplastic syndrome"/><FilterOption id="255" count="18" label="Parkinsons disease"/><FilterOption id="2243" count="16" label="Fallopian tube cancer"/><FilterOption id="70" count="16" label="Liver cirrhosis"/><FilterOption id="224" count="16" label="Myocardial infarction"/><FilterOption id="799" count="16" label="Ovary tumor"/><FilterOption id="3083" count="16" label="Peritoneal tumor"/><FilterOption id="3510" count="16" label="Pulmonary artery hypertension"/><FilterOption id="14" count="15" label="Alzheimers disease"/><FilterOption id="55" count="15" label="Cardiac failure"/><FilterOption id="80" count="15" label="Coronary artery disease"/><FilterOption id="1542" count="14" label="Atrial fibrillation"/><FilterOption id="1745" count="14" label="Follicle center lymphoma"/><FilterOption id="153" count="14" label="Hepatitis C virus infection"/><FilterOption id="3666" count="14" label="Metastatic stomach cancer"/><FilterOption id="1728" count="13" label="Acute lymphoblastic leukemia"/><FilterOption id="3667" count="13" label="Metastatic esophageal cancer"/><FilterOption id="319" count="13" label="Non-Hodgkin lymphoma"/><FilterOption id="1185" count="12" label="Chronic obstructive pulmonary disease"/><FilterOption id="1767" count="12" label="Hepatocellular carcinoma"/><FilterOption id="836" count="12" label="Insulin dependent diabetes"/><FilterOption id="3256" count="12" label="Stage III melanoma"/><FilterOption id="3676" count="11" label="Ischemic stroke"/><FilterOption id="3866" count="11" label="Metastatic ovary cancer"/><FilterOption id="3669" count="11" label="Metastatic pancreas cancer"/><FilterOption id="17" count="10" label="Anemia"/><FilterOption id="552" count="10" label="Bleeding"/><FilterOption id="1765" count="10" label="Cholangiocarcinoma"/><FilterOption id="2454" count="10" label="Glioblastoma"/><FilterOption id="3466" count="10" label="Metastatic bladder cancer"/><FilterOption id="3664" count="10" label="Metastatic prostate cancer"/><FilterOption id="20" count="10" label="Pain"/><FilterOption id="1867" count="10" label="Pulmonary hypertension"/><FilterOption id="3673" count="9" label="Metastatic head and neck cancer"/><FilterOption id="213" count="9" label="Multiple sclerosis"/><FilterOption id="2637" count="9" label="Non-alcoholic steatohepatitis"/><FilterOption id="1262" count="9" label="Non-small-cell lung cancer"/><FilterOption id="427" count="9" label="Uterine cervix tumor"/><FilterOption id="316" count="8" label="B-cell lymphoma"/><FilterOption id="1705" count="8" label="Endometrioid carcinoma"/><FilterOption id="837" count="8" label="Non-insulin dependent diabetes"/><FilterOption id="291" count="8" label="Rheumatoid arthritis"/><FilterOption id="1261" count="8" label="Small-cell lung cancer"/><FilterOption id="23" count="7" label="Angina"/><FilterOption id="31" count="7" label="Asthma"/><FilterOption id="1735" count="7" label="Chronic myelocytic leukemia"/><FilterOption id="152" count="7" label="Hepatitis B virus infection"/><FilterOption id="161" count="7" label="Hodgkins disease"/><FilterOption id="3771" count="7" label="Idiopathic pulmonary fibrosis"/><FilterOption id="2989" count="7" label="Kidney transplant rejection"/><FilterOption id="203" count="7" label="Lymphoma"/><FilterOption id="1995" count="7" label="Primary biliary cholangitis"/><FilterOption id="299" count="7" label="Schizophrenia"/><FilterOption id="3258" count="6" label="Acute coronary syndrome"/><FilterOption id="1729" count="6" label="B-cell acute lymphoblastic leukemia"/><FilterOption id="760" count="6" label="Brain tumor"/><FilterOption id="205" count="6" label="Melanoma"/><FilterOption id="245" count="6" label="Osteoarthritis"/><FilterOption id="318" count="6" label="Systemic lupus erythematosus"/><FilterOption id="3678" count="6" label="Urethral cancer"/><FilterOption id="3492" count="5" label="AL amyloidosis"/><FilterOption id="2380" count="5" label="Bladder cancer"/><FilterOption id="3919" count="5" label="Chronic liver failure"/><FilterOption id="89" count="5" label="Cytomegalovirus infection"/><FilterOption id="616" count="5" label="Graft versus host disease"/><FilterOption id="2212" count="5" label="Hepatorenal syndrome"/><FilterOption id="2318" count="5" label="Liver fibrosis"/><FilterOption id="2273" count="5" label="Oligodendroglioma"/><FilterOption id="3239" count="5" label="Portal hypertension"/><FilterOption id="330" count="5" label="Restenosis"/><FilterOption id="3395" count="4" label="Acute liver failure"/><FilterOption id="1102" count="4" label="Atopic dermatitis"/><FilterOption id="2432" count="4" label="Bronchiectasis"/><FilterOption id="989" count="4" label="Colorectal tumor"/><FilterOption id="3198" count="4" label="Larynx tumor"/><FilterOption id="2983" count="4" label="Liver transplantation"/><FilterOption id="3235" count="4" label="Merkel cell carcinoma"/><FilterOption id="793" count="4" label="Mouth tumor"/><FilterOption id="794" count="4" label="Pharynx tumor"/><FilterOption id="2319" count="4" label="Polycythemia vera"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8712" count="55" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8719" count="53" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8998" count="50" label="Breast tumor - Assessment of adverse events"/><FilterOption id="7879" count="49" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="9247" count="48" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8713" count="45" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7908" count="44" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9218" count="43" label="HIV infection - Assessment of Immune Response"/><FilterOption id="8078" count="42" label="Leukemia - Assessment of adverse events"/><FilterOption id="7538" count="42" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="8489" count="40" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8721" count="39" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8481" count="39" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9213" count="38" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="7547" count="38" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9215" count="36" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="7354" count="34" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="8722" count="33" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8738" count="33" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="7360" count="33" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8077" count="32" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7563" count="32" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8720" count="31" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7569" count="31" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7367" count="31" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8996" count="30" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="7680" count="29" label="Lymphoma - Assessment of adverse events"/><FilterOption id="7679" count="28" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="42921" count="28" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="7909" count="27" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8505" count="27" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="9153" count="27" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7611" count="27" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="6919" count="27" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="8109" count="25" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="7898" count="25" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7489" count="25" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="8744" count="24" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="9246" count="24" label="HIV infection - Assessment of Safety and Tolerability"/><FilterOption id="8640" count="24" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7027" count="24" label="Melanoma - Assessment of adverse events"/><FilterOption id="8140" count="23" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="8639" count="23" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="8714" count="22" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8725" count="22" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="8999" count="22" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="9238" count="22" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="9300" count="22" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="6924" count="22" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6940" count="22" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="7373" count="22" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7372" count="22" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7488" count="22" label="Multiple myeloma - Assessment of Safety and Tolerability"/><FilterOption id="7049" count="22" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8754" count="21" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="9212" count="21" label="HIV infection - Assessment of Viral Load"/><FilterOption id="9242" count="21" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="7891" count="21" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7907" count="21" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7906" count="21" label="Leukemia - Assessment of Response Rates (RR)"/><FilterOption id="10828" count="21" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="10830" count="21" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7045" count="21" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="11717" count="20" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="9122" count="20" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7558" count="20" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7393" count="20" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="10540" count="20" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"/><FilterOption id="10545" count="20" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8430" count="19" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="2622" count="19" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="7916" count="19" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="7564" count="19" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8759" count="18" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8147" count="18" label="Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease"/><FilterOption id="8663" count="18" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7395" count="18" label="Multiple myeloma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="43670" count="18" label="Other gastrointestinal disease - Assessment of adverse events"/><FilterOption id="7190" count="18" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="11728" count="17" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="37159" count="17" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="2492" count="17" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="9415" count="17" label="Lymphoma - Assessment of Disease Progression"/><FilterOption id="43526" count="17" label="Other gastrointestinal disease - Clinical Assessments"/><FilterOption id="11773" count="16" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8163" count="16" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9255" count="16" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="25660" count="16" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="15212" count="16" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="15287" count="16" label="Solid tumor - Assessment of adverse events"/><FilterOption id="15907" count="16" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="11722" count="15" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="2703" count="15" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="9272" count="15" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="7921" count="15" label="Leukemia - Assessment of Disease Relapse/Recurrence"/><FilterOption id="11735" count="14" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="9310" count="14" label="Breast tumor - Imaging/Radiological Assessments"/><FilterOption id="8522" count="14" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="11780" count="13" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8151" count="13" label="Colorectal tumor - Assessment of Overall Survival (OS)"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="10"><FilterOption id="L" count="771" label="Launched"/><FilterOption id="C3" count="113" label="Phase 3 Clinical"/><FilterOption id="C2" count="102" label="Phase 2 Clinical"/><FilterOption id="DX" count="61" label="Discontinued"/><FilterOption id="R" count="19" label="Registered"/><FilterOption id="C1" count="17" label="Phase 1 Clinical"/><FilterOption id="NDR" count="15" label="No Development Reported"/><FilterOption id="PR" count="12" label="Pre-registration"/><FilterOption id="DR" count="5" label="Discovery"/><FilterOption id="W" count="4" label="Withdrawn"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="19446" count="99" label="Roche Holding AG"/><FilterOption id="1039423" count="97" label="Hospital Clinic of Barcelona"/><FilterOption id="26178" count="79" label="F Hoffmann-La Roche AG"/><FilterOption id="18767" count="61" label="Pfizer Inc"/><FilterOption id="1038736" count="46" label="PETHEMA Foundation"/><FilterOption id="16450" count="36" label="Gilead Sciences Inc"/><FilterOption id="15331" count="35" label="Celgene Corp"/><FilterOption id="14881" count="30" label="Boehringer Ingelheim International GmbH"/><FilterOption id="15414" count="24" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="19453" count="20" label="Genentech Inc"/><FilterOption id="1067538" count="20" label="Janssen Research &amp; Development LLC"/><FilterOption id="1059823" count="18" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="1042061" count="17" label="Spanish Breast Cancer Research Group"/><FilterOption id="1091809" count="16" label="Janssen-Cilag International NV (BE)"/><FilterOption id="27847" count="14" label="Boston Scientific Corp"/><FilterOption id="1053612" count="14" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="23780" count="13" label="Actelion Ltd"/><FilterOption id="14455" count="13" label="Bayer AG"/><FilterOption id="22546" count="13" label="Boehringer Ingelheim GmbH"/><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="1042371" count="12" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="1103352" count="9" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="15065" count="9" label="Bristol-Myers Squibb Co"/><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1017513" count="9" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="21991" count="9" label="Takeda Oncology"/><FilterOption id="28611" count="8" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="22554" count="8" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="8" label="Boehringer Ingelheim Corp"/><FilterOption id="22563" count="8" label="Boehringer Ingelheim Ltd"/><FilterOption id="1020322" count="8" label="Daiichi Sankyo Inc"/><FilterOption id="1052299" count="8" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="1039086" count="8" label="Germans Trias i Pujol Hospital"/><FilterOption id="1122528" count="8" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="22598" count="8" label="Unilfarma Lda"/><FilterOption id="22549" count="7" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="17810" count="7" label="Eli Lilly &amp; Co"/><FilterOption id="1051470" count="7" label="Fundacio Clinic Per A La Recerca Biomedica"/><FilterOption id="1042252" count="7" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="17259" count="7" label="Ipsen"/><FilterOption id="1090417" count="7" label="Roche Singapore Pte Ltd"/><FilterOption id="22556" count="6" label="Boehringer Ingelheim France SARL"/><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"/><FilterOption id="19063" count="6" label="Pharmacyclics Inc"/><FilterOption id="1065375" count="6" label="Puma Biotechnology Inc"/><FilterOption id="1045513" count="6" label="Spanish Lung Cancer Group"/><FilterOption id="1063251" count="5" label="BeiGene Co Ltd"/><FilterOption id="22545" count="5" label="Boehringer Ingelheim AB"/><FilterOption id="22555" count="5" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="22560" count="5" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="1046331" count="5" label="Fundacion SEIMC-GESIDA"/><FilterOption id="1003065" count="5" label="Hospital Vall D'Hebron"/><FilterOption id="1091820" count="5" label="Roche China Co Ltd"/><FilterOption id="25439" count="5" label="United Therapeutics Corp"/><FilterOption id="13601" count="4" label="Abbott Laboratories"/><FilterOption id="1148005" count="4" label="BeiGene USA, Inc"/><FilterOption id="1005244" count="4" label="Biogen Inc"/><FilterOption id="31522" count="4" label="BIOTRONIK SE &amp; Co"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/><FilterOption id="1056497" count="4" label="CETLAM Group"/><FilterOption id="1035512" count="4" label="EMD Serono Inc"/><FilterOption id="1056260" count="4" label="Grupo Espanol de Investigacion en Cancer de Ovario"/><FilterOption id="1069025" count="4" label="Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"/><FilterOption id="1040940" count="4" label="Hospital Universitari de Bellvitge"/><FilterOption id="1017771" count="4" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="17437" count="4" label="Johnson &amp; Johnson Sdn Bhd"/><FilterOption id="1084801" count="4" label="Medica Scientia Innovation Research"/><FilterOption id="26327" count="4" label="Roche Diagnostics GmbH"/><FilterOption id="1082374" count="4" label="ROCHE Espana"/><FilterOption id="24652" count="4" label="Shire plc"/><FilterOption id="1073757" count="4" label="Spanish Society of Cardiology"/><FilterOption id="1076372" count="4" label="Stryker Neurovascular"/><FilterOption id="29151" count="4" label="Universitair Medisch Centrum Utrecht"/><FilterOption id="14109" count="3" label="Amgen Inc"/><FilterOption id="24968" count="3" label="Arena Pharmaceuticals Inc"/><FilterOption id="14296" count="3" label="ARIAD Pharmaceuticals Inc"/><FilterOption id="25902" count="3" label="Array BioPharma Inc"/><FilterOption id="1013295" count="3" label="Astellas Pharma Inc"/><FilterOption id="30062" count="3" label="AstraZeneca AB"/><FilterOption id="14190" count="3" label="AstraZeneca plc"/><FilterOption id="15133" count="3" label="Bristol-Myers Squibb International Corp"/><FilterOption id="1067616" count="3" label="Clinica Universidad de Navarra"/><FilterOption id="19620" count="3" label="Eisai Inc"/><FilterOption id="14913" count="3" label="Eisai Ltd"/><FilterOption id="1046616" count="3" label="European Organization for Research and Treatment of Cancer"/><FilterOption id="16581" count="3" label="Grifols SA"/><FilterOption id="1089015" count="3" label="Grupo Espanol Multidisciplinar de Melanoma"/><FilterOption id="1056537" count="3" label="Grupo Espanol de Linfoma y Trasplante de Medula Osea"/><FilterOption id="17002" count="3" label="Human Genome Sciences Inc"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="18101" count="3" label="Merck KGaA"/><FilterOption id="27954" count="3" label="Merrimack Pharmaceuticals Inc"/><FilterOption id="15938" count="3" label="Millennium Pharmaceuticals Ltd"/><FilterOption id="29741" count="3" label="Morphotek Inc"/><FilterOption id="1064629" count="3" label="Prothena Corp plc"/><FilterOption id="1109598" count="3" label="Roche Products India Pvt Ltd"/><FilterOption id="25554" count="3" label="Seattle Genetics Inc"/><FilterOption id="20300" count="3" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="1020514" count="2" label="Abraxis BioScience Inc"/><FilterOption id="13979" count="2" label="Alexion Pharmaceuticals Inc"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="7"><FilterOption id="4" count="549" label="Completed"/><FilterOption id="2" count="327" label="Recruiting"/><FilterOption id="3" count="216" label="No longer recruiting"/><FilterOption id="6" count="117" label="Terminated"/><FilterOption id="1" count="22" label="Not yet recruiting"/><FilterOption id="5" count="5" label="Suspended"/><FilterOption id="12" count="1" label="Status not specified"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="697" label="Yes"/><FilterOption id="NO" count="540" label="No"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="2399" count="18" label="Adenocarcinoma"/><FilterOption id="3657" count="12" label="Metastatic breast cancer"/><FilterOption id="3665" count="11" label="Metastatic non small cell lung cancer"/><FilterOption id="1069" count="10" label="Metastasis"/><FilterOption id="3713" count="9" label="Advanced solid tumor"/><FilterOption id="3658" count="8" label="Metastatic colorectal cancer"/><FilterOption id="3669" count="8" label="Metastatic pancreas cancer"/><FilterOption id="307" count="8" label="Squamous cell carcinoma"/><FilterOption id="159" count="6" label="HIV-1 infection"/><FilterOption id="3673" count="6" label="Metastatic head and neck cancer"/><FilterOption id="1771" count="6" label="Transitional cell carcinoma"/><FilterOption id="3246" count="5" label="Hormone refractory prostate cancer"/><FilterOption id="3667" count="5" label="Metastatic esophageal cancer"/><FilterOption id="3666" count="5" label="Metastatic stomach cancer"/><FilterOption id="3510" count="5" label="Pulmonary artery hypertension"/><FilterOption id="1731" count="4" label="Acute myelogenous leukemia"/><FilterOption id="1765" count="4" label="Cholangiocarcinoma"/><FilterOption id="84" count="4" label="Crohns disease"/><FilterOption id="2454" count="4" label="Glioblastoma"/><FilterOption id="1767" count="4" label="Hepatocellular carcinoma"/><FilterOption id="158" count="4" label="HIV infection"/><FilterOption id="3676" count="4" label="Ischemic stroke"/><FilterOption id="3466" count="4" label="Metastatic bladder cancer"/><FilterOption id="3866" count="4" label="Metastatic ovary cancer"/><FilterOption id="4250" count="4" label="Metastatic renal cell carcinoma"/><FilterOption id="1272" count="4" label="Myelodysplastic syndrome"/><FilterOption id="799" count="4" label="Ovary tumor"/><FilterOption id="1867" count="4" label="Pulmonary hypertension"/><FilterOption id="1261" count="4" label="Small-cell lung cancer"/><FilterOption id="3257" count="4" label="Stage IV melanoma"/><FilterOption id="427" count="4" label="Uterine cervix tumor"/><FilterOption id="3395" count="3" label="Acute liver failure"/><FilterOption id="14" count="3" label="Alzheimers disease"/><FilterOption id="2193" count="3" label="Anal tumor"/><FilterOption id="2380" count="3" label="Bladder cancer"/><FilterOption id="49" count="3" label="Breast tumor"/><FilterOption id="3919" count="3" label="Chronic liver failure"/><FilterOption id="989" count="3" label="Colorectal tumor"/><FilterOption id="3689" count="3" label="Compensated liver cirrhosis"/><FilterOption id="1705" count="3" label="Endometrioid carcinoma"/><FilterOption id="2243" count="3" label="Fallopian tube cancer"/><FilterOption id="2212" count="3" label="Hepatorenal syndrome"/><FilterOption id="70" count="3" label="Liver cirrhosis"/><FilterOption id="3235" count="3" label="Merkel cell carcinoma"/><FilterOption id="1240" count="3" label="Mesothelioma"/><FilterOption id="3664" count="3" label="Metastatic prostate cancer"/><FilterOption id="3467" count="3" label="Metastatic renal cancer"/><FilterOption id="793" count="3" label="Mouth tumor"/><FilterOption id="1828" count="3" label="Multiple myeloma"/><FilterOption id="319" count="3" label="Non-Hodgkin lymphoma"/><FilterOption id="3083" count="3" label="Peritoneal tumor"/><FilterOption id="794" count="3" label="Pharynx tumor"/><FilterOption id="3239" count="3" label="Portal hypertension"/><FilterOption id="1995" count="3" label="Primary biliary cholangitis"/><FilterOption id="3256" count="3" label="Stage III melanoma"/><FilterOption id="2567" count="2" label="Anaplastic astrocytoma"/><FilterOption id="1729" count="2" label="B-cell acute lymphoblastic leukemia"/><FilterOption id="316" count="2" label="B-cell lymphoma"/><FilterOption id="1815" count="2" label="Bacterial pneumonia"/><FilterOption id="1516" count="2" label="Biliary cancer"/><FilterOption id="2432" count="2" label="Bronchiectasis"/><FilterOption id="651" count="2" label="Cancer"/><FilterOption id="2217" count="2" label="Cholestasis"/><FilterOption id="1735" count="2" label="Chronic myelocytic leukemia"/><FilterOption id="97" count="2" label="Diabetes mellitus"/><FilterOption id="100" count="2" label="Diabetic nephropathy"/><FilterOption id="1011" count="2" label="Esophagus tumor"/><FilterOption id="1127" count="2" label="Fibrosis"/><FilterOption id="1745" count="2" label="Follicle center lymphoma"/><FilterOption id="616" count="2" label="Graft versus host disease"/><FilterOption id="152" count="2" label="Hepatitis B virus infection"/><FilterOption id="161" count="2" label="Hodgkins disease"/><FilterOption id="170" count="2" label="Huntingtons chorea"/><FilterOption id="3771" count="2" label="Idiopathic pulmonary fibrosis"/><FilterOption id="3198" count="2" label="Larynx tumor"/><FilterOption id="2318" count="2" label="Liver fibrosis"/><FilterOption id="3240" count="2" label="Medullary thyroid cancer"/><FilterOption id="3668" count="2" label="Metastatic lung cancer"/><FilterOption id="3465" count="2" label="Metastatic urinary tract cancer"/><FilterOption id="213" count="2" label="Multiple sclerosis"/><FilterOption id="273" count="2" label="Myeloproliferative disorder"/><FilterOption id="224" count="2" label="Myocardial infarction"/><FilterOption id="230" count="2" label="Neoplasm"/><FilterOption id="1262" count="2" label="Non-small-cell lung cancer"/><FilterOption id="2273" count="2" label="Oligodendroglioma"/><FilterOption id="3351" count="2" label="Papillary thyroid tumor"/><FilterOption id="396" count="2" label="Papillomavirus infection"/><FilterOption id="279" count="2" label="Pruritus"/><FilterOption id="286" count="2" label="Renal disease"/><FilterOption id="194" count="2" label="Sarcoma"/><FilterOption id="337" count="2" label="Ulcerative colitis"/><FilterOption id="3678" count="2" label="Urethral cancer"/><FilterOption id="738" count="2" label="Urinary tract tumor"/><FilterOption id="4" count="1" label="Acquired immune deficiency syndrome"/><FilterOption id="1728" count="1" label="Acute lymphoblastic leukemia"/><FilterOption id="2562" count="1" label="Adult respiratory distress syndrome"/><FilterOption id="3492" count="1" label="AL amyloidosis"/><FilterOption id="3769" count="1" label="Anaplastic thyroid cancer"/><FilterOption id="17" count="1" label="Anemia"/><FilterOption id="2453" count="1" label="Astrocytoma"/></Filter><Filter label="Registry Id" name="trialRegistries" total="24"><FilterOption id="1000" count="1228" label="CT.gov"/><FilterOption id="1001" count="850" label="EudraCT"/><FilterOption id="1030" count="155" label="RSRM CTR"/><FilterOption id="1006" count="112" label="JapicCTI"/><FilterOption id="1023" count="76" label="UKCRN"/><FilterOption id="1019" count="72" label="DRKS"/><FilterOption id="1035" count="47" label="Singapore HSA CTR"/><FilterOption id="1012" count="34" label="CTRI"/><FilterOption id="1039" count="32" label="CDE"/><FilterOption id="1004" count="27" label="WHO ICTRP"/><FilterOption id="1021" count="24" label="NMRR"/><FilterOption id="1033" count="21" label="Mexico CTR"/><FilterOption id="1009" count="20" label="HKClinicalTrials.com"/><FilterOption id="1002" count="17" label="ISRCTN"/><FilterOption id="1011" count="9" label="ANZCTR"/><FilterOption id="1010" count="6" label="CRiS"/><FilterOption id="1038" count="6" label="PHRR"/><FilterOption id="1015" count="3" label="NTR"/><FilterOption id="1003" count="3" label="UMIN"/><FilterOption id="1008" count="2" label="Hong Kong CCTCTR"/><FilterOption id="1040" count="2" label="REec"/><FilterOption id="1016" count="1" label="PACTR"/><FilterOption id="1020" count="1" label="ReBec"/><FilterOption id="1013" count="1" label="RPCEC"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="7"><FilterOption id="5" count="29" label="Patient Enrollment Issues"/><FilterOption id="1" count="28" label="Lack of Efficacy"/><FilterOption id="2" count="26" label="Not Reported"/><FilterOption id="4" count="17" label="Other"/><FilterOption id="8" count="15" label="Sponsor/Business Decision"/><FilterOption id="7" count="6" label="Safety Issues"/><FilterOption id="3" count="3" label="Operational Issues"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="44383" count="28" label="carboplatin"/><FilterOption id="3803" count="27" label="paclitaxel"/><FilterOption id="3199" count="25" label="gemcitabine"/><FilterOption id="2953" count="23" label="docetaxel"/><FilterOption id="12205" count="16" label="capecitabine"/><FilterOption id="6386" count="15" label="trastuzumab"/><FilterOption id="6736" count="12" label="rituximab"/><FilterOption id="7310" count="10" label="ritonavir"/><FilterOption id="49219" count="10" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="37370" count="8" label="azacitidine"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="14681" count="8" label="lopinavir + ritonavir"/><FilterOption id="15954" count="7" label="bortezomib"/><FilterOption id="3072" count="7" label="etoposide phosphate"/><FilterOption id="3536" count="7" label="pemetrexed disodium"/><FilterOption id="32981" count="6" label="darunavir"/><FilterOption id="7934" count="6" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="13022" count="6" label="epirubicin"/><FilterOption id="3313" count="6" label="fulvestrant"/><FilterOption id="3792" count="6" label="oxaliplatin"/><FilterOption id="10309" count="5" label="abiraterone"/><FilterOption id="27572" count="5" label="lenalidomide"/><FilterOption id="2784" count="5" label="letrozole"/><FilterOption id="28532" count="5" label="pertuzumab"/><FilterOption id="12973" count="5" label="sunitinib"/><FilterOption id="14493" count="5" label="tenofovir disoproxil fumarate"/><FilterOption id="6408" count="5" label="vinorelbine"/><FilterOption id="15254" count="4" label="atazanavir"/><FilterOption id="47000" count="4" label="bendamustine"/><FilterOption id="13239" count="4" label="decitabine"/><FilterOption id="10172" count="4" label="efavirenz"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="48181" count="4" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="33591" count="4" label="lapatinib"/><FilterOption id="29016" count="4" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="72699" count="3" label="atezolizumab"/><FilterOption id="2836" count="3" label="clopidogrel"/><FilterOption id="72148" count="3" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="13340" count="3" label="everolimus"/><FilterOption id="3081" count="3" label="exemestane"/><FilterOption id="6156" count="3" label="fludarabine"/><FilterOption id="2871" count="3" label="irinotecan"/><FilterOption id="11519" count="3" label="mitoxantrone"/><FilterOption id="53227" count="3" label="obinutuzumab"/><FilterOption id="23625" count="3" label="peginterferon alfa-2a"/><FilterOption id="70667" count="3" label="pembrolizumab"/><FilterOption id="54488" count="3" label="raltegravir"/><FilterOption id="5369" count="3" label="ribavirin"/><FilterOption id="44313" count="3" label="simvastatin"/><FilterOption id="4529" count="3" label="temozolomide"/><FilterOption id="8050" count="3" label="thalidomide, Celgene"/><FilterOption id="4577" count="3" label="topotecan"/><FilterOption id="12150" count="3" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="15130" count="3" label="vinflunine"/><FilterOption id="44375" count="3" label="warfarin"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="3321" count="2" label="anastrozole"/><FilterOption id="54601" count="2" label="carfilzomib"/><FilterOption id="62275" count="2" label="cobicistat"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="53200" count="2" label="daratumumab"/><FilterOption id="59062" count="2" label="dolutegravir"/><FilterOption id="51371" count="2" label="elvitegravir"/><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="13928" count="2" label="enoxaparin sodium"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="28773" count="2" label="eribulin mesylate"/><FilterOption id="30682" count="2" label="etravirine"/><FilterOption id="44292" count="2" label="fluconazole"/><FilterOption id="24471" count="2" label="fosamprenavir"/><FilterOption id="55237" count="2" label="ibrutinib"/><FilterOption id="6850" count="2" label="infliximab"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="5267" count="2" label="leuprorelin acetate"/><FilterOption id="3669" count="2" label="mycophenolate mofetil"/><FilterOption id="3700" count="2" label="nevirapine"/><FilterOption id="61287" count="2" label="niraparib"/><FilterOption id="54804" count="2" label="nivolumab"/><FilterOption id="4196" count="2" label="ramipril"/><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"/><FilterOption id="4259" count="2" label="saquinavir"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="44314" count="2" label="tamoxifen"/><FilterOption id="44401" count="2" label="vancomycin"/><FilterOption id="6242" count="1" label="abacavir"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"/><FilterOption id="7867" count="1" label="amprenavir"/><FilterOption id="52967" count="1" label="apixaban"/><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"/><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"/><FilterOption id="16905" count="1" label="atomoxetine"/><FilterOption id="11141" count="1" label="basiliximab"/><FilterOption id="100071" count="1" label="BMS-986177"/><FilterOption id="50935" count="1" label="cabozantinib S-malate"/><FilterOption id="16915" count="1" label="calcium levofolinate"/><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"/></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="6859" count="71" label="HIV infection - Pregnant or Breast Feeding Subjects"/><FilterOption id="6554" count="62" label="Leukemia - Subjects with Co-morbid Conditions"/><FilterOption id="6258" count="57" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="6294" count="55" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4702" count="45" label="Lymphoma - Subjects with Co-morbid Conditions"/><FilterOption id="6845" count="44" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6247" count="42" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"/><FilterOption id="6272" count="42" label="Breast tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6331" count="42" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6820" count="40" label="HIV infection - Subjects with Opportunistic/Other Infections"/><FilterOption id="6892" count="40" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="6377" count="38" label="Breast tumor - Subjects with history of/planned radiotherapy"/><FilterOption id="6534" count="38" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6393" count="36" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="5132" count="36" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5193" count="36" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6065" count="36" label="Multiple myeloma - Subjects with Co-morbid Conditions"/><FilterOption id="6259" count="34" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="5365" count="34" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="20282" count="33" label="Lung tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="4692" count="33" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6302" count="31" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"/><FilterOption id="6843" count="31" label="HIV infection - Subjects with Co-morbid Conditions"/><FilterOption id="17557" count="29" label="Breast tumor - Subjects with Abnormal Laboratory Findings"/><FilterOption id="6941" count="29" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="6660" count="29" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="4769" count="29" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6474" count="28" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="6082" count="28" label="Multiple myeloma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="20290" count="27" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="5125" count="27" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"/><FilterOption id="5345" count="27" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="6260" count="26" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="6361" count="25" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"/><FilterOption id="20292" count="25" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="5139" count="25" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="5270" count="25" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="5282" count="25" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"/><FilterOption id="10704" count="25" label="Solid tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6246" count="24" label="Breast tumor - Subjects by disease severity - Metastatic/TNM Stage IV Breast Cancer"/><FilterOption id="6328" count="24" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"/><FilterOption id="6850" count="24" label="HIV infection - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6530" count="24" label="Leukemia - Leukemia Subjects with Advanced Disease - Subjects with central nervous system involvement of leukemia"/><FilterOption id="5291" count="24" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="6767" count="24" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"/><FilterOption id="4730" count="24" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable liver function"/><FilterOption id="24372" count="24" label="Other gastrointestinal disease - Subjects with Protocol Specified Reproductive Status - Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception"/><FilterOption id="9003" count="23" label="Bladder cancer - Subjects with Co-morbid Conditions"/><FilterOption id="6253" count="23" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"/><FilterOption id="6504" count="23" label="Leukemia - Subjects with Acute Myeloid Leukemia - Subjects with promyelocytic leukemia (M3)"/><FilterOption id="6618" count="23" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="4909" count="23" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6951" count="22" label="HIV infection - Subjects with AIDS/AIDS Defining Events"/><FilterOption id="5128" count="22" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="4718" count="22" label="Lymphoma - Subjects co-morbid with infections - Subjects co-morbid with HIV infection"/><FilterOption id="20289" count="21" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"/><FilterOption id="4739" count="21" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"/><FilterOption id="5414" count="21" label="Melanoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6257" count="20" label="Breast tumor - Subjects co-morbid with endocrine/metabolic diseases/disorders"/><FilterOption id="6418" count="20" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects with noncompliance to study protocol"/><FilterOption id="6963" count="20" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication - Subjects with history/scheduled to receive immunomodulators for other indication"/><FilterOption id="6659" count="20" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of stem cell therapy"/><FilterOption id="5349" count="20" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"/><FilterOption id="5430" count="20" label="Melanoma - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5405" count="20" label="Melanoma - Subjects with Evidence of Metastasis - Subjects with central nervous system metastasis"/><FilterOption id="9810" count="20" label="Ovary tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6261" count="19" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6252" count="19" label="Breast tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5841" count="19" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5149" count="19" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="4831" count="19" label="Lymphoma - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="4810" count="19" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="4762" count="19" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subject with history of radiotherapy"/><FilterOption id="25164" count="19" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"/><FilterOption id="25158" count="19" label="Other gastrointestinal disease - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4847" count="19" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"/><FilterOption id="6834" count="18" label="HIV infection - Subjects co-morbid with Psychiatric Disease/Disorder"/><FilterOption id="5163" count="18" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="4731" count="18" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable renal function"/><FilterOption id="5547" count="18" label="Melanoma - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="6091" count="18" label="Multiple myeloma - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6124" count="18" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="24468" count="18" label="Other gastrointestinal disease - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="9809" count="18" label="Ovary tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6217" count="17" label="Breast tumor - Subjects with Other forms of Breast Cancer - Subjects with bilateral breast cancer"/><FilterOption id="5856" count="16" label="Colorectal tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="5921" count="16" label="Colorectal tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="6645" count="16" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="5285" count="16" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="5470" count="16" label="Melanoma - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6133" count="16" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="25163" count="16" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal hematological tests"/><FilterOption id="11871" count="15" label="Anemia - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="9016" count="15" label="Bladder cancer - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"/><FilterOption id="5826" count="15" label="Colorectal tumor - Subjects with Metastatic Colorectal Cancer - Subjects with brain metastases or leptomeningeal carcinomatosis"/><FilterOption id="6862" count="15" label="HIV infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"/><FilterOption id="25162" count="15" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"/><FilterOption id="24465" count="15" label="Other gastrointestinal disease - Subjects with history of psychiatric disease/disorder - Subjects with history of/current alcohol/drug/substance abuse"/><FilterOption id="4967" count="15" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="9002" count="14" label="Bladder cancer - Subjects with History of/Active Malignancy/Cancer"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="14" label="201509"/><FilterOption count="13" label="201905"/><FilterOption count="12" label="201904"/><FilterOption count="11" label="201705"/><FilterOption count="11" label="201712"/><FilterOption count="9" label="201803"/><FilterOption count="9" label="201812"/><FilterOption count="9" label="201902"/><FilterOption count="8" label="201402"/><FilterOption count="8" label="201512"/><FilterOption count="8" label="201605"/><FilterOption count="8" label="201809"/><FilterOption count="7" label="201110"/><FilterOption count="7" label="201210"/><FilterOption count="7" label="201310"/><FilterOption count="7" label="201504"/><FilterOption count="7" label="201506"/><FilterOption count="7" label="201601"/><FilterOption count="7" label="201603"/><FilterOption count="7" label="201612"/><FilterOption count="7" label="201702"/><FilterOption count="7" label="201706"/><FilterOption count="7" label="201708"/><FilterOption count="7" label="201709"/><FilterOption count="7" label="201710"/><FilterOption count="7" label="201807"/><FilterOption count="7" label="201810"/><FilterOption count="6" label="201202"/><FilterOption count="6" label="201411"/><FilterOption count="6" label="201505"/><FilterOption count="6" label="201510"/><FilterOption count="6" label="201511"/><FilterOption count="6" label="201801"/><FilterOption count="6" label="201802"/><FilterOption count="6" label="201804"/><FilterOption count="6" label="201805"/><FilterOption count="6" label="201811"/><FilterOption count="6" label="201906"/><FilterOption count="5" label="200905"/><FilterOption count="5" label="201003"/><FilterOption count="5" label="201108"/><FilterOption count="5" label="201307"/><FilterOption count="5" label="201312"/><FilterOption count="5" label="201401"/><FilterOption count="5" label="201404"/><FilterOption count="5" label="201409"/><FilterOption count="5" label="201502"/><FilterOption count="5" label="201507"/><FilterOption count="5" label="201608"/><FilterOption count="5" label="201609"/><FilterOption count="5" label="201703"/><FilterOption count="5" label="201711"/><FilterOption count="5" label="201808"/><FilterOption count="5" label="201901"/><FilterOption count="5" label="201903"/><FilterOption count="4" label="200810"/><FilterOption count="4" label="200906"/><FilterOption count="4" label="200910"/><FilterOption count="4" label="201106"/><FilterOption count="4" label="201107"/><FilterOption count="4" label="201203"/><FilterOption count="4" label="201301"/><FilterOption count="4" label="201302"/><FilterOption count="4" label="201305"/><FilterOption count="4" label="201306"/><FilterOption count="4" label="201405"/><FilterOption count="4" label="201408"/><FilterOption count="4" label="201410"/><FilterOption count="4" label="201412"/><FilterOption count="4" label="201503"/><FilterOption count="4" label="201602"/><FilterOption count="4" label="201610"/><FilterOption count="4" label="201701"/><FilterOption count="4" label="201704"/><FilterOption count="4" label="201707"/><FilterOption count="3" label="200703"/><FilterOption count="3" label="200901"/><FilterOption count="3" label="200902"/><FilterOption count="3" label="200903"/><FilterOption count="3" label="200908"/><FilterOption count="3" label="201001"/><FilterOption count="3" label="201009"/><FilterOption count="3" label="201103"/><FilterOption count="3" label="201104"/><FilterOption count="3" label="201105"/><FilterOption count="3" label="201112"/><FilterOption count="3" label="201204"/><FilterOption count="3" label="201206"/><FilterOption count="3" label="201209"/><FilterOption count="3" label="201309"/><FilterOption count="3" label="201311"/><FilterOption count="3" label="201508"/><FilterOption count="3" label="201607"/><FilterOption count="3" label="201806"/><FilterOption count="2" label="200601"/><FilterOption count="2" label="200612"/><FilterOption count="2" label="200706"/><FilterOption count="2" label="200712"/><FilterOption count="2" label="200801"/><FilterOption count="2" label="200803"/></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="919" label="Company"/><FilterOption id="ACA" count="470" label="Academic"/><FilterOption id="GOV" count="16" label="Government"/><FilterOption id="OTH" count="12" label="Others"/><FilterOption id="NGO" count="5" label="Non-Government"/></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="1237" label="Northern, Southern &amp; Western Europe"/><FilterOption id="USCA" count="610" label="US &amp; Canada"/><FilterOption id="EEUR" count="528" label="Eastern Europe"/><FilterOption id="AUNZ" count="352" label="Australia &amp; New Zealand"/><FilterOption id="EAPO" count="318" label="East Asia &amp; Pacific Ocean"/><FilterOption id="MENA" count="300" label="Middle East &amp; North Africa"/><FilterOption id="SOAM" count="239" label="South America"/><FilterOption id="CAAC" count="170" label="Central America &amp; Caribbean"/><FilterOption id="CSAF" count="96" label="Central &amp; Southern Africa"/><FilterOption id="SOCA" count="58" label="Southern &amp; Central Asia"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="7126" count="72" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"/><FilterOption id="3954" count="52" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"/><FilterOption id="3952" count="40" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"/><FilterOption id="3937" count="38" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3634" count="38" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"/><FilterOption id="3936" count="35" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="3977" count="34" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3617" count="34" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3931" count="31" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="3965" count="29" label="Breast tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="10295" count="28" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"/><FilterOption id="3975" count="26" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="3530" count="26" label="Lymphoma - Subjects with Treatment Resistant Disease"/><FilterOption id="3926" count="26" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"/><FilterOption id="3564" count="26" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"/><FilterOption id="3472" count="25" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="3525" count="24" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"/><FilterOption id="3680" count="24" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="3923" count="24" label="Multiple myeloma - Subjects with Treatment Resistant Disease"/><FilterOption id="3956" count="22" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"/><FilterOption id="3667" count="22" label="Melanoma - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3824" count="21" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"/><FilterOption id="3502" count="21" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"/><FilterOption id="7961" count="21" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"/><FilterOption id="7810" count="20" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"/><FilterOption id="3950" count="20" label="Breast tumor - Subjects with Early Stage Breast Cancer"/><FilterOption id="12845" count="20" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"/><FilterOption id="3999" count="20" label="Leukemia - Subjects with Treatment Resistant Disease"/><FilterOption id="3932" count="19" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="3944" count="19" label="Breast tumor - Subjects with Stage II Breast Cancer"/><FilterOption id="7108" count="19" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"/><FilterOption id="3980" count="19" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"/><FilterOption id="4003" count="19" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"/><FilterOption id="3500" count="19" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"/><FilterOption id="3870" count="19" label="Multiple myeloma - Subjects with Symptomatic Disease"/><FilterOption id="7415" count="19" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"/><FilterOption id="7809" count="18" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"/><FilterOption id="3966" count="18" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"/><FilterOption id="3473" count="18" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="3489" count="18" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="3583" count="18" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="3938" count="17" label="Breast tumor - Subjects with Triple Negative Breast Cancer"/><FilterOption id="7107" count="17" label="HIV infection - Treatment Naive Subjects"/><FilterOption id="12053" count="17" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="3698" count="17" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"/><FilterOption id="3979" count="16" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="3647" count="16" label="Lung tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="12018" count="16" label="Prostate tumor - Subjects with adenocarcinoma of prostate"/><FilterOption id="7967" count="16" label="Solid tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="7806" count="15" label="Bladder cancer - Subjects with Locally Advanced Bladder Cancer"/><FilterOption id="3945" count="15" label="Breast tumor - Subjects with Stage III Breast Cancer"/><FilterOption id="461" count="15" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"/><FilterOption id="7879" count="15" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"/><FilterOption id="3814" count="14" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="3813" count="14" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="7109" count="14" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors"/><FilterOption id="3623" count="14" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"/><FilterOption id="3565" count="14" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="7414" count="14" label="Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma"/><FilterOption id="8010" count="14" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"/><FilterOption id="3955" count="13" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"/><FilterOption id="3946" count="13" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer"/><FilterOption id="368" count="13" label="Coronary artery disease - Subjects with Myocardial Ischemia"/><FilterOption id="3501" count="13" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"/><FilterOption id="15979" count="13" label="Other gastrointestinal disease - Subjects with specific disease - Subjects with Liver Cirrhosis"/><FilterOption id="11242" count="13" label="Pulmonary artery hypertension - Subjects with Idiopathic PAH (IPAH)"/><FilterOption id="11954" count="12" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"/><FilterOption id="3426" count="12" label="Crohns disease - Subjects with Treatment Resistant Disease"/><FilterOption id="7112" count="12" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART"/><FilterOption id="3681" count="12" label="Melanoma - Subjects with Evidence of Metastasis"/><FilterOption id="12005" count="11" label="Breast tumor - Subjects with invasive breast cancer"/><FilterOption id="77" count="11" label="Cardiac failure - Subjects with NYHA Functional Class - Moderate/NYHA Functional Class III Heart Failure Subjects"/><FilterOption id="201" count="11" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"/><FilterOption id="19047" count="11" label="Melanoma - Treatment Naive Subjects"/><FilterOption id="7402" count="11" label="Renal cell carcinoma - Subjects with Clear Cell Renal Cell Carcinoma"/><FilterOption id="7814" count="10" label="Bladder cancer - Subjects with Unresectable Bladder Cancer"/><FilterOption id="3943" count="10" label="Breast tumor - Subjects with Stage I Breast Cancer"/><FilterOption id="7700" count="10" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"/><FilterOption id="3774" count="10" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"/><FilterOption id="7877" count="10" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"/><FilterOption id="3650" count="10" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"/><FilterOption id="3496" count="10" label="Lymphoma - Subjects with specific Ann Arbor stage - Subjects with Ann Arbor Stage II Lymphoma"/><FilterOption id="8073" count="10" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"/><FilterOption id="3586" count="10" label="Prostate tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="11631" count="10" label="Stroke - Subjects with Ischemic Stroke"/><FilterOption id="302" count="9" label="Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects"/><FilterOption id="7808" count="9" label="Bladder cancer - Subjects with Stage III Bladder Cancer"/><FilterOption id="3970" count="9" label="Breast tumor - Others - Subjects with node positive breast cancer"/><FilterOption id="3934" count="9" label="Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer"/><FilterOption id="3935" count="9" label="Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer"/><FilterOption id="78" count="9" label="Cardiac failure - Subjects with NYHA Functional Class - Severe/NYHA Functional Class IV Heart Failure Subjects"/><FilterOption id="178" count="9" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)"/><FilterOption id="3404" count="9" label="Crohns disease - Subjects with Active Crohns Disease"/><FilterOption id="7111" count="9" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors"/><FilterOption id="12889" count="9" label="Leukemia - Subjects with gene variants - BCR_ABL1_HUMAN_Fusion"/><FilterOption id="3710" count="9" label="Melanoma - Subjects with Treatment Resistant Disease"/><FilterOption id="18822" count="9" label="Other gastrointestinal disease - Subjects with specific disease - Nonalcoholic steatohepatitis (NASH) subjects"/><FilterOption id="11487" count="9" label="Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT"/><FilterOption id="8784" count="9" label="Ulcerative colitis - Subjects with Active Ulcerative Colitis"/><FilterOption id="7820" count="8" label="Bladder cancer - Subjects with Treatment Resistant Disease"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="35" label="201912"/><FilterOption count="20" label="202012"/><FilterOption count="17" label="201810"/><FilterOption count="16" label="201906"/><FilterOption count="16" label="202001"/><FilterOption count="15" label="201812"/><FilterOption count="15" label="201908"/><FilterOption count="15" label="201910"/><FilterOption count="15" label="202011"/><FilterOption count="14" label="201612"/><FilterOption count="14" label="202006"/><FilterOption count="13" label="201905"/><FilterOption count="13" label="201909"/><FilterOption count="13" label="202007"/><FilterOption count="13" label="202106"/><FilterOption count="13" label="202109"/><FilterOption count="12" label="201803"/><FilterOption count="12" label="201911"/><FilterOption count="12" label="202003"/><FilterOption count="12" label="202103"/><FilterOption count="11" label="201409"/><FilterOption count="11" label="201512"/><FilterOption count="11" label="201607"/><FilterOption count="11" label="201709"/><FilterOption count="11" label="201808"/><FilterOption count="11" label="201907"/><FilterOption count="11" label="202005"/><FilterOption count="11" label="202009"/><FilterOption count="10" label="201604"/><FilterOption count="10" label="201704"/><FilterOption count="10" label="201707"/><FilterOption count="9" label="201111"/><FilterOption count="9" label="201712"/><FilterOption count="9" label="201809"/><FilterOption count="9" label="202004"/><FilterOption count="8" label="201006"/><FilterOption count="8" label="201112"/><FilterOption count="8" label="201207"/><FilterOption count="8" label="201310"/><FilterOption count="8" label="201408"/><FilterOption count="8" label="201505"/><FilterOption count="8" label="201609"/><FilterOption count="8" label="201705"/><FilterOption count="8" label="201710"/><FilterOption count="8" label="201801"/><FilterOption count="8" label="201805"/><FilterOption count="8" label="201807"/><FilterOption count="8" label="201811"/><FilterOption count="8" label="201904"/><FilterOption count="7" label="201001"/><FilterOption count="7" label="201106"/><FilterOption count="7" label="201301"/><FilterOption count="7" label="201307"/><FilterOption count="7" label="201406"/><FilterOption count="7" label="201411"/><FilterOption count="7" label="201506"/><FilterOption count="7" label="201605"/><FilterOption count="7" label="201610"/><FilterOption count="7" label="201611"/><FilterOption count="7" label="201703"/><FilterOption count="7" label="201711"/><FilterOption count="7" label="202002"/><FilterOption count="7" label="202104"/><FilterOption count="7" label="202112"/><FilterOption count="6" label="200812"/><FilterOption count="6" label="201204"/><FilterOption count="6" label="201302"/><FilterOption count="6" label="201305"/><FilterOption count="6" label="201312"/><FilterOption count="6" label="201407"/><FilterOption count="6" label="201410"/><FilterOption count="6" label="201501"/><FilterOption count="6" label="201502"/><FilterOption count="6" label="201507"/><FilterOption count="6" label="201602"/><FilterOption count="6" label="201606"/><FilterOption count="6" label="201706"/><FilterOption count="6" label="201802"/><FilterOption count="6" label="202010"/><FilterOption count="6" label="202204"/><FilterOption count="5" label="200807"/><FilterOption count="5" label="200905"/><FilterOption count="5" label="201011"/><FilterOption count="5" label="201012"/><FilterOption count="5" label="201203"/><FilterOption count="5" label="201209"/><FilterOption count="5" label="201311"/><FilterOption count="5" label="201402"/><FilterOption count="5" label="201405"/><FilterOption count="5" label="201504"/><FilterOption count="5" label="201601"/><FilterOption count="5" label="201608"/><FilterOption count="5" label="201804"/><FilterOption count="5" label="201901"/><FilterOption count="5" label="201903"/><FilterOption count="5" label="202008"/><FilterOption count="5" label="202110"/><FilterOption count="4" label="200809"/><FilterOption count="4" label="200911"/><FilterOption count="4" label="201103"/></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="ES" count="1237" label="Spain"/><FilterOption id="DE" count="613" label="Germany"/><FilterOption id="FR" count="611" label="France"/><FilterOption id="IT" count="591" label="Italy"/><FilterOption id="US" count="575" label="US"/><FilterOption id="GB" count="561" label="UK"/><FilterOption id="BE" count="466" label="Belgium"/><FilterOption id="CA" count="421" label="Canada"/><FilterOption id="PL" count="369" label="Poland"/><FilterOption id="NL" count="348" label="Netherlands"/><FilterOption id="AU" count="347" label="Australia"/><FilterOption id="AT" count="293" label="Austria"/><FilterOption id="CZ" count="275" label="Czech Republic"/><FilterOption id="IL" count="243" label="Israel"/><FilterOption id="HU" count="240" label="Hungary"/><FilterOption id="RU" count="238" label="Russian Federation"/><FilterOption id="KR" count="232" label="South Korea"/><FilterOption id="SE" count="220" label="Sweden"/><FilterOption id="CH" count="198" label="Switzerland"/><FilterOption id="DK" count="194" label="Denmark"/><FilterOption id="PT" count="192" label="Portugal"/><FilterOption id="BR" count="188" label="Brazil"/><FilterOption id="TW" count="160" label="Taiwan"/><FilterOption id="JP" count="156" label="Japan"/><FilterOption id="GR" count="151" label="Greece"/><FilterOption id="AR" count="146" label="Argentina"/><FilterOption id="MX" count="141" label="Mexico"/><FilterOption id="RO" count="125" label="Romania"/><FilterOption id="TR" count="122" label="Turkey"/><FilterOption id="UA" count="114" label="Ukraine"/><FilterOption id="FI" count="109" label="Finland"/><FilterOption id="NZ" count="108" label="New Zealand"/><FilterOption id="BG" count="106" label="Bulgaria"/><FilterOption id="IE" count="103" label="Ireland"/><FilterOption id="CN" count="101" label="China"/><FilterOption id="ZA" count="94" label="South Africa"/><FilterOption id="SK" count="93" label="Slovakia"/><FilterOption id="SG" count="92" label="Singapore"/><FilterOption id="NO" count="91" label="Norway"/><FilterOption id="HK" count="82" label="Hong Kong"/><FilterOption id="CL" count="79" label="Chile"/><FilterOption id="RS" count="76" label="Serbia"/><FilterOption id="TH" count="70" label="Thailand"/><FilterOption id="PE" count="65" label="Peru"/><FilterOption id="HR" count="63" label="Croatia"/><FilterOption id="CO" count="61" label="Colombia"/><FilterOption id="IN" count="56" label="India"/><FilterOption id="LV" count="51" label="Latvia"/><FilterOption id="PR" count="51" label="Puerto Rico"/><FilterOption id="X5" count="47" label="Europe"/><FilterOption id="LT" count="47" label="Lithuania"/><FilterOption id="MY" count="45" label="Malaysia"/><FilterOption id="EE" count="44" label="Estonia"/><FilterOption id="SI" count="30" label="Slovenia"/><FilterOption id="PH" count="22" label="Philippines"/><FilterOption id="XD" count="20" label="North America"/><FilterOption id="BA" count="19" label="Bosnia and Herzegovina"/><FilterOption id="PA" count="19" label="Panama"/><FilterOption id="X2" count="18" label="Asia"/><FilterOption id="CR" count="15" label="Costa Rica"/><FilterOption id="EG" count="15" label="Egypt"/><FilterOption id="GE" count="15" label="Georgia"/><FilterOption id="GT" count="14" label="Guatemala"/><FilterOption id="XE" count="12" label="South America"/><FilterOption id="LU" count="11" label="Luxembourg"/><FilterOption id="SA" count="11" label="Saudi Arabia"/><FilterOption id="BY" count="10" label="Belarus"/><FilterOption id="MA" count="8" label="Morocco"/><FilterOption id="VN" count="8" label="Vietnam"/><FilterOption id="DZ" count="7" label="Algeria"/><FilterOption id="KP" count="7" label="North Korea"/><FilterOption id="DO" count="6" label="Dominican Republic"/><FilterOption id="MK" count="6" label="Macedonia, The Former Yugoslav Republic of"/><FilterOption id="VE" count="6" label="Venezuela"/><FilterOption id="EC" count="5" label="Ecuador"/><FilterOption id="SV" count="5" label="El Salvador"/><FilterOption id="EU" count="5" label="EU"/><FilterOption id="LB" count="5" label="Lebanon"/><FilterOption id="IS" count="4" label="Iceland"/><FilterOption id="AE" count="4" label="United Arab Emirates"/><FilterOption id="UY" count="4" label="Uruguay"/><FilterOption id="AL" count="3" label="Albania"/><FilterOption id="BS" count="3" label="Bahamas"/><FilterOption id="ID" count="3" label="Indonesia"/><FilterOption id="TN" count="3" label="Tunisia"/><FilterOption id="X0" count="2" label="Africa"/><FilterOption id="CY" count="2" label="Cyprus"/><FilterOption id="JO" count="2" label="Jordan"/><FilterOption id="KZ" count="2" label="Kazakhstan"/><FilterOption id="KW" count="2" label="Kuwait"/><FilterOption id="MT" count="2" label="Malta"/><FilterOption id="MD" count="2" label="Moldova, Republic of"/><FilterOption id="PK" count="2" label="Pakistan"/><FilterOption id="PW" count="2" label="Palau"/><FilterOption id="UG" count="2" label="Uganda"/><FilterOption id="XW" count="2" label="Western Europe"/><FilterOption id="X1" count="1" label="Americas"/><FilterOption id="BH" count="1" label="Bahrain"/><FilterOption id="BN" count="1" label="Brunei"/><FilterOption id="MM" count="1" label="Burma"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="17"><FilterOption id="EAMAA" count="1171" label="Middle-aged Adults (45-64 yrs)"/><FilterOption id="EAYAD" count="1145" label="Young Adults (18-44 yrs)"/><FilterOption id="EAAAD" count="1137" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAELD" count="969" label="Elderly Adults (80 and over)"/><FilterOption id="EGFEM" count="100" label="Female"/><FilterOption id="EAADL" count="67" label="Adolescents (13-17 yrs)"/><FilterOption id="EACHI" count="49" label="Children (6-12 yrs)"/><FilterOption id="EVHVA" count="40" label="Healthy volunteers accepted"/><FilterOption id="EGMAL" count="38" label="Male"/><FilterOption id="EAPRE" count="17" label="Preschool Children (2-5 yrs)"/><FilterOption id="ECASI" count="13" label="Asian Ancestry"/><FilterOption id="EAINF" count="12" label="Infants (6-23 months)"/><FilterOption id="EANEW" count="12" label="Newborn Infants (up to 5 months)"/><FilterOption id="ECJAP" count="9" label="Japanese Ancestry"/><FilterOption id="ECAFR" count="4" label="African Ancestry"/><FilterOption id="EVHVO" count="4" label="Healthy volunteers only"/><FilterOption id="ECEUR" count="1" label="European Ancestry"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="25"><FilterOption id="SSTINV" count="1137" label="Interventional"/><FilterOption id="SIPTRE" count="1053" label="Treatment"/><FilterOption id="SIARND" count="840" label="Randomized"/><FilterOption id="SISPRL" count="821" label="Parallel Assignment"/><FilterOption id="SIMOPN" count="647" label="Open Label"/><FilterOption id="SIMMBD" count="435" label="Multiple Blind"/><FilterOption id="SICPLC" count="407" label="Placebo Control"/><FilterOption id="SICACT" count="296" label="Active Control"/><FilterOption id="SISSNG" count="254" label="Single Group Assignment"/><FilterOption id="SIANON" count="198" label="Non-Randomized"/><FilterOption id="SICNOC" count="158" label="No Control"/><FilterOption id="SSTOBS" count="100" label="Observational"/><FilterOption id="SOTPRO" count="75" label="Prospective"/><FilterOption id="SOSCOH" count="68" label="Cohort"/><FilterOption id="SIPPRE" count="67" label="Prevention"/><FilterOption id="SIMSBD" count="48" label="Single Blind"/><FilterOption id="SISXOV" count="26" label="Crossover Assignment"/><FilterOption id="SOTRET" count="20" label="Retrospective"/><FilterOption id="SIPDIA" count="13" label="Diagnosis"/><FilterOption id="SOSCSC" count="10" label="Case Control"/><FilterOption id="SODXSC" count="8" label="Cross-sectional"/><FilterOption id="SODLNG" count="5" label="Longitudinal"/><FilterOption id="SICDSC" count="3" label="Dose Comparison"/><FilterOption id="SISFCT" count="2" label="Factorial Assignment"/><FilterOption id="SISEAA" count="1" label="Expanded Access Assignment"/></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="721" label="ClinicalTrials.gov and others"/><FilterOption id="CTGOV" count="499" label="ClinicalTrials.gov only"/><FilterOption id="OTHERS" count="8" label="Others only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="487" label="Anticancer"/><FilterOption id="55685" count="258" label="Anticancer monoclonal antibody"/><FilterOption id="2953" count="256" label="Anti-inflammatory"/><FilterOption id="62255" count="203" label="Anticancer protein kinase inhibitor"/><FilterOption id="991" count="184" label="Antiviral"/><FilterOption id="1589" count="179" label="Apoptosis stimulator"/><FilterOption id="767" count="154" label="Cell cycle inhibitor"/><FilterOption id="7293" count="123" label="Synergist"/><FilterOption id="61" count="120" label="Angiogenesis inhibitor"/><FilterOption id="393" count="119" label="Immunostimulant"/><FilterOption id="7761" count="112" label="T-lymphocyte stimulator"/><FilterOption id="50" count="84" label="Anticancer alkylating agent"/><FilterOption id="140" count="82" label="DNA synthesis inhibitor"/><FilterOption id="1569" count="71" label="Anticancer antimetabolite"/><FilterOption id="1596" count="60" label="Immunomodulator"/><FilterOption id="2657" count="55" label="Antihypertensive"/><FilterOption id="2575" count="50" label="Microtubule inhibitor"/><FilterOption id="2576" count="46" label="Microtubule stabilizer"/><FilterOption id="2660" count="42" label="Vasoprotectant"/><FilterOption id="382" count="39" label="TNF alpha synthesis inhibitor"/><FilterOption id="747" count="34" label="HIV replication inhibitor"/><FilterOption id="396" count="34" label="Immunosuppressant"/><FilterOption id="2946" count="32" label="Analgesic"/><FilterOption id="750" count="26" label="DNA intercalator"/><FilterOption id="1615" count="26" label="Neuroprotectant"/><FilterOption id="15184" count="24" label="Systemic antipsoriatic product"/><FilterOption id="539" count="23" label="Immunotoxin"/><FilterOption id="12379" count="23" label="Therapeutic vaccine"/><FilterOption id="1594" count="22" label="Antibacterial"/><FilterOption id="62254" count="20" label="Anticancer hormone antagonist"/><FilterOption id="664" count="20" label="Fibrosuppressant"/><FilterOption id="399" count="20" label="Hypoglycemic agent"/><FilterOption id="2947" count="19" label="Antiparkinsonian"/><FilterOption id="388" count="17" label="Vasodilator"/><FilterOption id="70" count="14" label="Anticonvulsant agent"/><FilterOption id="2941" count="14" label="Antidepressant"/><FilterOption id="284" count="14" label="Nootropic agent"/><FilterOption id="312" count="14" label="Platelet aggregation inhibitor"/><FilterOption id="2659" count="13" label="Cardioprotectant"/><FilterOption id="449" count="12" label="Antiarrhythmic agent"/><FilterOption id="2943" count="12" label="Antipsychotic"/><FilterOption id="55684" count="11" label="Anticancer antibody"/><FilterOption id="71" count="11" label="Antihypercholesterolemic agent"/><FilterOption id="5704" count="11" label="B-lymphocyte adhesion inhibitor"/><FilterOption id="5710" count="11" label="B-lymphocyte migration inhibitor"/><FilterOption id="5580" count="11" label="Chemotaxis inhibitor"/><FilterOption id="659" count="11" label="Coagulation inhibitor"/><FilterOption id="1332" count="11" label="Gastrointestinal system agent"/><FilterOption id="610" count="11" label="Hematopoietic stimulator"/><FilterOption id="695" count="11" label="Metastasis inhibitor"/><FilterOption id="439" count="11" label="RNA synthesis inhibitor"/><FilterOption id="59620" count="11" label="Unspecified drug target"/><FilterOption id="646" count="10" label="Bronchodilator"/><FilterOption id="3980" count="10" label="HIV fusion inhibitor"/><FilterOption id="12372" count="10" label="Protein subunit vaccine"/><FilterOption id="32411" count="9" label="Hepatitis B virus replication inhibitor"/><FilterOption id="12378" count="9" label="Prophylactic vaccine"/><FilterOption id="104" count="8" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="285" count="8" label="Norepinephrine uptake inhibitor"/><FilterOption id="15187" count="8" label="Systemic dermatological antibacterial product"/><FilterOption id="1532" count="8" label="Viral replication inhibitor"/><FilterOption id="7292" count="8" label="Vulnerary agent"/><FilterOption id="1590" count="7" label="Apoptosis inhibitor"/><FilterOption id="3984" count="7" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="863" count="7" label="Bile acid modulator"/><FilterOption id="966" count="7" label="Cardiac agent"/><FilterOption id="805" count="7" label="Folate modulator"/><FilterOption id="1748" count="7" label="Fungicide"/><FilterOption id="15128" count="7" label="Ophthalmological agent"/><FilterOption id="937" count="6" label="Androgen synthesis inhibitor"/><FilterOption id="74" count="6" label="Antioxidant agent"/><FilterOption id="137" count="6" label="Diuretic agent"/><FilterOption id="151" count="6" label="Dopamine uptake inhibitor"/><FilterOption id="7760" count="6" label="T-lymphocyte inhibitor"/><FilterOption id="524" count="5" label="Adjuvant"/><FilterOption id="7294" count="5" label="Antisense oligonucleotide inhibitor"/><FilterOption id="89" count="5" label="Bone resorption inhibitor"/><FilterOption id="7211" count="5" label="CNS diagnostic agent"/><FilterOption id="11593" count="5" label="DNA repair inhibitor"/><FilterOption id="1129" count="5" label="Non-steroid hormone receptor antagonist"/><FilterOption id="26035" count="5" label="siRNA agent"/><FilterOption id="53558" count="5" label="Stem cell modulator"/><FilterOption id="2970" count="4" label="Anti-emetic"/><FilterOption id="4007" count="4" label="Antidiarrhoeal"/><FilterOption id="2638" count="4" label="Antiparasitic"/><FilterOption id="2942" count="4" label="Anxiolytic"/><FilterOption id="65" count="4" label="Class I antiarrhythmic agent"/><FilterOption id="66" count="4" label="Class II antiarrhythmic agent"/><FilterOption id="2939" count="4" label="CNS modulator"/><FilterOption id="161" count="4" label="Ergosterol synthesis inhibitor"/><FilterOption id="166" count="4" label="Fibrinolysis stimulator"/><FilterOption id="4790" count="4" label="Genetically engineered autologous cell therapy"/><FilterOption id="3272" count="4" label="Growth hormone release inhibitor"/><FilterOption id="12596" count="4" label="Osteoclast inhibitor"/><FilterOption id="5555" count="4" label="PET contrast agent"/><FilterOption id="339" count="4" label="Protein synthesis inhibitor"/><FilterOption id="5720" count="4" label="Radiodiagnostic"/><FilterOption id="15178" count="4" label="Systemic dermatological antifungal product"/><FilterOption id="882" count="3" label="5-HETE modulator"/><FilterOption id="3" count="3" label="5-HT uptake inhibitor"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="291" label="Unspecified"/><FilterOption id="YES" count="178" label="Yes"/><FilterOption id="NO" count="89" label="No"/></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8712" count="51" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8719" count="44" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7538" count="36" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="8721" count="35" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8998" count="35" label="Breast tumor - Assessment of adverse events"/><FilterOption id="7879" count="34" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="9218" count="33" label="HIV infection - Assessment of Immune Response"/><FilterOption id="9247" count="32" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8738" count="31" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="8481" count="31" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8720" count="29" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8078" count="29" label="Leukemia - Assessment of adverse events"/><FilterOption id="8713" count="28" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7354" count="28" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="8722" count="27" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8489" count="27" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9215" count="26" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="9213" count="24" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="7908" count="24" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7611" count="24" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="9153" count="23" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7547" count="23" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7563" count="22" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7680" count="22" label="Lymphoma - Assessment of adverse events"/><FilterOption id="6919" count="22" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="7679" count="21" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="7360" count="21" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8725" count="20" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="8999" count="20" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8996" count="20" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="9300" count="20" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="8505" count="20" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7393" count="20" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="8754" count="19" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8522" count="19" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="6924" count="19" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6940" count="19" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="10828" count="19" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8714" count="18" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="7909" count="18" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8077" count="18" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7898" count="18" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7027" count="18" label="Melanoma - Assessment of adverse events"/><FilterOption id="7367" count="18" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8744" count="17" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="9242" count="17" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="7569" count="17" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7489" count="17" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="10540" count="17" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"/><FilterOption id="11728" count="16" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8109" count="16" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="9122" count="15" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="2622" count="15" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="9238" count="15" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="9212" count="15" label="HIV infection - Assessment of Viral Load"/><FilterOption id="8663" count="15" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8640" count="15" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7558" count="15" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7372" count="15" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7190" count="15" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8759" count="14" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8430" count="14" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="2492" count="14" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="7907" count="14" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8147" count="14" label="Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease"/><FilterOption id="7564" count="14" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="43526" count="14" label="Other gastrointestinal disease - Clinical Assessments"/><FilterOption id="10545" count="14" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11717" count="13" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="11780" count="13" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="11735" count="13" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="37159" count="13" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="2703" count="13" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="8639" count="13" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="6951" count="13" label="Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="7373" count="13" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="42921" count="13" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="10839" count="13" label="Ovary tumor - Assessment of Response Rates (RR) - Assessment of overall/objective response rate(ORR)"/><FilterOption id="7045" count="13" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="15907" count="13" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="11722" count="12" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9310" count="12" label="Breast tumor - Imaging/Radiological Assessments"/><FilterOption id="8151" count="12" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="2623" count="12" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"/><FilterOption id="10830" count="12" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15212" count="12" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="12156" count="12" label="Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8764" count="11" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30"/><FilterOption id="6863" count="11" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="7891" count="11" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7916" count="11" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="6972" count="11" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="43670" count="11" label="Other gastrointestinal disease - Assessment of adverse events"/><FilterOption id="7088" count="11" label="Prostate tumor - Assessment of Disease Progression"/><FilterOption id="15218" count="11" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="11773" count="10" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="10187" count="10" label="Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part III scale/score"/><FilterOption id="11730" count="9" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="11729" count="9" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8745" count="9" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1211" count="100" label="Alanine transaminase"/><FilterOption id="3" count="85" label="HER2"/><FilterOption id="213" count="82" label="Creatinine"/><FilterOption id="2527" count="81" label="Aspartate aminotransferase"/><FilterOption id="2054" count="73" label="Blood platelets"/><FilterOption id="1236" count="70" label="Hemoglobin"/><FilterOption id="12058" count="70" label="Total body mass"/><FilterOption id="1857" count="62" label="T-cell surface glycoprotein CD4"/><FilterOption id="1925" count="61" label="Neutrophils"/><FilterOption id="5" count="53" label="Estrogen receptor"/><FilterOption id="2387" count="52" label="Bilirubin"/><FilterOption id="46" count="51" label="C-reactive protein"/><FilterOption id="824" count="51" label="Programmed cell death 1 ligand 1"/><FilterOption id="1880" count="47" label="T-Helper Lymphocytes"/><FilterOption id="1904" count="45" label="Heart rate"/><FilterOption id="2586" count="40" label="Blood pressure"/><FilterOption id="125" count="40" label="Leukocyte count"/><FilterOption id="3447" count="40" label="T-cell surface glycoprotein CD8 alpha chain"/><FilterOption id="6" count="39" label="Progesterone receptor"/><FilterOption id="1735" count="38" label="Glucose"/><FilterOption id="118" count="37" label="Albumin"/><FilterOption id="28899" count="37" label="Alkaline phosphatase"/><FilterOption id="44218" count="37" label="Human immunodeficiency virus RNA"/><FilterOption id="176" count="37" label="Interleukin-6"/><FilterOption id="133" count="36" label="Total cholesterol"/><FilterOption id="152" count="35" label="Low-density lipoprotein cholesterol"/><FilterOption id="217" count="34" label="Triglycerides"/><FilterOption id="7895" count="32" label="Estimated glomerular filtration rate"/><FilterOption id="4806" count="32" label="Lymphocytes"/><FilterOption id="8" count="31" label="Epidermal growth factor receptor"/><FilterOption id="147" count="31" label="Six-minute walk distance"/><FilterOption id="46505" count="30" label="Cytotoxic T-Lymphocytes"/><FilterOption id="153" count="29" label="High-density lipoprotein cholesterol"/><FilterOption id="38" count="29" label="Prostate-specific antigen"/><FilterOption id="330" count="29" label="Systolic blood pressure"/><FilterOption id="82" count="28" label="B-Raf proto-oncogene serine/threonine-protein kinase"/><FilterOption id="14767" count="28" label="Lipids"/><FilterOption id="113" count="27" label="Body Mass Index"/><FilterOption id="36136" count="27" label="Cytokines"/><FilterOption id="8458" count="27" label="gamma-Glutamyltransferase"/><FilterOption id="106" count="26" label="N-terminal Pro Brain Natriuretic Peptide"/><FilterOption id="1945" count="25" label="Left ventricular ejection fraction"/><FilterOption id="46506" count="25" label="T-Lymphocytes"/><FilterOption id="8024" count="24" label="Creatine kinase"/><FilterOption id="332" count="24" label="Diastolic blood pressure"/><FilterOption id="44216" count="21" label="Body temperature"/><FilterOption id="4522" count="21" label="Erythrocytes"/><FilterOption id="2662" count="21" label="Sodium"/><FilterOption id="5700" count="19" label="ALK receptor"/><FilterOption id="1731" count="19" label="B-lymphocyte antigen CD20"/><FilterOption id="2417" count="19" label="Calcium"/><FilterOption id="148" count="19" label="QT interval"/><FilterOption id="7" count="18" label="Antigen KI-67"/><FilterOption id="3374" count="18" label="Bone mineral density"/><FilterOption id="252" count="18" label="Interferon gamma"/><FilterOption id="2098" count="18" label="Potassium"/><FilterOption id="274" count="18" label="Tumor necrosis factor"/><FilterOption id="6663" count="17" label="B-lymphocytes"/><FilterOption id="165" count="17" label="Beta-2-microglobulin"/><FilterOption id="10684" count="17" label="Blood cells"/><FilterOption id="289" count="17" label="Hemoglobin A, glycosylated"/><FilterOption id="154" count="17" label="Lactate dehydrogenase"/><FilterOption id="22" count="16" label="Breast cancer type 1 susceptibility protein"/><FilterOption id="1912" count="16" label="Forced Vital Capacity"/><FilterOption id="1289" count="16" label="Tumor mass"/><FilterOption id="41" count="15" label="Breast cancer type 2 susceptibility protein"/><FilterOption id="2713" count="15" label="Forced expiratory volume"/><FilterOption id="749" count="15" label="Free light chains"/><FilterOption id="71" count="14" label="CA-125 antigen"/><FilterOption id="9" count="14" label="Cellular tumor antigen p53"/><FilterOption id="7033" count="14" label="Lipase"/><FilterOption id="13158" count="14" label="Myeloma protein"/><FilterOption id="3098" count="13" label="Calprotectin"/><FilterOption id="92" count="13" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"/><FilterOption id="17697" count="12" label="Body height"/><FilterOption id="2254" count="12" label="HLA-DR Antigens"/><FilterOption id="808" count="12" label="Insulin"/><FilterOption id="175" count="12" label="Interleukin-10"/><FilterOption id="11117" count="12" label="Plasma cells"/><FilterOption id="11857" count="12" label="Transaminases"/><FilterOption id="12516" count="12" label="Urinary protein"/><FilterOption id="769" count="11" label="ADP-ribosyl cyclase 1"/><FilterOption id="126" count="11" label="BCR-ABL1 fusion protein"/><FilterOption id="64" count="11" label="Circulating Tumor Cells"/><FilterOption id="10306" count="11" label="Ejection fraction"/><FilterOption id="2412" count="11" label="Immunoglobulin M"/><FilterOption id="900" count="11" label="Microtubule associated protein tau"/><FilterOption id="2613" count="11" label="Norepinephrine"/><FilterOption id="2411" count="11" label="Pulmonary vascular resistance"/><FilterOption id="122" count="11" label="Renin"/><FilterOption id="46244" count="10" label="Circulating tumor DNA"/><FilterOption id="3451" count="10" label="Immunoglobulin G"/><FilterOption id="8097" count="10" label="Monocytes"/><FilterOption id="10833" count="10" label="Myomesin-2"/><FilterOption id="2139" count="10" label="Pulmonary arterial pressure"/><FilterOption id="6993" count="9" label="Alpha-amylase 1"/><FilterOption id="11114" count="9" label="Brain"/><FilterOption id="5393" count="9" label="Chromosome locus 17p"/><FilterOption id="52" count="9" label="GTPase KRas"/><FilterOption id="1221" count="9" label="Hematocrit"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="5"><FilterOption id="SIEEFC" count="1120" label="Efficacy"/><FilterOption id="SIESFT" count="1062" label="Safety"/><FilterOption id="SIEPCK" count="430" label="Pharmacokinetics"/><FilterOption id="SIEPCD" count="230" label="Pharmacodynamics"/><FilterOption id="SIEBAV" count="4" label="Bioavailability"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3803" count="36" label="paclitaxel"/><FilterOption id="44383" count="33" label="carboplatin"/><FilterOption id="3199" count="31" label="gemcitabine"/><FilterOption id="72699" count="30" label="atezolizumab"/><FilterOption id="6736" count="29" label="rituximab"/><FilterOption id="8047" count="23" label="bevacizumab"/><FilterOption id="2953" count="20" label="docetaxel"/><FilterOption id="6386" count="20" label="trastuzumab"/><FilterOption id="15954" count="18" label="bortezomib"/><FilterOption id="27572" count="18" label="lenalidomide"/><FilterOption id="3072" count="16" label="etoposide phosphate"/><FilterOption id="3792" count="16" label="oxaliplatin"/><FilterOption id="7310" count="16" label="ritonavir"/><FilterOption id="12205" count="14" label="capecitabine"/><FilterOption id="70667" count="14" label="pembrolizumab"/><FilterOption id="28532" count="14" label="pertuzumab"/><FilterOption id="2784" count="13" label="letrozole"/><FilterOption id="54804" count="12" label="nivolumab"/><FilterOption id="3313" count="11" label="fulvestrant"/><FilterOption id="47000" count="10" label="bendamustine"/><FilterOption id="56544" count="10" label="cobimetinib"/><FilterOption id="13022" count="9" label="epirubicin"/><FilterOption id="6156" count="9" label="fludarabine"/><FilterOption id="55237" count="9" label="ibrutinib"/><FilterOption id="14681" count="9" label="lopinavir + ritonavir"/><FilterOption id="29016" count="9" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="5369" count="9" label="ribavirin"/><FilterOption id="54601" count="8" label="carfilzomib"/><FilterOption id="32981" count="8" label="darunavir"/><FilterOption id="3081" count="8" label="exemestane"/><FilterOption id="3474" count="8" label="lamivudine"/><FilterOption id="11519" count="8" label="mitoxantrone"/><FilterOption id="54488" count="8" label="raltegravir"/><FilterOption id="37370" count="7" label="azacitidine"/><FilterOption id="53200" count="7" label="daratumumab"/><FilterOption id="36630" count="7" label="ipilimumab"/><FilterOption id="53227" count="7" label="obinutuzumab"/><FilterOption id="3536" count="7" label="pemetrexed disodium"/><FilterOption id="14493" count="7" label="tenofovir disoproxil fumarate"/><FilterOption id="54469" count="7" label="vemurafenib"/><FilterOption id="12150" count="7" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="10309" count="6" label="abiraterone"/><FilterOption id="15254" count="6" label="atazanavir"/><FilterOption id="10388" count="6" label="cetuximab"/><FilterOption id="4728" count="6" label="emtricitabine"/><FilterOption id="11961" count="6" label="erlotinib"/><FilterOption id="45841" count="6" label="lenvatinib mesylate"/><FilterOption id="10271" count="6" label="palbociclib"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="23625" count="6" label="peginterferon alfa-2a"/><FilterOption id="44314" count="6" label="tamoxifen"/><FilterOption id="6242" count="5" label="abacavir"/><FilterOption id="3321" count="5" label="anastrozole"/><FilterOption id="83065" count="5" label="avelumab"/><FilterOption id="5999" count="5" label="ciclosporin, Novartis"/><FilterOption id="59062" count="5" label="dolutegravir"/><FilterOption id="81193" count="5" label="durvalumab"/><FilterOption id="2871" count="5" label="irinotecan"/><FilterOption id="37613" count="5" label="maraviroc"/><FilterOption id="27696" count="5" label="pomalidomide"/><FilterOption id="55305" count="4" label="binimetinib"/><FilterOption id="2836" count="4" label="clopidogrel"/><FilterOption id="10172" count="4" label="efavirenz"/><FilterOption id="73843" count="4" label="encorafenib"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="13340" count="4" label="everolimus"/><FilterOption id="3130" count="4" label="filgrastim"/><FilterOption id="48319" count="4" label="idelalisib"/><FilterOption id="66051" count="4" label="ipatasertib dihydrochloride"/><FilterOption id="4510" count="4" label="tacrolimus"/><FilterOption id="49219" count="4" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="70678" count="4" label="xentuzumab"/><FilterOption id="39172" count="3" label="brentuximab vedotin"/><FilterOption id="13239" count="3" label="decitabine"/><FilterOption id="7934" count="3" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="4563" count="3" label="doxorubicin (liposome formulation), Cephalon"/><FilterOption id="48099" count="3" label="farletuzumab"/><FilterOption id="11460" count="3" label="imatinib"/><FilterOption id="3669" count="3" label="mycophenolate mofetil"/><FilterOption id="61287" count="3" label="niraparib"/><FilterOption id="16063" count="3" label="olaparib"/><FilterOption id="4200" count="3" label="sirolimus"/><FilterOption id="70199" count="3" label="taselisib"/><FilterOption id="45562" count="3" label="tremelimumab"/><FilterOption id="70895" count="3" label="venetoclax"/><FilterOption id="6408" count="3" label="vinorelbine"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="72538" count="2" label="abemaciclib"/><FilterOption id="24885" count="2" label="albinterferon alfa-2b"/><FilterOption id="69066" count="2" label="alectinib"/><FilterOption id="2716" count="2" label="alemtuzumab"/><FilterOption id="7867" count="2" label="amprenavir"/><FilterOption id="66828" count="2" label="bemcentinib"/><FilterOption id="50935" count="2" label="cabozantinib S-malate"/><FilterOption id="44384" count="2" label="ceftriaxone"/><FilterOption id="64231" count="2" label="copanlisib hydrochloride"/><FilterOption id="9049" count="2" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="55085" count="2" label="filanesib"/><FilterOption id="5202" count="2" label="gemtuzumab ozogamicin"/></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="424" label="Other Publications"/><FilterOption id="PR" count="414" label="Press Releases"/><FilterOption id="SERIAL" count="372" label="Serial Publications"/><FilterOption id="CORPORATE" count="113" label="Corporate Publications"/><FilterOption id="CONFERENCE" count="79" label="Conference Reports"/></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="72699" count="13" label="atezolizumab"/><FilterOption id="27572" count="12" label="lenalidomide"/><FilterOption id="52854" count="8" label="macitentan"/><FilterOption id="14681" count="7" label="lopinavir + ritonavir"/><FilterOption id="70667" count="7" label="pembrolizumab"/><FilterOption id="45499" count="7" label="tofacitinib citrate (oral, inflammation), Pfizer"/><FilterOption id="8047" count="6" label="bevacizumab"/><FilterOption id="57369" count="6" label="etrolizumab"/><FilterOption id="55237" count="6" label="ibrutinib"/><FilterOption id="6736" count="6" label="rituximab"/><FilterOption id="14163" count="5" label="adalimumab"/><FilterOption id="83065" count="5" label="avelumab"/><FilterOption id="3700" count="5" label="nevirapine"/><FilterOption id="50963" count="5" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"/><FilterOption id="54488" count="5" label="raltegravir"/><FilterOption id="36669" count="5" label="trastuzumab emtansine"/><FilterOption id="69066" count="4" label="alectinib"/><FilterOption id="30379" count="4" label="bosutinib"/><FilterOption id="24343" count="4" label="dabigatran etexilate"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="11961" count="4" label="erlotinib"/><FilterOption id="6850" count="4" label="infliximab"/><FilterOption id="37613" count="4" label="maraviroc"/><FilterOption id="54804" count="4" label="nivolumab"/><FilterOption id="16063" count="4" label="olaparib"/><FilterOption id="43738" count="4" label="pazopanib"/><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"/><FilterOption id="12973" count="4" label="sunitinib"/><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"/><FilterOption id="42858" count="4" label="ustekinumab"/><FilterOption id="7781" count="3" label="aripiprazole"/><FilterOption id="100097" count="3" label="bictegravir + emtricitabine + tenofovir alafenamide (HIV-1 infection), Gilead"/><FilterOption id="72743" count="3" label="birtamimab"/><FilterOption id="15954" count="3" label="bortezomib"/><FilterOption id="5871" count="3" label="bosentan"/><FilterOption id="8955" count="3" label="carvedilol"/><FilterOption id="62277" count="3" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="89500" count="3" label="esketamine (intranasal), Janssen Research &amp; Development"/><FilterOption id="4567" count="3" label="etanercept"/><FilterOption id="13340" count="3" label="everolimus"/><FilterOption id="53840" count="3" label="gantenerumab"/><FilterOption id="3199" count="3" label="gemcitabine"/><FilterOption id="42857" count="3" label="golimumab"/><FilterOption id="56776" count="3" label="SHP-647"/><FilterOption id="4529" count="3" label="temozolomide"/><FilterOption id="50038" count="3" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"/><FilterOption id="50961" count="2" label="abobotulinumtoxinA"/><FilterOption id="84728" count="2" label="abrocitinib"/><FilterOption id="64893" count="2" label="acetylsalicylic acid + simvastatin + ramipril (oral, cardiovascular disease), Ferrer Internacional"/><FilterOption id="6306" count="2" label="aldesleukin"/><FilterOption id="6893" count="2" label="alteplase"/><FilterOption id="44374" count="2" label="amiodarone"/><FilterOption id="15254" count="2" label="atazanavir"/><FilterOption id="39209" count="2" label="axitinib"/><FilterOption id="37370" count="2" label="azacitidine"/><FilterOption id="94069" count="2" label="BAY-1213790"/><FilterOption id="31831" count="2" label="belimumab"/><FilterOption id="34140" count="2" label="blinatumomab"/><FilterOption id="105633" count="2" label="bumetanide (autism), Servier/ Neurochlore"/><FilterOption id="5929" count="2" label="bupropion (oral sustained release), GlaxoSmithKline"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="63587" count="2" label="Cx-611"/><FilterOption id="9049" count="2" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="63586" count="2" label="darvadstrocel"/><FilterOption id="54116" count="2" label="disitertide"/><FilterOption id="2953" count="2" label="docetaxel"/><FilterOption id="81193" count="2" label="durvalumab"/><FilterOption id="15593" count="2" label="eculizumab"/><FilterOption id="51255" count="2" label="edoxaban"/><FilterOption id="10172" count="2" label="efavirenz"/><FilterOption id="55066" count="2" label="elafibranor"/><FilterOption id="58762" count="2" label="empagliflozin"/><FilterOption id="16156" count="2" label="emricasan (oral, islet transplant rejection/liver disease), Novartis"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="60512" count="2" label="erdafitinib"/><FilterOption id="87805" count="2" label="faricimab"/><FilterOption id="78759" count="2" label="infliximab biosimilar, Celltrion/Nippon Kayaku/Hospira/Orion/EGIS Gyogyszergyar"/><FilterOption id="67653" count="2" label="inotersen"/><FilterOption id="2714" count="2" label="inotuzumab ozogamicin"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="55488" count="2" label="lanabecestat"/><FilterOption id="9313" count="2" label="lanreotide"/><FilterOption id="52798" count="2" label="lebrikizumab"/><FilterOption id="62073" count="2" label="mongersen"/><FilterOption id="60575" count="2" label="murepavadin"/><FilterOption id="50341" count="2" label="neratinib"/><FilterOption id="3705" count="2" label="nicotine"/><FilterOption id="51160" count="2" label="nintedanib"/><FilterOption id="48638" count="2" label="ocrelizumab"/><FilterOption id="3738" count="2" label="olanzapine"/><FilterOption id="2534" count="2" label="omalizumab"/><FilterOption id="3803" count="2" label="paclitaxel"/><FilterOption id="10271" count="2" label="palbociclib"/><FilterOption id="54422" count="2" label="QPI-1002"/><FilterOption id="63895" count="2" label="ralinepag"/><FilterOption id="4199" count="2" label="ranolazine"/><FilterOption id="32677" count="2" label="rivaroxaban"/><FilterOption id="81852" count="2" label="selonsertib"/><FilterOption id="7707" count="2" label="seocalcitol"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="100"><FilterOption id="44383" count="27" label="carboplatin"/><FilterOption id="3199" count="21" label="gemcitabine"/><FilterOption id="3803" count="21" label="paclitaxel"/><FilterOption id="2953" count="16" label="docetaxel"/><FilterOption id="6386" count="14" label="trastuzumab"/><FilterOption id="12205" count="12" label="capecitabine"/><FilterOption id="6736" count="12" label="rituximab"/><FilterOption id="7310" count="9" label="ritonavir"/><FilterOption id="49219" count="9" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="8047" count="8" label="bevacizumab"/><FilterOption id="15954" count="7" label="bortezomib"/><FilterOption id="3072" count="7" label="etoposide phosphate"/><FilterOption id="3536" count="7" label="pemetrexed disodium"/><FilterOption id="32981" count="6" label="darunavir"/><FilterOption id="13022" count="6" label="epirubicin"/><FilterOption id="14681" count="6" label="lopinavir + ritonavir"/><FilterOption id="3792" count="6" label="oxaliplatin"/><FilterOption id="10309" count="5" label="abiraterone"/><FilterOption id="27572" count="5" label="lenalidomide"/><FilterOption id="28532" count="5" label="pertuzumab"/><FilterOption id="15254" count="4" label="atazanavir"/><FilterOption id="47000" count="4" label="bendamustine"/><FilterOption id="7934" count="4" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="48181" count="4" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="33591" count="4" label="lapatinib"/><FilterOption id="29016" count="4" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="10172" count="3" label="efavirenz"/><FilterOption id="6156" count="3" label="fludarabine"/><FilterOption id="11519" count="3" label="mitoxantrone"/><FilterOption id="53227" count="3" label="obinutuzumab"/><FilterOption id="23625" count="3" label="peginterferon alfa-2a"/><FilterOption id="54488" count="3" label="raltegravir"/><FilterOption id="5369" count="3" label="ribavirin"/><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"/><FilterOption id="8050" count="3" label="thalidomide, Celgene"/><FilterOption id="12150" count="3" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="6408" count="3" label="vinorelbine"/><FilterOption id="72699" count="2" label="atezolizumab"/><FilterOption id="37370" count="2" label="azacitidine"/><FilterOption id="54601" count="2" label="carfilzomib"/><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="62275" count="2" label="cobicistat"/><FilterOption id="72148" count="2" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="59062" count="2" label="dolutegravir"/><FilterOption id="51371" count="2" label="elvitegravir"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="30682" count="2" label="etravirine"/><FilterOption id="13340" count="2" label="everolimus"/><FilterOption id="3081" count="2" label="exemestane"/><FilterOption id="24471" count="2" label="fosamprenavir"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="3700" count="2" label="nevirapine"/><FilterOption id="4196" count="2" label="ramipril"/><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"/><FilterOption id="4259" count="2" label="saquinavir"/><FilterOption id="44313" count="2" label="simvastatin"/><FilterOption id="15130" count="2" label="vinflunine"/><FilterOption id="44375" count="2" label="warfarin"/><FilterOption id="6242" count="1" label="abacavir"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="7867" count="1" label="amprenavir"/><FilterOption id="3321" count="1" label="anastrozole"/><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"/><FilterOption id="16915" count="1" label="calcium levofolinate"/><FilterOption id="12544" count="1" label="caspofungin"/><FilterOption id="44384" count="1" label="ceftriaxone"/><FilterOption id="5999" count="1" label="ciclosporin, Novartis"/><FilterOption id="44370" count="1" label="clindamycin"/><FilterOption id="9049" count="1" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="13239" count="1" label="decitabine"/><FilterOption id="2935" count="1" label="didanosine"/><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="53981" count="1" label="enzalutamide"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="3130" count="1" label="filgrastim"/><FilterOption id="44292" count="1" label="fluconazole"/><FilterOption id="3195" count="1" label="ganciclovir (oral), Roche Bioscience"/><FilterOption id="36630" count="1" label="ipilimumab"/><FilterOption id="2871" count="1" label="irinotecan"/><FilterOption id="65757" count="1" label="JNJ-3989"/><FilterOption id="100866" count="1" label="JNJ-56136379"/><FilterOption id="26574" count="1" label="lamivudine + abacavir + zidovudine, GSK"/><FilterOption id="16696" count="1" label="lamivudine + zidovudine, GlaxoSmithKline"/><FilterOption id="3488" count="1" label="leflunomide"/><FilterOption id="2784" count="1" label="letrozole"/><FilterOption id="37613" count="1" label="maraviroc"/><FilterOption id="61287" count="1" label="niraparib"/><FilterOption id="54804" count="1" label="nivolumab"/><FilterOption id="52139" count="1" label="ofloxacin"/><FilterOption id="21374" count="1" label="pegfilgrastim"/><FilterOption id="4481" count="1" label="stavudine"/><FilterOption id="12973" count="1" label="sunitinib"/><FilterOption id="44314" count="1" label="tamoxifen"/><FilterOption id="4529" count="1" label="temozolomide"/><FilterOption id="40532" count="1" label="tenofovir alafenamide fumarate"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="4577" count="1" label="topotecan"/><FilterOption id="25182" count="1" label="valganciclovir"/><FilterOption id="44401" count="1" label="vancomycin"/></Filter><Filter label="Trial Category" name="trialCategory" total="16"><FilterOption id="4" count="854" label="Small molecule"/><FilterOption id="3" count="443" label="Biological"/><FilterOption id="8" count="107" label="Medical device"/><FilterOption id="9" count="60" label="Medical procedure"/><FilterOption id="5" count="33" label="Vaccine"/><FilterOption id="16" count="32" label="Behavioral intervention"/><FilterOption id="15" count="28" label="Radiation therapy"/><FilterOption id="6" count="21" label="Cell therapy"/><FilterOption id="7" count="19" label="Gene therapy"/><FilterOption id="11" count="18" label="Dietary supplement"/><FilterOption id="18" count="12" label="Pathophysiology"/><FilterOption id="14" count="10" label="Diagnostic"/><FilterOption id="17" count="9" label="Biomarker identification"/><FilterOption id="19" count="2" label="Surgical procedure"/><FilterOption id="10" count="1" label="Borderline product"/><FilterOption id="13" count="1" label="Hospital solutions"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="NO" count="678" label="No"/><FilterOption id="YES" count="559" label="Yes"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="14007" count="57" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="5085" count="45" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="67136" count="45" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="740" count="43" label="Epidermal growth factor receptor antagonist"/><FilterOption id="3756" count="38" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="1832" count="38" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="3808" count="34" label="Kit tyrosine kinase inhibitor"/><FilterOption id="142" count="33" label="Topoisomerase II inhibitor"/><FilterOption id="1016" count="32" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="4917" count="31" label="Proteasome inhibitor"/><FilterOption id="3848" count="31" label="VEGF-2 receptor antagonist"/><FilterOption id="138" count="30" label="DNA polymerase inhibitor"/><FilterOption id="3846" count="30" label="VEGF-1 receptor antagonist"/><FilterOption id="204" count="29" label="HIV protease inhibitor"/><FilterOption id="7588" count="29" label="HIV-1 integrase inhibitor"/><FilterOption id="3850" count="29" label="VEGF-3 receptor antagonist"/><FilterOption id="768" count="27" label="HIV-1 protease inhibitor"/><FilterOption id="12521" count="25" label="VEGF ligand inhibitor"/><FilterOption id="3806" count="23" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="48492" count="23" label="PDGF receptor beta antagonist"/><FilterOption id="372" count="23" label="Thymidylate synthase inhibitor"/><FilterOption id="948" count="22" label="PDGF receptor antagonist"/><FilterOption id="76469" count="21" label="26S proteasome complex inhibitor"/><FilterOption id="76" count="21" label="Aromatase inhibitor"/><FilterOption id="10240" count="20" label="mTOR inhibitor"/><FilterOption id="4548" count="20" label="Raf B protein kinase inhibitor"/><FilterOption id="3682" count="19" label="FGF1 receptor antagonist"/><FilterOption id="3688" count="19" label="FGF3 receptor antagonist"/><FilterOption id="48489" count="19" label="PDGF receptor alpha antagonist"/><FilterOption id="7424" count="18" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="286" count="18" label="Estrogen receptor antagonist"/><FilterOption id="38283" count="17" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="38286" count="17" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="3816" count="17" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="1722" count="17" label="VEGF receptor antagonist"/><FilterOption id="3754" count="16" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="4762" count="16" label="MEK-1 protein kinase inhibitor"/><FilterOption id="4764" count="16" label="MEK-2 protein kinase inhibitor"/><FilterOption id="1833" count="16" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="4760" count="15" label="MEK protein kinase inhibitor"/><FilterOption id="4314" count="14" label="Cyclin-dependent kinase-4 inhibitor"/><FilterOption id="4318" count="14" label="Cyclin-dependent kinase-6 inhibitor"/><FilterOption id="770" count="14" label="Endothelin ET-A receptor antagonist"/><FilterOption id="3685" count="14" label="FGF2 receptor antagonist"/><FilterOption id="3592" count="13" label="Btk tyrosine kinase inhibitor"/><FilterOption id="5482" count="13" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="3154" count="12" label="CSF-1 antagonist"/><FilterOption id="3562" count="12" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="385" count="12" label="Protein tyrosine kinase inhibitor"/><FilterOption id="3576" count="12" label="Src tyrosine kinase inhibitor"/><FilterOption id="541" count="12" label="Tubulin receptor antagonist"/><FilterOption id="60" count="11" label="Androgen receptor antagonist"/><FilterOption id="4010" count="11" label="Calcineurin inhibitor"/><FilterOption id="771" count="11" label="Endothelin ET-B receptor antagonist"/><FilterOption id="214" count="11" label="Interferon alpha 2 ligand"/><FilterOption id="13571" count="10" label="Bcr protein inhibitor"/><FilterOption id="6512" count="10" label="DNA methyltransferase inhibitor"/><FilterOption id="675" count="10" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="3584" count="10" label="Lck tyrosine kinase inhibitor"/><FilterOption id="2506" count="10" label="PARP modulator"/><FilterOption id="3818" count="10" label="Ret tyrosine kinase receptor inhibitor"/><FilterOption id="3524" count="9" label="Abl tyrosine kinase inhibitor"/><FilterOption id="5136" count="9" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="3736" count="9" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="3107" count="9" label="CCR5 chemokine antagonist"/><FilterOption id="5027" count="9" label="CD4 agonist"/><FilterOption id="82444" count="9" label="DNA helicase inhibitor"/><FilterOption id="51708" count="9" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="9" label="DNA primase inhibitor"/><FilterOption id="120" count="9" label="Factor Xa antagonist"/><FilterOption id="168" count="9" label="FGF receptor antagonist"/><FilterOption id="11219" count="9" label="HIV-1 gp120 protein inhibitor"/><FilterOption id="3560" count="9" label="JAK tyrosine kinase inhibitor"/><FilterOption id="3566" count="9" label="Jak3 tyrosine kinase inhibitor"/><FilterOption id="76090" count="9" label="mTOR complex 1 inhibitor"/><FilterOption id="347" count="9" label="RNA polymerase inhibitor"/><FilterOption id="381" count="9" label="TNF alpha ligand inhibitor"/><FilterOption id="721" count="9" label="TNF binding agent"/><FilterOption id="1513" count="9" label="Topoisomerase II modulator"/><FilterOption id="3851" count="8" label="ALK tyrosine kinase receptor family inhibitor"/><FilterOption id="621" count="8" label="Amyloid protein deposition inhibitor"/><FilterOption id="7418" count="8" label="Cytochrome P450 3 inhibitor"/><FilterOption id="135" count="8" label="DHFR inhibitor"/><FilterOption id="431" count="8" label="DNA gyrase inhibitor"/><FilterOption id="144" count="8" label="Dopamine receptor agonist"/><FilterOption id="3755" count="8" label="Erbb2 tyrosine kinase receptor modulator"/><FilterOption id="3760" count="8" label="Erbb4 tyrosine kinase receptor inhibitor"/><FilterOption id="3691" count="8" label="FGF4 receptor antagonist"/><FilterOption id="71851" count="8" label="HIV GAG POL polyprotein inhibitor"/><FilterOption id="12395" count="8" label="HIV GAG protein inhibitor"/><FilterOption id="205" count="8" label="HMG CoA reductase inhibitor"/><FilterOption id="2950" count="8" label="Integrin alpha-4/beta-7 antagonist"/><FilterOption id="2507" count="8" label="PARP inhibitor"/><FilterOption id="327" count="8" label="PGI2 agonist"/><FilterOption id="38289" count="8" label="Poly ADP ribose polymerase 3 inhibitor"/><FilterOption id="19467" count="8" label="Retinoblastoma associated protein modulator"/><FilterOption id="346" count="8" label="Ribonucleotide reductase inhibitor"/><FilterOption id="141" count="8" label="Topoisomerase I inhibitor"/><FilterOption id="814" count="8" label="Tubulin modulator"/><FilterOption id="58716" count="8" label="Ubiquitin inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="18767" count="19" label="Pfizer Inc"/><FilterOption id="19446" count="19" label="Roche Holding AG"/><FilterOption id="1039423" count="18" label="Hospital Clinic of Barcelona"/><FilterOption id="1017818" count="17" label="Instituto de Salud Carlos III"/><FilterOption id="20300" count="16" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="15331" count="15" label="Celgene Corp"/><FilterOption id="28355" count="12" label="GlaxoSmithKline plc"/><FilterOption id="14109" count="11" label="Amgen Inc"/><FilterOption id="14190" count="11" label="AstraZeneca plc"/><FilterOption id="15065" count="11" label="Bristol-Myers Squibb Co"/><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."/><FilterOption id="1059823" count="10" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="23137" count="10" label="Novartis AG"/><FilterOption id="17810" count="9" label="Eli Lilly &amp; Co"/><FilterOption id="19453" count="9" label="Genentech Inc"/><FilterOption id="1039086" count="9" label="Germans Trias i Pujol Hospital"/><FilterOption id="1017771" count="9" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="1013295" count="8" label="Astellas Pharma Inc"/><FilterOption id="26178" count="8" label="F Hoffmann-La Roche AG"/><FilterOption id="1067538" count="8" label="Janssen Research &amp; Development LLC"/><FilterOption id="13601" count="7" label="Abbott Laboratories"/><FilterOption id="19620" count="6" label="Eisai Inc"/><FilterOption id="1059977" count="6" label="European Commission"/><FilterOption id="1053612" count="6" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="18077" count="6" label="Merck &amp; Co Inc"/><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="25902" count="5" label="Array BioPharma Inc"/><FilterOption id="14455" count="5" label="Bayer AG"/><FilterOption id="1045910" count="5" label="Hospital Clinico San Carlos"/><FilterOption id="17416" count="5" label="Janssen LP"/><FilterOption id="17401" count="5" label="Janssen-Cilag SA"/><FilterOption id="20519" count="5" label="National Cancer Institute"/><FilterOption id="1067340" count="5" label="Pivotal SL"/><FilterOption id="25554" count="5" label="Seattle Genetics Inc"/><FilterOption id="1061163" count="4" label="Abbott Vascular"/><FilterOption id="1072507" count="4" label="AbbVie Inc"/><FilterOption id="1042255" count="4" label="Breast International Group"/><FilterOption id="1041980" count="4" label="Charite University"/><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"/><FilterOption id="22676" count="4" label="Exelixis Inc"/><FilterOption id="1039087" count="4" label="Fundacio Lluita Contra La Sida"/><FilterOption id="28959" count="4" label="Hannover Medical School"/><FilterOption id="1040862" count="4" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="1003065" count="4" label="Hospital Vall D'Hebron"/><FilterOption id="18438" count="4" label="Medical Research Council"/><FilterOption id="18101" count="4" label="Merck KGaA"/><FilterOption id="1074428" count="4" label="Ministerio de Economia y Competitividad"/><FilterOption id="1053488" count="4" label="NCIC Clinical Trials Group"/><FilterOption id="1116693" count="4" label="Productos Roche, S.A. de C.V."/><FilterOption id="1009547" count="4" label="Sanofi SA"/><FilterOption id="1114403" count="4" label="TFS Trial Form Support"/><FilterOption id="21279" count="4" label="Universite Catholique de Louvain"/><FilterOption id="19864" count="3" label="Adir &amp; Co"/><FilterOption id="1038808" count="3" label="Azienda Ospedaliera di Padova"/><FilterOption id="1052569" count="3" label="B Braun Surgical Sa"/><FilterOption id="1103224" count="3" label="Centro Hospitalar do Porto"/><FilterOption id="15414" count="3" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1091345" count="3" label="Complejo Hospitalario de Navarra"/><FilterOption id="1069026" count="3" label="Effice Servicios Para la Investigacion"/><FilterOption id="1062976" count="3" label="Europath Biosciences Sl"/><FilterOption id="1084506" count="3" label="European Network of Gynaecological Oncological Trial Groups"/><FilterOption id="1063203" count="3" label="Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico"/><FilterOption id="1073758" count="3" label="Fondo de Investigacion Sanitaria"/><FilterOption id="13738" count="3" label="Fresenius SE &amp; Co KGaA"/><FilterOption id="1045896" count="3" label="Fundacion Para La Investigacion Hospital La Fe"/><FilterOption id="1017513" count="3" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="1033112" count="3" label="Hospital Universitario 12 de Octubre"/><FilterOption id="1006639" count="3" label="Hospital Universitario Ramon y Cajal"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1056690" count="3" label="Institut Investigació Biomèdica Bellvitge"/><FilterOption id="1101929" count="3" label="IQVIA Holdings Inc"/><FilterOption id="17392" count="3" label="Janssen-Cilag Ltd"/><FilterOption id="21110" count="3" label="Karolinska Institutet"/><FilterOption id="1075878" count="3" label="Klinikum der Universität Köln"/><FilterOption id="22137" count="3" label="Ludwig-Maximilians University of Munich"/><FilterOption id="1175391" count="3" label="Medivation LLC"/><FilterOption id="21404" count="3" label="MorphoSys AG"/><FilterOption id="19087" count="3" label="Pierre Fabre SA"/><FilterOption id="1114888" count="3" label="Quartz Bio SA"/><FilterOption id="1119200" count="3" label="Sanofi-Aventis Research and Development"/><FilterOption id="1058089" count="3" label="Servicio Andaluz De Salud"/><FilterOption id="1096345" count="3" label="Servicio Cántabro De Salud"/><FilterOption id="21991" count="3" label="Takeda Oncology"/><FilterOption id="1054559" count="3" label="TESARO Inc"/><FilterOption id="1119462" count="3" label="The Cyprus Foundation For Muscular Dystrophy Research"/><FilterOption id="1104050" count="3" label="UCB Biopharma SPRL"/><FilterOption id="20625" count="3" label="Universita degli Studi di Milano"/><FilterOption id="1003992" count="3" label="Universitat de Barcelona"/><FilterOption id="1042041" count="3" label="University Hospital, Brest"/><FilterOption id="24222" count="3" label="University of Geneva"/><FilterOption id="25460" count="3" label="University of Granada"/><FilterOption id="DOL1000156" count="3" label="University of Szeged"/><FilterOption id="21082" count="3" label="Walter and Eliza Hall Institute of Medical Research"/><FilterOption id="1150199" count="2" label="A2F-Associates Limited"/><FilterOption id="1012474" count="2" label="AC Immune SA"/><FilterOption id="1117605" count="2" label="Adknoma Health Research"/><FilterOption id="1150200" count="2" label="alphabioresearch"/><FilterOption id="23948" count="2" label="Assistance Publique Hopitaux de Paris"/><FilterOption id="1037956" count="2" label="Astellas Pharma Global Development Inc"/><FilterOption id="1045129" count="2" label="Australasian Leukaemia and Lymphoma Group"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="94"><FilterOption id="1545" count="171" label="Anticancer"/><FilterOption id="767" count="73" label="Cell cycle inhibitor"/><FilterOption id="1569" count="55" label="Anticancer antimetabolite"/><FilterOption id="55685" count="54" label="Anticancer monoclonal antibody"/><FilterOption id="140" count="51" label="DNA synthesis inhibitor"/><FilterOption id="991" count="47" label="Antiviral"/><FilterOption id="2953" count="45" label="Anti-inflammatory"/><FilterOption id="50" count="43" label="Anticancer alkylating agent"/><FilterOption id="1589" count="41" label="Apoptosis stimulator"/><FilterOption id="62255" count="38" label="Anticancer protein kinase inhibitor"/><FilterOption id="2575" count="31" label="Microtubule inhibitor"/><FilterOption id="2576" count="31" label="Microtubule stabilizer"/><FilterOption id="61" count="28" label="Angiogenesis inhibitor"/><FilterOption id="2660" count="27" label="Vasoprotectant"/><FilterOption id="7293" count="21" label="Synergist"/><FilterOption id="750" count="15" label="DNA intercalator"/><FilterOption id="1596" count="13" label="Immunomodulator"/><FilterOption id="747" count="12" label="HIV replication inhibitor"/><FilterOption id="393" count="10" label="Immunostimulant"/><FilterOption id="7761" count="10" label="T-lymphocyte stimulator"/><FilterOption id="396" count="9" label="Immunosuppressant"/><FilterOption id="62254" count="8" label="Anticancer hormone antagonist"/><FilterOption id="382" count="8" label="TNF alpha synthesis inhibitor"/><FilterOption id="2657" count="7" label="Antihypertensive"/><FilterOption id="805" count="7" label="Folate modulator"/><FilterOption id="1594" count="6" label="Antibacterial"/><FilterOption id="937" count="5" label="Androgen synthesis inhibitor"/><FilterOption id="659" count="5" label="Coagulation inhibitor"/><FilterOption id="32411" count="5" label="Hepatitis B virus replication inhibitor"/><FilterOption id="2946" count="4" label="Analgesic"/><FilterOption id="1748" count="4" label="Fungicide"/><FilterOption id="399" count="4" label="Hypoglycemic agent"/><FilterOption id="312" count="4" label="Platelet aggregation inhibitor"/><FilterOption id="439" count="4" label="RNA synthesis inhibitor"/><FilterOption id="15184" count="4" label="Systemic antipsoriatic product"/><FilterOption id="1532" count="4" label="Viral replication inhibitor"/><FilterOption id="70" count="3" label="Anticonvulsant agent"/><FilterOption id="71" count="3" label="Antihypercholesterolemic agent"/><FilterOption id="2947" count="3" label="Antiparkinsonian"/><FilterOption id="563" count="3" label="Microtubule modulator"/><FilterOption id="15148" count="3" label="Ocular antineovascularisation agent"/><FilterOption id="5704" count="2" label="B-lymphocyte adhesion inhibitor"/><FilterOption id="5710" count="2" label="B-lymphocyte migration inhibitor"/><FilterOption id="104" count="2" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="1538" count="2" label="Bacterial protein synthesis inhibitor"/><FilterOption id="2659" count="2" label="Cardioprotectant"/><FilterOption id="5580" count="2" label="Chemotaxis inhibitor"/><FilterOption id="7211" count="2" label="CNS diagnostic agent"/><FilterOption id="11593" count="2" label="DNA repair inhibitor"/><FilterOption id="664" count="2" label="Fibrosuppressant"/><FilterOption id="610" count="2" label="Hematopoietic stimulator"/><FilterOption id="38211" count="2" label="Human insulin fast acting product"/><FilterOption id="211" count="2" label="Inotropic agent"/><FilterOption id="1129" count="2" label="Non-steroid hormone receptor antagonist"/><FilterOption id="5555" count="2" label="PET contrast agent"/><FilterOption id="5720" count="2" label="Radiodiagnostic"/><FilterOption id="1479" count="2" label="RNA synthesis modulator"/><FilterOption id="26035" count="2" label="siRNA agent"/><FilterOption id="15187" count="2" label="Systemic dermatological antibacterial product"/><FilterOption id="15178" count="2" label="Systemic dermatological antifungal product"/><FilterOption id="388" count="2" label="Vasodilator"/><FilterOption id="882" count="1" label="5-HETE modulator"/><FilterOption id="449" count="1" label="Antiarrhythmic agent"/><FilterOption id="2941" count="1" label="Antidepressant"/><FilterOption id="15135" count="1" label="Antiglaucoma agent"/><FilterOption id="955" count="1" label="Antimicrobial permeability enhancer"/><FilterOption id="2638" count="1" label="Antiparasitic"/><FilterOption id="2942" count="1" label="Anxiolytic"/><FilterOption id="38206" count="1" label="Biguanide antidiabetic product"/><FilterOption id="863" count="1" label="Bile acid modulator"/><FilterOption id="743" count="1" label="Bile acid transport inhibitor"/><FilterOption id="646" count="1" label="Bronchodilator"/><FilterOption id="1260" count="1" label="Calcium metabolism modulator"/><FilterOption id="1537" count="1" label="Cephalosporin"/><FilterOption id="2833" count="1" label="CMV replication inhibitor"/><FilterOption id="2939" count="1" label="CNS modulator"/><FilterOption id="124" count="1" label="Collagen synthesis inhibitor"/><FilterOption id="137" count="1" label="Diuretic agent"/><FilterOption id="839" count="1" label="Ergosterol modulator"/><FilterOption id="7251" count="1" label="Female contraceptive"/><FilterOption id="686" count="1" label="Folic acid analog"/><FilterOption id="1668" count="1" label="General anesthetic"/><FilterOption id="3980" count="1" label="HIV fusion inhibitor"/><FilterOption id="539" count="1" label="Immunotoxin"/><FilterOption id="3246" count="1" label="Insulin release stimulator"/><FilterOption id="1540" count="1" label="Macrolide antibiotic"/><FilterOption id="695" count="1" label="Metastasis inhibitor"/><FilterOption id="1615" count="1" label="Neuroprotectant"/><FilterOption id="285" count="1" label="Norepinephrine uptake inhibitor"/><FilterOption id="15128" count="1" label="Ophthalmological agent"/><FilterOption id="472" count="1" label="Phosphate lowering agent"/><FilterOption id="463" count="1" label="Ribosome binding agent"/><FilterOption id="5717" count="1" label="Sensitizer"/><FilterOption id="38205" count="1" label="Sulphonylurea antidiabetic product"/></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="649" label="Proteomic"/><FilterOption id="38" count="634" label="Genomic"/><FilterOption id="31" count="261" label="Physiological"/><FilterOption id="32" count="255" label="Biochemical"/><FilterOption id="75" count="233" label="Cellular"/><FilterOption id="40" count="93" label="Structural (imaging)"/><FilterOption id="39" count="92" label="Anthropomorphic"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="633" label="Therapeutic effect marker"/><FilterOption id="1571666123" count="348" label="Disease marker"/><FilterOption id="730490367" count="170" label="Toxic effect marker"/><FilterOption id="3242045531" count="7" label="Not determined"/></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="72699" count="39" label="atezolizumab"/><FilterOption id="3803" count="37" label="paclitaxel"/><FilterOption id="44383" count="33" label="carboplatin"/><FilterOption id="6736" count="32" label="rituximab"/><FilterOption id="3199" count="31" label="gemcitabine"/><FilterOption id="27572" count="28" label="lenalidomide"/><FilterOption id="8047" count="25" label="bevacizumab"/><FilterOption id="6386" count="22" label="trastuzumab"/><FilterOption id="15954" count="21" label="bortezomib"/><FilterOption id="2953" count="21" label="docetaxel"/><FilterOption id="70667" count="20" label="pembrolizumab"/><FilterOption id="7310" count="18" label="ritonavir"/><FilterOption id="3072" count="17" label="etoposide phosphate"/><FilterOption id="3792" count="16" label="oxaliplatin"/><FilterOption id="12205" count="15" label="capecitabine"/><FilterOption id="14681" count="15" label="lopinavir + ritonavir"/><FilterOption id="2784" count="14" label="letrozole"/><FilterOption id="54804" count="14" label="nivolumab"/><FilterOption id="28532" count="14" label="pertuzumab"/><FilterOption id="54488" count="14" label="raltegravir"/><FilterOption id="3313" count="11" label="fulvestrant"/><FilterOption id="55237" count="11" label="ibrutinib"/><FilterOption id="29016" count="11" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="83065" count="10" label="avelumab"/><FilterOption id="47000" count="10" label="bendamustine"/><FilterOption id="56544" count="10" label="cobimetinib"/><FilterOption id="11961" count="10" label="erlotinib"/><FilterOption id="5369" count="10" label="ribavirin"/><FilterOption id="37370" count="9" label="azacitidine"/><FilterOption id="32981" count="9" label="darunavir"/><FilterOption id="13022" count="9" label="epirubicin"/><FilterOption id="3081" count="9" label="exemestane"/><FilterOption id="6156" count="9" label="fludarabine"/><FilterOption id="36630" count="9" label="ipilimumab"/><FilterOption id="3474" count="9" label="lamivudine"/><FilterOption id="37613" count="9" label="maraviroc"/><FilterOption id="11519" count="9" label="mitoxantrone"/><FilterOption id="14493" count="9" label="tenofovir disoproxil fumarate"/><FilterOption id="54469" count="9" label="vemurafenib"/><FilterOption id="15254" count="8" label="atazanavir"/><FilterOption id="54601" count="8" label="carfilzomib"/><FilterOption id="4728" count="8" label="emtricitabine"/><FilterOption id="52854" count="8" label="macitentan"/><FilterOption id="10271" count="8" label="palbociclib"/><FilterOption id="45499" count="8" label="tofacitinib citrate (oral, inflammation), Pfizer"/><FilterOption id="53200" count="7" label="daratumumab"/><FilterOption id="53981" count="7" label="enzalutamide"/><FilterOption id="13340" count="7" label="everolimus"/><FilterOption id="53227" count="7" label="obinutuzumab"/><FilterOption id="16063" count="7" label="olaparib"/><FilterOption id="23625" count="7" label="peginterferon alfa-2a"/><FilterOption id="3536" count="7" label="pemetrexed disodium"/><FilterOption id="27696" count="7" label="pomalidomide"/><FilterOption id="44314" count="7" label="tamoxifen"/><FilterOption id="4529" count="7" label="temozolomide"/><FilterOption id="49219" count="7" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="36669" count="7" label="trastuzumab emtansine"/><FilterOption id="12150" count="7" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="6242" count="6" label="abacavir"/><FilterOption id="10309" count="6" label="abiraterone"/><FilterOption id="14163" count="6" label="adalimumab"/><FilterOption id="3321" count="6" label="anastrozole"/><FilterOption id="10388" count="6" label="cetuximab"/><FilterOption id="59062" count="6" label="dolutegravir"/><FilterOption id="10172" count="6" label="efavirenz"/><FilterOption id="57369" count="6" label="etrolizumab"/><FilterOption id="45841" count="6" label="lenvatinib mesylate"/><FilterOption id="50341" count="6" label="neratinib"/><FilterOption id="50963" count="6" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="69066" count="5" label="alectinib"/><FilterOption id="55305" count="5" label="binimetinib"/><FilterOption id="5999" count="5" label="ciclosporin, Novartis"/><FilterOption id="24343" count="5" label="dabigatran etexilate"/><FilterOption id="81193" count="5" label="durvalumab"/><FilterOption id="3130" count="5" label="filgrastim"/><FilterOption id="3700" count="5" label="nevirapine"/><FilterOption id="61287" count="5" label="niraparib"/><FilterOption id="43738" count="5" label="pazopanib"/><FilterOption id="12973" count="5" label="sunitinib"/><FilterOption id="30379" count="4" label="bosutinib"/><FilterOption id="2836" count="4" label="clopidogrel"/><FilterOption id="9049" count="4" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="73843" count="4" label="encorafenib"/><FilterOption id="13486" count="4" label="entecavir"/><FilterOption id="48319" count="4" label="idelalisib"/><FilterOption id="6850" count="4" label="infliximab"/><FilterOption id="66051" count="4" label="ipatasertib dihydrochloride"/><FilterOption id="2871" count="4" label="irinotecan"/><FilterOption id="16696" count="4" label="lamivudine + zidovudine, GlaxoSmithKline"/><FilterOption id="4200" count="4" label="sirolimus"/><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"/><FilterOption id="29831" count="4" label="sorafenib"/><FilterOption id="4510" count="4" label="tacrolimus"/><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"/><FilterOption id="42858" count="4" label="ustekinumab"/><FilterOption id="70678" count="4" label="xentuzumab"/><FilterOption id="72538" count="3" label="abemaciclib"/><FilterOption id="6306" count="3" label="aldesleukin"/><FilterOption id="72743" count="3" label="birtamimab"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="8713" count="26" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8489" count="23" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9213" count="22" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="7908" count="21" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9247" count="20" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7547" count="19" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8721" count="18" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9153" count="18" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="8140" count="17" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="7563" count="15" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7360" count="15" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8719" count="14" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7367" count="14" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="10830" count="14" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8714" count="13" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="9215" count="13" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="9218" count="13" label="HIV infection - Assessment of Immune Response"/><FilterOption id="7909" count="12" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7906" count="12" label="Leukemia - Assessment of Response Rates (RR)"/><FilterOption id="8744" count="11" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8720" count="11" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="2622" count="11" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="3736" count="11" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"/><FilterOption id="7879" count="11" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="8078" count="11" label="Leukemia - Assessment of adverse events"/><FilterOption id="8505" count="11" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="42921" count="11" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="7049" count="11" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8998" count="10" label="Breast tumor - Assessment of adverse events"/><FilterOption id="2492" count="10" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="8523" count="10" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="6924" count="10" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="10545" count="10" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15287" count="10" label="Solid tumor - Assessment of adverse events"/><FilterOption id="8759" count="9" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="9272" count="9" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="9212" count="9" label="HIV infection - Assessment of Viral Load"/><FilterOption id="9242" count="9" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="7891" count="9" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6940" count="9" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="6972" count="9" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7372" count="9" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="25660" count="9" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="15293" count="9" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="15907" count="9" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="11773" count="8" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8163" count="8" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6863" count="8" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="7916" count="8" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="9155" count="8" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="15285" count="8" label="Solid tumor - Assessment of Safety and Tolerability"/><FilterOption id="17356" count="7" label="Anemia - Assessment of adverse events"/><FilterOption id="9510" count="7" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"/><FilterOption id="11949" count="7" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="8754" count="7" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8996" count="7" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="9310" count="7" label="Breast tumor - Imaging/Radiological Assessments"/><FilterOption id="9238" count="7" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="9246" count="7" label="HIV infection - Assessment of Safety and Tolerability"/><FilterOption id="9255" count="7" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="8109" count="7" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="7907" count="7" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7914" count="7" label="Leukemia - Assessment of Response Rates (RR) - Assessment of cytogenetic response"/><FilterOption id="8481" count="7" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9415" count="7" label="Lymphoma - Assessment of Disease Progression"/><FilterOption id="7680" count="7" label="Lymphoma - Assessment of adverse events"/><FilterOption id="7374" count="7" label="Multiple myeloma - Assessment of Therapy Related Outcomes"/><FilterOption id="43670" count="7" label="Other gastrointestinal disease - Assessment of adverse events"/><FilterOption id="10224" count="7" label="Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of OFF state of Parkinson's disease"/><FilterOption id="7045" count="7" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="15212" count="7" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="26827" count="7" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="2332" count="6" label="Alzheimers disease - Assessment of Dementia - Clinical dementia rating sum of boxes (CDR-SOB)"/><FilterOption id="11778" count="6" label="Bladder cancer - Assessment of Mortality/Death Rates"/><FilterOption id="11786" count="6" label="Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of imaging/diagnostic tests"/><FilterOption id="2619" count="6" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="12048" count="6" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9174" count="6" label="HIV infection - Assessment of AIDS Defining Events(CDC Criteria)"/><FilterOption id="7898" count="6" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="8514" count="6" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8513" count="6" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8640" count="6" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7569" count="6" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7373" count="6" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7188" count="6" label="Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessments by radiography/imaging"/><FilterOption id="7211" count="6" label="Prostate tumor - Assessment of Mortality/Death Rates"/><FilterOption id="10664" count="6" label="Renal cell carcinoma - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="12148" count="6" label="Stomach tumor - Assessment of Overall Survival (OS)"/><FilterOption id="15936" count="6" label="Ulcerative colitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="2981" count="5" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="9504" count="5" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of ischemic stroke"/><FilterOption id="9519" count="5" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"/><FilterOption id="11793" count="5" label="Bladder cancer - Assessment of Disease Progression"/><FilterOption id="11717" count="5" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="8730" count="5" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of histo-pathologic response"/><FilterOption id="2703" count="5" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="6339" count="5" label="Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score"/><FilterOption id="8077" count="5" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="6952" count="5" label="Melanoma - Assessment of Disease Progression"/><FilterOption id="46305" count="5" label="Other gastrointestinal disease - Assessment of Liver Functions - Alkaline phosphatase levels"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="19446" count="118" label="Roche Holding AG"/><FilterOption id="1039423" count="115" label="Hospital Clinic of Barcelona"/><FilterOption id="26178" count="87" label="F Hoffmann-La Roche AG"/><FilterOption id="18767" count="80" label="Pfizer Inc"/><FilterOption id="15331" count="50" label="Celgene Corp"/><FilterOption id="1038736" count="46" label="PETHEMA Foundation"/><FilterOption id="16450" count="38" label="Gilead Sciences Inc"/><FilterOption id="14881" count="31" label="Boehringer Ingelheim International GmbH"/><FilterOption id="19453" count="29" label="Genentech Inc"/><FilterOption id="1067538" count="28" label="Janssen Research &amp; Development LLC"/><FilterOption id="1059823" count="28" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="15414" count="27" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="15065" count="20" label="Bristol-Myers Squibb Co"/><FilterOption id="1053612" count="20" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="20300" count="20" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="1017818" count="19" label="Instituto de Salud Carlos III"/><FilterOption id="14455" count="18" label="Bayer AG"/><FilterOption id="1039086" count="17" label="Germans Trias i Pujol Hospital"/><FilterOption id="1042061" count="17" label="Spanish Breast Cancer Research Group"/><FilterOption id="27847" count="16" label="Boston Scientific Corp"/><FilterOption id="17810" count="16" label="Eli Lilly &amp; Co"/><FilterOption id="1091809" count="16" label="Janssen-Cilag International NV (BE)"/><FilterOption id="14109" count="14" label="Amgen Inc"/><FilterOption id="14190" count="14" label="AstraZeneca plc"/><FilterOption id="22546" count="14" label="Boehringer Ingelheim GmbH"/><FilterOption id="23780" count="13" label="Actelion Ltd"/><FilterOption id="1017771" count="13" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="1042371" count="13" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="21991" count="13" label="Takeda Oncology"/><FilterOption id="1017513" count="12" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="28355" count="12" label="GlaxoSmithKline plc"/><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="23137" count="12" label="Novartis AG"/><FilterOption id="13601" count="11" label="Abbott Laboratories"/><FilterOption id="1013295" count="11" label="Astellas Pharma Inc"/><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."/><FilterOption id="19620" count="10" label="Eisai Inc"/><FilterOption id="1052299" count="10" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="1103352" count="9" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="1020322" count="9" label="Daiichi Sankyo Inc"/><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1051470" count="9" label="Fundacio Clinic Per A La Recerca Biomedica"/><FilterOption id="1042252" count="9" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="1003065" count="9" label="Hospital Vall D'Hebron"/><FilterOption id="28611" count="8" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="25902" count="8" label="Array BioPharma Inc"/><FilterOption id="22554" count="8" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="8" label="Boehringer Ingelheim Corp"/><FilterOption id="22563" count="8" label="Boehringer Ingelheim Ltd"/><FilterOption id="17259" count="8" label="Ipsen"/><FilterOption id="18077" count="8" label="Merck &amp; Co Inc"/><FilterOption id="18101" count="8" label="Merck KGaA"/><FilterOption id="1122528" count="8" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="25554" count="8" label="Seattle Genetics Inc"/><FilterOption id="22598" count="8" label="Unilfarma Lda"/><FilterOption id="22549" count="7" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="1040940" count="7" label="Hospital Universitari de Bellvitge"/><FilterOption id="20519" count="7" label="National Cancer Institute"/><FilterOption id="22560" count="6" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="1059977" count="6" label="European Commission"/><FilterOption id="1045910" count="6" label="Hospital Clinico San Carlos"/><FilterOption id="1072647" count="6" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"/><FilterOption id="15938" count="6" label="Millennium Pharmaceuticals Ltd"/><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="1063251" count="5" label="BeiGene Co Ltd"/><FilterOption id="1005244" count="5" label="Biogen Inc"/><FilterOption id="22555" count="5" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="22556" count="5" label="Boehringer Ingelheim France SARL"/><FilterOption id="1056497" count="5" label="CETLAM Group"/><FilterOption id="1035512" count="5" label="EMD Serono Inc"/><FilterOption id="1046331" count="5" label="Fundacion SEIMC-GESIDA"/><FilterOption id="1046875" count="5" label="Grupo Espanol de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Solidos"/><FilterOption id="1040862" count="5" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="17401" count="5" label="Janssen-Cilag SA"/><FilterOption id="1053488" count="5" label="NCIC Clinical Trials Group"/><FilterOption id="19063" count="5" label="Pharmacyclics Inc"/><FilterOption id="1067340" count="5" label="Pivotal SL"/><FilterOption id="1091820" count="5" label="Roche China Co Ltd"/><FilterOption id="1090417" count="5" label="Roche Singapore Pte Ltd"/><FilterOption id="1009547" count="5" label="Sanofi SA"/><FilterOption id="1045513" count="5" label="Spanish Lung Cancer Group"/><FilterOption id="1073757" count="5" label="Spanish Society of Cardiology"/><FilterOption id="22545" count="4" label="Boehringer Ingelheim AB"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/><FilterOption id="1042255" count="4" label="Breast International Group"/><FilterOption id="1067616" count="4" label="Clinica Universidad de Navarra"/><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"/><FilterOption id="22676" count="4" label="Exelixis Inc"/><FilterOption id="16118" count="4" label="Ferrer Internacional SA"/><FilterOption id="1073758" count="4" label="Fondo de Investigacion Sanitaria"/><FilterOption id="1079783" count="4" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"/><FilterOption id="1056260" count="4" label="Grupo Espanol de Investigacion en Cancer de Ovario"/><FilterOption id="1069025" count="4" label="Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa"/><FilterOption id="28959" count="4" label="Hannover Medical School"/><FilterOption id="1006639" count="4" label="Hospital Universitario Ramon y Cajal"/><FilterOption id="1056690" count="4" label="Institut Investigació Biomèdica Bellvitge"/><FilterOption id="17392" count="4" label="Janssen-Cilag Ltd"/><FilterOption id="1084801" count="4" label="Medica Scientia Innovation Research"/><FilterOption id="18438" count="4" label="Medical Research Council"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="36" label="2019-01-24"/><FilterOption count="24" label="2018-10-14"/><FilterOption count="24" label="2019-01-25"/><FilterOption count="24" label="2019-01-26"/><FilterOption count="23" label="2019-07-02"/><FilterOption count="22" label="2019-06-27"/><FilterOption count="21" label="2019-06-19"/><FilterOption count="20" label="2018-10-13"/><FilterOption count="20" label="2018-10-15"/><FilterOption count="20" label="2019-07-03"/><FilterOption count="19" label="2019-06-20"/><FilterOption count="18" label="2019-06-21"/><FilterOption count="17" label="2019-06-14"/><FilterOption count="16" label="2019-03-07"/><FilterOption count="16" label="2019-06-28"/><FilterOption count="15" label="2018-10-12"/><FilterOption count="15" label="2019-06-26"/><FilterOption count="15" label="2019-07-01"/><FilterOption count="14" label="2019-06-07"/><FilterOption count="13" label="2019-06-25"/><FilterOption count="12" label="2019-05-17"/><FilterOption count="12" label="2019-06-13"/><FilterOption count="10" label="2013-12-02"/><FilterOption count="10" label="2019-05-23"/><FilterOption count="9" label="2019-06-06"/><FilterOption count="9" label="2019-06-12"/><FilterOption count="8" label="2019-05-07"/><FilterOption count="8" label="2019-05-24"/><FilterOption count="8" label="2019-05-27"/><FilterOption count="8" label="2019-06-10"/><FilterOption count="8" label="2019-06-11"/><FilterOption count="8" label="2019-06-22"/><FilterOption count="8" label="2019-06-24"/><FilterOption count="7" label="2018-07-07"/><FilterOption count="7" label="2018-10-16"/><FilterOption count="7" label="2018-12-12"/><FilterOption count="7" label="2019-04-22"/><FilterOption count="6" label="2013-09-13"/><FilterOption count="6" label="2018-06-23"/><FilterOption count="6" label="2018-12-13"/><FilterOption count="6" label="2018-12-14"/><FilterOption count="6" label="2019-02-08"/><FilterOption count="6" label="2019-04-15"/><FilterOption count="6" label="2019-04-23"/><FilterOption count="5" label="2018-05-26"/><FilterOption count="5" label="2019-01-09"/><FilterOption count="5" label="2019-02-04"/><FilterOption count="5" label="2019-02-20"/><FilterOption count="5" label="2019-03-20"/><FilterOption count="5" label="2019-03-21"/><FilterOption count="5" label="2019-04-05"/><FilterOption count="5" label="2019-04-12"/><FilterOption count="5" label="2019-05-10"/><FilterOption count="5" label="2019-05-13"/><FilterOption count="5" label="2019-05-31"/><FilterOption count="5" label="2019-06-04"/><FilterOption count="5" label="2019-06-08"/><FilterOption count="5" label="2019-06-17"/><FilterOption count="4" label="2018-07-14"/><FilterOption count="4" label="2018-12-18"/><FilterOption count="4" label="2019-01-28"/><FilterOption count="4" label="2019-02-22"/><FilterOption count="4" label="2019-03-01"/><FilterOption count="4" label="2019-03-15"/><FilterOption count="4" label="2019-04-10"/><FilterOption count="4" label="2019-05-08"/><FilterOption count="4" label="2019-05-09"/><FilterOption count="4" label="2019-05-22"/><FilterOption count="4" label="2019-06-03"/><FilterOption count="4" label="2019-06-05"/><FilterOption count="4" label="2019-06-18"/><FilterOption count="4" label="2019-06-29"/><FilterOption count="3" label="2013-09-14"/><FilterOption count="3" label="2018-01-24"/><FilterOption count="3" label="2018-03-01"/><FilterOption count="3" label="2018-04-28"/><FilterOption count="3" label="2018-05-19"/><FilterOption count="3" label="2018-11-19"/><FilterOption count="3" label="2018-11-20"/><FilterOption count="3" label="2018-11-28"/><FilterOption count="3" label="2018-12-03"/><FilterOption count="3" label="2018-12-05"/><FilterOption count="3" label="2019-01-04"/><FilterOption count="3" label="2019-02-06"/><FilterOption count="3" label="2019-02-07"/><FilterOption count="3" label="2019-02-11"/><FilterOption count="3" label="2019-03-05"/><FilterOption count="3" label="2019-03-18"/><FilterOption count="3" label="2019-03-19"/><FilterOption count="3" label="2019-03-22"/><FilterOption count="3" label="2019-04-01"/><FilterOption count="3" label="2019-04-02"/><FilterOption count="3" label="2019-04-03"/><FilterOption count="3" label="2019-04-24"/><FilterOption count="3" label="2019-05-30"/><FilterOption count="3" label="2019-06-15"/><FilterOption count="2" label="2013-02-12"/><FilterOption count="2" label="2014-03-25"/><FilterOption count="2" label="2015-09-21"/><FilterOption count="2" label="2016-12-06"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="25" label="201912"/><FilterOption count="20" label="202012"/><FilterOption count="18" label="202112"/><FilterOption count="14" label="202006"/><FilterOption count="14" label="202007"/><FilterOption count="13" label="201612"/><FilterOption count="13" label="201712"/><FilterOption count="13" label="201909"/><FilterOption count="13" label="201910"/><FilterOption count="13" label="202003"/><FilterOption count="13" label="202109"/><FilterOption count="12" label="201812"/><FilterOption count="12" label="201901"/><FilterOption count="12" label="202005"/><FilterOption count="12" label="202103"/><FilterOption count="12" label="202106"/><FilterOption count="11" label="201112"/><FilterOption count="11" label="201409"/><FilterOption count="11" label="201801"/><FilterOption count="11" label="201805"/><FilterOption count="11" label="201806"/><FilterOption count="11" label="201808"/><FilterOption count="11" label="201810"/><FilterOption count="10" label="201710"/><FilterOption count="10" label="201903"/><FilterOption count="10" label="201911"/><FilterOption count="9" label="201704"/><FilterOption count="9" label="201908"/><FilterOption count="9" label="202001"/><FilterOption count="9" label="202009"/><FilterOption count="9" label="202107"/><FilterOption count="9" label="202209"/><FilterOption count="8" label="201307"/><FilterOption count="8" label="201312"/><FilterOption count="8" label="201401"/><FilterOption count="8" label="201405"/><FilterOption count="8" label="201604"/><FilterOption count="8" label="201607"/><FilterOption count="8" label="201709"/><FilterOption count="8" label="201803"/><FilterOption count="8" label="201807"/><FilterOption count="8" label="201811"/><FilterOption count="8" label="201907"/><FilterOption count="8" label="202011"/><FilterOption count="8" label="202206"/><FilterOption count="7" label="201012"/><FilterOption count="7" label="201106"/><FilterOption count="7" label="201412"/><FilterOption count="7" label="201512"/><FilterOption count="7" label="201605"/><FilterOption count="7" label="201609"/><FilterOption count="7" label="201905"/><FilterOption count="7" label="201906"/><FilterOption count="7" label="202004"/><FilterOption count="7" label="202202"/><FilterOption count="7" label="202204"/><FilterOption count="7" label="202205"/><FilterOption count="6" label="201203"/><FilterOption count="6" label="201302"/><FilterOption count="6" label="201411"/><FilterOption count="6" label="201504"/><FilterOption count="6" label="201505"/><FilterOption count="6" label="201506"/><FilterOption count="6" label="201601"/><FilterOption count="6" label="201702"/><FilterOption count="6" label="201706"/><FilterOption count="6" label="201711"/><FilterOption count="6" label="201804"/><FilterOption count="6" label="201809"/><FilterOption count="6" label="201904"/><FilterOption count="6" label="202008"/><FilterOption count="6" label="202010"/><FilterOption count="6" label="202102"/><FilterOption count="6" label="202105"/><FilterOption count="6" label="202212"/><FilterOption count="6" label="202303"/><FilterOption count="6" label="202307"/><FilterOption count="5" label="200812"/><FilterOption count="5" label="201006"/><FilterOption count="5" label="201205"/><FilterOption count="5" label="201207"/><FilterOption count="5" label="201212"/><FilterOption count="5" label="201310"/><FilterOption count="5" label="201410"/><FilterOption count="5" label="201508"/><FilterOption count="5" label="201603"/><FilterOption count="5" label="201610"/><FilterOption count="5" label="201611"/><FilterOption count="5" label="201701"/><FilterOption count="5" label="201705"/><FilterOption count="5" label="201707"/><FilterOption count="5" label="202002"/><FilterOption count="5" label="202101"/><FilterOption count="5" label="202110"/><FilterOption count="5" label="202201"/><FilterOption count="5" label="202203"/><FilterOption count="5" label="202304"/><FilterOption count="5" label="202404"/><FilterOption count="5" label="202412"/><FilterOption count="4" label="200712"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="16" label="201706"/><FilterOption count="16" label="201711"/><FilterOption count="16" label="201806"/><FilterOption count="15" label="201606"/><FilterOption count="15" label="201707"/><FilterOption count="14" label="201001"/><FilterOption count="14" label="201411"/><FilterOption count="14" label="201701"/><FilterOption count="14" label="201805"/><FilterOption count="13" label="201212"/><FilterOption count="13" label="201810"/><FilterOption count="12" label="201210"/><FilterOption count="12" label="201504"/><FilterOption count="12" label="201512"/><FilterOption count="12" label="201710"/><FilterOption count="12" label="201801"/><FilterOption count="12" label="201811"/><FilterOption count="12" label="201812"/><FilterOption count="11" label="200711"/><FilterOption count="11" label="201110"/><FilterOption count="11" label="201407"/><FilterOption count="11" label="201506"/><FilterOption count="11" label="201604"/><FilterOption count="11" label="201703"/><FilterOption count="11" label="201704"/><FilterOption count="11" label="201705"/><FilterOption count="11" label="201803"/><FilterOption count="10" label="201009"/><FilterOption count="10" label="201103"/><FilterOption count="10" label="201204"/><FilterOption count="10" label="201301"/><FilterOption count="10" label="201402"/><FilterOption count="10" label="201405"/><FilterOption count="10" label="201501"/><FilterOption count="10" label="201503"/><FilterOption count="10" label="201607"/><FilterOption count="10" label="201611"/><FilterOption count="10" label="201709"/><FilterOption count="10" label="201807"/><FilterOption count="10" label="201902"/><FilterOption count="9" label="201011"/><FilterOption count="9" label="201107"/><FilterOption count="9" label="201303"/><FilterOption count="9" label="201309"/><FilterOption count="9" label="201412"/><FilterOption count="9" label="201603"/><FilterOption count="9" label="201605"/><FilterOption count="9" label="201612"/><FilterOption count="9" label="201712"/><FilterOption count="9" label="201804"/><FilterOption count="8" label="200610"/><FilterOption count="8" label="201006"/><FilterOption count="8" label="201101"/><FilterOption count="8" label="201102"/><FilterOption count="8" label="201111"/><FilterOption count="8" label="201310"/><FilterOption count="8" label="201404"/><FilterOption count="8" label="201808"/><FilterOption count="8" label="201901"/><FilterOption count="8" label="201904"/><FilterOption count="8" label="201905"/><FilterOption count="7" label="200808"/><FilterOption count="7" label="200812"/><FilterOption count="7" label="200904"/><FilterOption count="7" label="201007"/><FilterOption count="7" label="201109"/><FilterOption count="7" label="201201"/><FilterOption count="7" label="201206"/><FilterOption count="7" label="201208"/><FilterOption count="7" label="201305"/><FilterOption count="7" label="201306"/><FilterOption count="7" label="201307"/><FilterOption count="7" label="201403"/><FilterOption count="7" label="201502"/><FilterOption count="7" label="201602"/><FilterOption count="7" label="201610"/><FilterOption count="7" label="201702"/><FilterOption count="7" label="201809"/><FilterOption count="7" label="201903"/><FilterOption count="7" label="201906"/><FilterOption count="6" label="200601"/><FilterOption count="6" label="200807"/><FilterOption count="6" label="200902"/><FilterOption count="6" label="200907"/><FilterOption count="6" label="200911"/><FilterOption count="6" label="201003"/><FilterOption count="6" label="201105"/><FilterOption count="6" label="201207"/><FilterOption count="6" label="201211"/><FilterOption count="6" label="201312"/><FilterOption count="6" label="201406"/><FilterOption count="6" label="201507"/><FilterOption count="6" label="201509"/><FilterOption count="6" label="201511"/><FilterOption count="6" label="201609"/><FilterOption count="5" label="200301"/><FilterOption count="5" label="200509"/><FilterOption count="5" label="200603"/><FilterOption count="5" label="200706"/><FilterOption count="5" label="200712"/></Filter><Filter label="Trial Phase" name="trialPhase" total="14"><FilterOption id="C3" count="422" label="Phase 3 Clinical"/><FilterOption id="C2" count="296" label="Phase 2 Clinical"/><FilterOption id="C4" count="167" label="Phase 4 Clinical"/><FilterOption id="PNA" count="114" label="Phase Not Applicable"/><FilterOption id="C12" count="58" label="Phase 1/Phase 2 Clinical"/><FilterOption id="C1" count="38" label="Phase 1 Clinical"/><FilterOption id="C2B" count="31" label="Phase 2b Clinical"/><FilterOption id="C23" count="27" label="Phase 2/Phase 3 Clinical"/><FilterOption id="C3B" count="25" label="Phase 3b Clinical"/><FilterOption id="NS" count="23" label="Phase not specified"/><FilterOption id="C2A" count="16" label="Phase 2a Clinical"/><FilterOption id="C1B" count="15" label="Phase 1b Clinical"/><FilterOption id="C0" count="4" label="Phase 0 Clinical"/><FilterOption id="C1A" count="1" label="Phase 1a Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="4879" count="67" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4880" count="67" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5418" count="56" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"/><FilterOption id="4840" count="49" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3976" count="48" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3977" count="48" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5317" count="47" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"/><FilterOption id="5086" count="46" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3537" count="46" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3538" count="46" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5087" count="45" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="22417" count="40" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="5088" count="40" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="3539" count="39" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4814" count="38" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3957" count="38" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"/><FilterOption id="3900" count="38" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="4691" count="38" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4692" count="38" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4813" count="35" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="4928" count="34" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4981" count="34" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3548" count="34" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"/><FilterOption id="5322" count="33" label="HIV infection - Subjects with Protocol Specified CD4+ T Cell Counts"/><FilterOption id="3936" count="33" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"/><FilterOption id="4808" count="32" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="5074" count="30" label="Leukemia - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="22381" count="30" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"/><FilterOption id="5073" count="29" label="Leukemia - Subjects with Normal/Acceptable Organ Function - Subjects with normal/adequate liver function"/><FilterOption id="3940" count="29" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4693" count="29" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4857" count="27" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4973" count="27" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="4817" count="26" label="Breast tumor - Postmenopausal Breast Cancer Women"/><FilterOption id="4864" count="26" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"/><FilterOption id="22405" count="26" label="Leukemia - Treatment Naive Subjects"/><FilterOption id="4024" count="26" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4169" count="26" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4170" count="26" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4628" count="26" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum M-protein"/><FilterOption id="7091" count="26" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4922" count="25" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4955" count="25" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="3447" count="25" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="3642" count="25" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4672" count="25" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological status"/><FilterOption id="4675" count="25" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4767" count="25" label="Multiple myeloma - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="32953" count="25" label="Other gastrointestinal disease - Protocol Specified Other Inclusion Criteria"/><FilterOption id="4041" count="24" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4074" count="24" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4032" count="24" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4139" count="24" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="4676" count="24" label="Multiple myeloma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4894" count="23" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="3914" count="23" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4106" count="23" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"/><FilterOption id="4162" count="23" label="Melanoma - Subjects with Diagnosis of Melanoma - Subjects with histological diagnosis of melanoma"/><FilterOption id="7465" count="22" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="22416" count="22" label="Breast tumor - Subjects with Unresectable Breast Cancer"/><FilterOption id="3622" count="22" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4756" count="22" label="Multiple myeloma - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="13096" count="22" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7441" count="21" label="Bladder cancer - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7464" count="21" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4877" count="21" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"/><FilterOption id="4957" count="21" label="Breast tumor - Subjects with Protocol Specified Reproductive Status - Subjects with adequate contraception"/><FilterOption id="4483" count="21" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4527" count="21" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4528" count="21" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5344" count="21" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"/><FilterOption id="5164" count="21" label="Leukemia - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4630" count="21" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum/urine light chain"/><FilterOption id="22418" count="20" label="Breast tumor - Subjects with Early Breast Cancer"/><FilterOption id="4809" count="20" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="4866" count="20" label="Breast tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4985" count="20" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="3448" count="20" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="4198" count="20" label="Melanoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="33170" count="19" label="Breast tumor - Protocol Specified Other Inclusion Criteria - Subjects with a cytological diagnostic and/or pathology of breast cancer"/><FilterOption id="4865" count="19" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4923" count="19" label="Breast tumor - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="7485" count="18" label="Bladder cancer - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4856" count="18" label="Breast tumor - Subjects with Measurable Disease"/><FilterOption id="4509" count="18" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"/><FilterOption id="4569" count="18" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"/><FilterOption id="5331" count="18" label="HIV infection - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable liver function tests"/><FilterOption id="3477" count="18" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with aggressive (high grade) lymphoma"/><FilterOption id="3475" count="18" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with indolent (slow-growing, low grade) lymphoma"/><FilterOption id="7445" count="17" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"/><FilterOption id="4815" count="17" label="Breast tumor - Subjects with Triple Negative Breast Cancer"/><FilterOption id="3935" count="17" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"/><FilterOption id="4208" count="17" label="Melanoma - Subjects with Feasibility for Specific Treatment Modalities - Subjects with surgically non-resectable melanoma"/><FilterOption id="3715" count="17" label="Prostate tumor - Subjects with Histologically/Cytologically Confirmed Prostate Cancer - Subjects with adenocarcinoma of prostate"/><FilterOption id="13129" count="17" label="Solid tumor - Subjects with Treatment Refractory Disease"/><FilterOption id="4564" count="16" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="5278" count="16" label="HIV infection - Subjects with HIV Infection"/><FilterOption id="5332" count="16" label="HIV infection - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable renal function tests"/><FilterOption id="5329" count="16" label="HIV infection - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3971" count="16" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="100"><FilterOption id="2953" count="7" label="docetaxel"/><FilterOption id="37370" count="6" label="azacitidine"/><FilterOption id="3313" count="6" label="fulvestrant"/><FilterOption id="3803" count="6" label="paclitaxel"/><FilterOption id="12205" count="4" label="capecitabine"/><FilterOption id="3199" count="4" label="gemcitabine"/><FilterOption id="2784" count="4" label="letrozole"/><FilterOption id="12973" count="4" label="sunitinib"/><FilterOption id="13239" count="3" label="decitabine"/><FilterOption id="53981" count="3" label="enzalutamide"/><FilterOption id="70667" count="3" label="pembrolizumab"/><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="53200" count="2" label="daratumumab"/><FilterOption id="7934" count="2" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="13928" count="2" label="enoxaparin sodium"/><FilterOption id="55237" count="2" label="ibrutinib"/><FilterOption id="6850" count="2" label="infliximab"/><FilterOption id="2871" count="2" label="irinotecan"/><FilterOption id="5267" count="2" label="leuprorelin acetate"/><FilterOption id="14681" count="2" label="lopinavir + ritonavir"/><FilterOption id="3669" count="2" label="mycophenolate mofetil"/><FilterOption id="54804" count="2" label="nivolumab"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="4529" count="2" label="temozolomide"/><FilterOption id="4577" count="2" label="topotecan"/><FilterOption id="6408" count="2" label="vinorelbine"/><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"/><FilterOption id="3321" count="1" label="anastrozole"/><FilterOption id="52967" count="1" label="apixaban"/><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"/><FilterOption id="72699" count="1" label="atezolizumab"/><FilterOption id="16905" count="1" label="atomoxetine"/><FilterOption id="11141" count="1" label="basiliximab"/><FilterOption id="8047" count="1" label="bevacizumab"/><FilterOption id="100071" count="1" label="BMS-986177"/><FilterOption id="50935" count="1" label="cabozantinib S-malate"/><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"/><FilterOption id="44388" count="1" label="carbidopa + levodopa"/><FilterOption id="44383" count="1" label="carboplatin"/><FilterOption id="95204" count="1" label="cemiplimab"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="2911" count="1" label="daptomycin"/><FilterOption id="72148" count="1" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="72153" count="1" label="darunavir + tenofovir alafenamide + emtricitabine + cobicistat (single tablet regimen, HIV-1),Janssen R&amp;D"/><FilterOption id="10172" count="1" label="efavirenz"/><FilterOption id="4728" count="1" label="emtricitabine"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="14603" count="1" label="eplerenone"/><FilterOption id="67892" count="1" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="13340" count="1" label="everolimus"/><FilterOption id="3081" count="1" label="exemestane"/><FilterOption id="44292" count="1" label="fluconazole"/><FilterOption id="8832" count="1" label="glimepiride"/><FilterOption id="8888" count="1" label="hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS"/><FilterOption id="44397" count="1" label="hylan G-F 20"/><FilterOption id="62922" count="1" label="IFX-1"/><FilterOption id="11460" count="1" label="imatinib"/><FilterOption id="10411" count="1" label="insulin aspart"/><FilterOption id="3353" count="1" label="insulin lispro"/><FilterOption id="3360" count="1" label="interferon beta-1a, Biogen"/><FilterOption id="36630" count="1" label="ipilimumab"/><FilterOption id="9819" count="1" label="lanthanum carbonate"/><FilterOption id="9443" count="1" label="levosimendan"/><FilterOption id="6050" count="1" label="metformin hydrochloride"/><FilterOption id="44303" count="1" label="midazolam hydrochloride"/><FilterOption id="10634" count="1" label="milrinone"/><FilterOption id="61287" count="1" label="niraparib"/><FilterOption id="42299" count="1" label="ofatumumab"/><FilterOption id="13460" count="1" label="oseltamivir"/><FilterOption id="8747" count="1" label="palivizumab"/><FilterOption id="67037" count="1" label="patisiran"/><FilterOption id="7871" count="1" label="pirfenidone"/><FilterOption id="22395" count="1" label="ranibizumab"/><FilterOption id="9702" count="1" label="recombinant interferon beta-1a, Merck Serono"/><FilterOption id="54624" count="1" label="regorafenib"/><FilterOption id="7310" count="1" label="ritonavir"/><FilterOption id="54662" count="1" label="ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis"/><FilterOption id="44312" count="1" label="salmeterol"/><FilterOption id="8713" count="1" label="sildenafil citrate"/><FilterOption id="44313" count="1" label="simvastatin"/><FilterOption id="44314" count="1" label="tamoxifen"/><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="50038" count="1" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"/><FilterOption id="8050" count="1" label="thalidomide, Celgene"/><FilterOption id="44315" count="1" label="timolol"/><FilterOption id="6386" count="1" label="trastuzumab"/><FilterOption id="36669" count="1" label="trastuzumab emtansine"/><FilterOption id="23239" count="1" label="ulipristal"/><FilterOption id="61574" count="1" label="umirolimus stent (BioMatrix, restenosis), Biosensors"/><FilterOption id="13338" count="1" label="ursodeoxycholic acid"/><FilterOption id="2773" count="1" label="valsartan"/><FilterOption id="44401" count="1" label="vancomycin"/><FilterOption id="54469" count="1" label="vemurafenib"/><FilterOption id="15130" count="1" label="vinflunine"/><FilterOption id="44375" count="1" label="warfarin"/></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="372" count="23" label="Thymidylate synthase inhibitor"/><FilterOption id="142" count="19" label="Topoisomerase II inhibitor"/><FilterOption id="1016" count="18" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="3756" count="17" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="5085" count="16" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="1832" count="16" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="204" count="15" label="HIV protease inhibitor"/><FilterOption id="138" count="14" label="DNA polymerase inhibitor"/><FilterOption id="768" count="12" label="HIV-1 protease inhibitor"/><FilterOption id="7424" count="10" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="3808" count="10" label="Kit tyrosine kinase inhibitor"/><FilterOption id="3846" count="10" label="VEGF-1 receptor antagonist"/><FilterOption id="3848" count="10" label="VEGF-2 receptor antagonist"/><FilterOption id="76" count="9" label="Aromatase inhibitor"/><FilterOption id="740" count="9" label="Epidermal growth factor receptor antagonist"/><FilterOption id="4917" count="9" label="Proteasome inhibitor"/><FilterOption id="3816" count="9" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="3850" count="9" label="VEGF-3 receptor antagonist"/><FilterOption id="6512" count="8" label="DNA methyltransferase inhibitor"/><FilterOption id="286" count="8" label="Estrogen receptor antagonist"/><FilterOption id="3806" count="8" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="374" count="8" label="Transferase inhibitor"/><FilterOption id="12521" count="8" label="VEGF ligand inhibitor"/><FilterOption id="76469" count="7" label="26S proteasome complex inhibitor"/><FilterOption id="135" count="7" label="DHFR inhibitor"/><FilterOption id="181" count="7" label="GAR transformylase inhibitor"/><FilterOption id="48492" count="7" label="PDGF receptor beta antagonist"/><FilterOption id="7418" count="6" label="Cytochrome P450 3 inhibitor"/><FilterOption id="82444" count="6" label="DNA helicase inhibitor"/><FilterOption id="7588" count="6" label="HIV-1 integrase inhibitor"/><FilterOption id="67136" count="6" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="141" count="6" label="Topoisomerase I inhibitor"/><FilterOption id="814" count="6" label="Tubulin modulator"/><FilterOption id="3154" count="5" label="CSF-1 antagonist"/><FilterOption id="7472" count="5" label="Cytochrome P450 17 inhibitor"/><FilterOption id="1833" count="5" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="48489" count="5" label="PDGF receptor alpha antagonist"/><FilterOption id="60" count="4" label="Androgen receptor antagonist"/><FilterOption id="7423" count="4" label="Cytochrome P450 3A4 stimulator"/><FilterOption id="6515" count="4" label="Cytosine DNA methyltransferase inhibitor"/><FilterOption id="18889" count="4" label="DNA binding protein inhibitor"/><FilterOption id="71851" count="4" label="HIV GAG POL polyprotein inhibitor"/><FilterOption id="12395" count="4" label="HIV GAG protein inhibitor"/><FilterOption id="1671" count="4" label="HIV integrase inhibitor"/><FilterOption id="10240" count="4" label="mTOR inhibitor"/><FilterOption id="2506" count="4" label="PARP modulator"/><FilterOption id="948" count="4" label="PDGF receptor antagonist"/><FilterOption id="35354" count="4" label="Prostate specific antigen modulator"/><FilterOption id="4548" count="4" label="Raf B protein kinase inhibitor"/><FilterOption id="346" count="4" label="Ribonucleotide reductase inhibitor"/><FilterOption id="78089" count="4" label="Translocation associated protein inhibitor"/><FilterOption id="1722" count="4" label="VEGF receptor antagonist"/><FilterOption id="51708" count="3" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="3" label="DNA primase inhibitor"/><FilterOption id="111" count="3" label="Factor IIa antagonist"/><FilterOption id="113" count="3" label="Factor IX antagonist"/><FilterOption id="114" count="3" label="Factor VII antagonist"/><FilterOption id="119" count="3" label="Factor X antagonist"/><FilterOption id="675" count="3" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="205" count="3" label="HMG CoA reductase inhibitor"/><FilterOption id="214" count="3" label="Interferon alpha 2 ligand"/><FilterOption id="3796" count="3" label="MET tyrosine kinase receptor family inhibitor"/><FilterOption id="76090" count="3" label="mTOR complex 1 inhibitor"/><FilterOption id="4913" count="3" label="P2Y12 purinoceptor antagonist"/><FilterOption id="14007" count="3" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="4550" count="3" label="Raf 1 protein kinase inhibitor"/><FilterOption id="381" count="3" label="TNF alpha ligand inhibitor"/><FilterOption id="721" count="3" label="TNF binding agent"/><FilterOption id="1513" count="3" label="Topoisomerase II modulator"/><FilterOption id="10583" count="3" label="Vitamin K epoxide reductase inhibitor"/><FilterOption id="18" count="2" label="ACE inhibitor"/><FilterOption id="5136" count="2" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="3851" count="2" label="ALK tyrosine kinase receptor family inhibitor"/><FilterOption id="3736" count="2" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="77" count="2" label="Aspartic protease inhibitor"/><FilterOption id="3592" count="2" label="Btk tyrosine kinase inhibitor"/><FilterOption id="5482" count="2" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="5554" count="2" label="Dopa decarboxylase inhibitor"/><FilterOption id="144" count="2" label="Dopamine receptor agonist"/><FilterOption id="48389" count="2" label="Echinoderm microtubule like protein 4 inhibitor"/><FilterOption id="1092" count="2" label="GNRH receptor agonist"/><FilterOption id="629" count="2" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="23014" count="2" label="Insulin ligand"/><FilterOption id="400" count="2" label="Insulin receptor agonist"/><FilterOption id="481" count="2" label="Interferon beta ligand"/><FilterOption id="777" count="2" label="Lanosterol-14 demethylase inhibitor"/><FilterOption id="1741" count="2" label="Low molecular weight heparin"/><FilterOption id="57003" count="2" label="Peptidoglycan recognition protein inhibitor"/><FilterOption id="15904" count="2" label="Placenta growth factor ligand inhibitor"/><FilterOption id="38283" count="2" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="38286" count="2" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="11778" count="2" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="4542" count="2" label="Raf protein kinase inhibitor"/><FilterOption id="345" count="2" label="Reverse transcriptase inhibitor"/><FilterOption id="551" count="2" label="RNA DNA polymerase inhibitor"/><FilterOption id="3826" count="2" label="Ros1 tyrosine kinase receptor inhibitor"/><FilterOption id="2422" count="2" label="Tau protein modulator"/><FilterOption id="3834" count="2" label="Tek tyrosine kinase receptor inhibitor"/><FilterOption id="58716" count="2" label="Ubiquitin inhibitor"/><FilterOption id="1689" count="2" label="VEGF-A ligand inhibitor"/></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="145" label="Diarrhea"/><FilterOption id="226" count="133" label="Nausea"/><FilterOption id="1991" count="125" label="Neutropenia"/><FilterOption id="829" count="124" label="Fatigue"/><FilterOption id="17" count="110" label="Anemia"/><FilterOption id="324" count="98" label="Thrombocytopenia"/><FilterOption id="110" count="79" label="Emesis"/><FilterOption id="148" count="65" label="Headache"/><FilterOption id="404" count="58" label="Constipation"/><FilterOption id="3038" count="53" label="Appetite loss"/><FilterOption id="3020" count="53" label="Skin rash"/><FilterOption id="1833" count="52" label="Fever"/><FilterOption id="360" count="50" label="Pneumonia"/><FilterOption id="746" count="46" label="Infectious disease"/><FilterOption id="3795" count="43" label="Febrile neutropenia"/><FilterOption id="3062" count="41" label="Death"/><FilterOption id="680" count="40" label="Leukopenia"/><FilterOption id="178" count="37" label="Hypertension"/><FilterOption id="259" count="37" label="Peripheral neuropathy"/><FilterOption id="2439" count="34" label="Arthralgia"/><FilterOption id="82" count="34" label="Cough"/><FilterOption id="402" count="30" label="Edema"/><FilterOption id="3472" count="29" label="Abdominal pain"/><FilterOption id="2400" count="29" label="Dyspnea"/><FilterOption id="516" count="29" label="Upper respiratory tract infection"/><FilterOption id="2274" count="27" label="Rhinopharyngitis"/><FilterOption id="3221" count="25" label="Back pain"/><FilterOption id="13" count="22" label="Alopecia"/><FilterOption id="181" count="22" label="Hypokalemia"/><FilterOption id="3454" count="20" label="Dizziness"/><FilterOption id="1821" count="20" label="Hyperglycemia"/><FilterOption id="279" count="20" label="Pruritus"/><FilterOption id="552" count="19" label="Bleeding"/><FilterOption id="1078" count="19" label="Lung embolism"/><FilterOption id="1039" count="19" label="Myalgia"/><FilterOption id="750" count="18" label="Insomnia"/><FilterOption id="1992" count="18" label="Lymphocytopenia"/><FilterOption id="20" count="18" label="Pain"/><FilterOption id="1009" count="17" label="Urinary tract infection"/><FilterOption id="129" count="16" label="Gastrointestinal disease"/><FilterOption id="574" count="15" label="Deep vein thrombosis"/><FilterOption id="1016" count="14" label="Stomatitis"/><FilterOption id="2576" count="13" label="Dysgeusia"/><FilterOption id="114" count="12" label="Sepsis"/><FilterOption id="50" count="11" label="Bronchitis"/><FilterOption id="3050" count="11" label="Chill"/><FilterOption id="408" count="10" label="Hypotension"/><FilterOption id="224" count="10" label="Myocardial infarction"/><FilterOption id="1072" count="9" label="Colitis"/><FilterOption id="2955" count="9" label="Weight loss"/><FilterOption id="1280" count="8" label="Hypophosphatemia"/><FilterOption id="1263" count="8" label="Mucositis"/><FilterOption id="2440" count="8" label="Musculoskeletal pain"/><FilterOption id="93" count="7" label="Depression"/><FilterOption id="182" count="7" label="Hypothyroidism"/><FilterOption id="201" count="7" label="Liver disease"/><FilterOption id="358" count="7" label="Muscle spasm"/><FilterOption id="69" count="7" label="Renal failure"/><FilterOption id="307" count="7" label="Squamous cell carcinoma"/><FilterOption id="325" count="7" label="Thromboembolism"/><FilterOption id="55" count="6" label="Cardiac failure"/><FilterOption id="1835" count="6" label="Epistaxis"/><FilterOption id="2024" count="6" label="Erythema"/><FilterOption id="154" count="6" label="Hepatitis"/><FilterOption id="2529" count="6" label="Hot flashes"/><FilterOption id="172" count="6" label="Hyperbilirubinemia"/><FilterOption id="191" count="6" label="Influenza virus infection"/><FilterOption id="678" count="6" label="Neuropathy"/><FilterOption id="2948" count="6" label="Tumor lysis syndrome"/><FilterOption id="1063" count="6" label="Xerostomia"/><FilterOption id="6832" count="5" label="Acral erythema"/><FilterOption id="2184" count="5" label="Gastrointestinal bleeding"/><FilterOption id="626" count="5" label="Heart disease"/><FilterOption id="505" count="5" label="Hypersensitivity"/><FilterOption id="277" count="5" label="Proteinuria"/><FilterOption id="286" count="5" label="Renal disease"/><FilterOption id="25" count="4" label="Anxiety disorder"/><FilterOption id="57" count="4" label="Cardiovascular disease"/><FilterOption id="2525" count="4" label="Cellulitis"/><FilterOption id="95" count="4" label="Dermatological disease"/><FilterOption id="3073" count="4" label="Drowsiness"/><FilterOption id="432" count="4" label="Dyspepsia"/><FilterOption id="1632" count="4" label="Intracranial hemorrhage"/><FilterOption id="511" count="4" label="Lower respiratory tract infection"/><FilterOption id="668" count="4" label="Muscle weakness"/><FilterOption id="509" count="4" label="Respiratory tract infection"/><FilterOption id="816" count="4" label="Septic shock"/><FilterOption id="1076" count="4" label="Thrombosis"/><FilterOption id="2434" count="4" label="Vertigo"/><FilterOption id="1731" count="3" label="Acute myelogenous leukemia"/><FilterOption id="1542" count="3" label="Atrial fibrillation"/><FilterOption id="3826" count="3" label="Bone marrow depression"/><FilterOption id="412" count="3" label="Bradycardia"/><FilterOption id="1308" count="3" label="Candida infection"/><FilterOption id="3414" count="3" label="Cerebral hemorrhage"/><FilterOption id="1559" count="3" label="Congestive heart failure"/><FilterOption id="89" count="3" label="Cytomegalovirus infection"/><FilterOption id="3063" count="3" label="Delirium"/><FilterOption id="2749" count="3" label="Hematoma"/><FilterOption id="2291" count="3" label="Hematuria"/></Filter></Filters><SearchResults><Trial Id="367216"><Indications><Indication>Vascular fistula</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2012-11-01T00:00:00Z</DateStart><Identifiers><Identifier>HOSPITAL CLINIC INVESTIGATIONAL COMMITTEE REGISTRATION: 2013/8042 (HOSPITAL CLINIC, BARCELONA, SPAIN</Identifier><Identifier>ISRCTN15802482</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Usual lifestyle alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>exercise program alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>82</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to determine whether a postoperative exercise program could really increase arteriovenous fistula (AVF) maturation at 1 month, and was to determine if exercises after AVF creation could or could not be recommended. The invsetigator hypothesized that a postoperative exercise program would increase arteriovenous fistula maturation after its surgical creation.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of vascular structure/function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Physical Examination</EndpointIndex><EndpointIndex>End stage renal disease - Clinical Assessments</EndpointIndex><EndpointIndex>End stage renal disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TitleDisplay>Effect of a postoperative exercise program on arteriovenous fistula maturation</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects Received/Scheduled for Other Therapies - Subjects received/scheduled for hemodialysis</PatientSegment><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Fontsere</Name></ContactNames></Trial><Trial Id="267627"><Indications><Indication>Acute liver failure</Indication><Indication>Chronic liver failure</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Stem cell therapy</Technology></Technologies><CompaniesCollaborator><Company>Clinica Universidad de Navarra</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-25T00:00:00Z</DateChangeLast><DateEnd>2020-02-29T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2012-003900-11</Identifier><Identifier>Liveradvance</Identifier><Identifier>NCT02857010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mesenchymal stem cell therapy (liver failure), Hospital Clinic of Barcelona/Clinica Universidad de Navarra alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this double-blind, placebo randomized, controlled trial is to investigate the effects of allogenic bone marrow derived mesenchymal stem cells (MSCs) transplantation on liver and other organ functions and systemic inflammation in patients with acute-on-chronic liver failure (ACLF). Expected results: therapy with MSCs could have beneficial effects on the evolution of patients with ACLF (modulation of inflammatory response and improvement of liver and extra-hepatic organ function) what</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Liveradvance: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure</TitleDisplay><BiomarkerNames><BiomarkerName>Ammonia </BiomarkerName><BiomarkerName> Bile acids and salts </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Hepatic venous pressure gradient </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Nitric oxide </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Javier Fernandez, MD PhD</Name><Name>Javier Fernandez, MD, PhD</Name><Name>PERE GINES, MD PhD</Name><Name>Pere Ginès, MD, PhD</Name></ContactNames></Trial><Trial Id="86451"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG protein modulator</Action><Action>HIV gp120 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action><Action>Unspecified virus based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-08-09T00:00:00Z</DateChangeLast><DateEnd>2013-05-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016578-34</Identifier><Identifier>NCT01571466</Identifier><Identifier>RISVAC03</Identifier><Identifier>RisVac 03</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA vaccine (HIV-1 infection), Esteve/IrsiCaixa Institute/Hospital Clinic Barcelona alone</Intervention><Intervention>disulfiram alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>2015 [ 1690064 ]. In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466) were presented. The aim of this pooled...doses [ 1730248 ]. In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466) were presented. The aim of this pooled... The purpose of this phase &lt;b&gt;I&lt;/b&gt;, double-blind study was to evaluate the safety and efficacy of the HIV-1 vaccine, MVA HIV-B in chronic HIV-1 infected patients successfully</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of virological response - Virological breakthrough</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RISVAC03: A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - Subjects with HIV Infection - Subjects with HIV-1 infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Bonaventur Clotet</Name><Name>Felipe Garcia</Name><Name>Josep Gatell</Name><Name>Juan Quiros</Name></ContactNames></Trial><Trial Id="176830"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG protein modulator</Action><Action>HIV gp120 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action><Action>Therapeutic vaccine</Action><Action>Unspecified virus based gene therapy</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-15T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EUDRACT: 2007-002367-27</Identifier><Identifier>NCT00679497</Identifier><Identifier>R02</Identifier><Identifier>RISVAC02</Identifier><Identifier>RisVac02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA vaccine (HIV-1 infection), Esteve/IrsiCaixa Institute/Hospital Clinic Barcelona alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466 ) were presented. The aim of this pooled analysis was to compare the safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected... In October 2016, results of a pooled analysis of two phase &lt;b&gt;I&lt;/b&gt; trials (R02; NCT00679497 and R03; NCT01571466 ) were presented. The aim of this pooled analysis was to compare the safety and immunogenicity of MVA-B in HIV-uninfected and HIV-infected</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Reactogenicity(local/systemic reactions)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of anti-body titers/antibody responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of peripheral blood mononuclear cells (PBMC)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>RisVac02: A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - HIV Seronegative Subjects</PatientSegment><PatientSegment>HIV infection - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Josep M Gatell, MD</Name></ContactNames></Trial><Trial Id="64569"><Indications><Indication>HIV infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Dendritic cell vaccine</Action><Action>Genetically engineered autologous cell vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-08-23T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>DCV-02/MANON07</Identifier><Identifier>NCT00402142</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous dendritic cell vaccine (HIV-1 infection), University of Barcelona alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Confirmed HIV infection CD4&gt; 450 x 10(6)/l Baseline VL&gt; 10,000 c/ml before any HAART Part &lt;b&gt;I&lt;/b&gt;, patients off HAART at least during 6 months Part II, patients on HAART with PVL&amp;lt; 200 copies/ml at least during 6 months Written informed consent</Teaser><TrialCategories><Category>Cell therapy</Category><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of virological response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Dendritic Cell Vaccine in HIV-1 Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV Vaccine - Subjects with HIV Infection - Subjects with HIV-1 infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>61 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Felipe García, MD, PhD</Name></ContactNames></Trial><Trial Id="247707"><Indications><Indication>Crohns disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Fundacion Clinic per a la Recerca Biomédica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2014-001083-35</Identifier><Identifier>NCT02622763</Identifier><Identifier>TOLDEC-CD-INTRA</Identifier><Identifier>TolDecCDintra</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tolerogenic dendritic cell therapy (injectable, Crohns disease), Hospital Clinic of Barcelona/Fundacio Clinic alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective is to evaluate the safety and clinical response of intralesional injection of autologous peripheral blood differentiated adult dendritic cells expanded tolerogenic ( tolerogenic dendritic cell therapy ) in patients with refractory Crohn's disease treatment.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Clinical Response - Clinical response measured by crohn's disease activity index (CDAI) score by &gt; or = 100 points</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Remission - Crohn's disease activity index (CDAI) score &lt; 150</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability - Drug related adverse event</EndpointIndex><EndpointIndex>Crohns disease - Crohn's Disease Activity Assessed by Capsule Endoscopy/Endoscopy - Crohn's disease endoscopic index of severity (CDEIS) score</EndpointIndex><EndpointIndex>Crohns disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Inflammatory Bowel Disease Questionnaire (IBDQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TolDecCDintra: Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with Active Crohns Disease</PatientSegment><PatientSegment>Crohns disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Daniel Benitez, BS (Biology) PhD</Name><Name>Elena Ricart, MD PhD</Name><Name>Elena Ricart, MD, PhD</Name><Name>Sara Varea</Name><Name>Sara Varea, BS (Biology)</Name></ContactNames></Trial><Trial Id="73490"><ActionsPrimaryInterventionsPrimary><Action>5-HT 2 receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Company><Company>Fundacion Clinic per a la Recerca Biomédica</Company><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-12T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2009-016519-40</Identifier><Identifier>APSEP</Identifier><Identifier>NCT01259973</Identifier><Identifier>TRA-065</Identifier><Identifier>TRA-065</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>haloperidol alone</Intervention><Intervention>risperidone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>h and until +24 h (depending on each scale used). Subjects would be hospitalized for 3 complete days (separated between them by 1 wash-out week after each treatment) from 8.00 h to 8.00 h of the following day at phase &lt;b&gt;I&lt;/b&gt; unit of '&lt;b&gt;Hospital&lt;/b&gt; &lt;b&gt;de&lt;/b&gt; Sant Pau &lt;b&gt;i&lt;/b&gt; &lt;b&gt;de&lt;/b&gt; la Santa Creu', in &lt;b&gt;Barcelona&lt;/b&gt;, in order to monitor the results obtained after each treatment. During their hospitalization, subjects would be given food and drink every 2-h.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Hormone Levels - Assessment of prolactin levels</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Neuropsychological Function - Assessment of attention</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of adverse events(AEs)/side effects</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of extra pyramidal symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of subjects by Barnes Akathisia Rating Scale (BARS)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of subjects by Simpson Angus Scale (SAS)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Sleep</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of aggressive symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of positive symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of psychotic symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by BPRS (Brief Psychiatric Rating Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of subjects by SANS (Schedule for Assessment of Negative Symptoms)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of ocular function</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP2D6_HUMAN_Duplication</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP3A5_HUMAN_rs776746(A)</EndpointIndex><EndpointIndex>Schizophrenia - Gene variants involved in outcome measures - CYP3A5_HUMAN_rs776746(G)</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of subjects by VAS scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>APSEP: Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - CYP2D6_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytochrome P450 2D6 </BiomarkerName><BiomarkerName> Cytochrome P450 3A5 </BiomarkerName><BiomarkerName> Prolactin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Amalia Lafuente Flo, Pharmacology professor</Name><Name>Analía Azaro, Clinical Pharmacologist</Name><Name>Eva Ferrando Martorell, Pre-doc</Name><Name>Gemma Trias Lafuente, Psychologist</Name><Name>Ignasi Carrió Gasset, Head of Nuclear Med Service</Name><Name>Miquel Bernardo Arroyo, Head of Psychiatry</Name><Name>Rosa M Antonijoan, Clinical Pharmacologist</Name><Name>Sergi Mas Herrero, Pos-doc assistant professor</Name></ContactNames></Trial><Trial Id="221060"><Indications><Indication>Schizophrenia</Indication></Indications><CompaniesCollaborator><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-09-13T00:00:00Z</DateChangeLast><DateEnd>2016-03-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02341131</Identifier><Identifier>PI 11/01958</Identifier></Identifiers><InterventionsControlDisplay><Intervention>psychoeducation alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>cognitive remediation therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to analyze the role of a neurotrophic factor (brain-derived neurotrophic factor [BDNF]) as a putative biological marker of the cognitive recovery in schizophrenia following a Cognitive Remediation Therapy (CRT). Additionally, the role as outcome predictors of BDNF serum levels and the val66met polymorphism and data from functional and structural neuroimaging would be studied.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia</EndpointIndex><EndpointIndex>Schizophrenia - Cognitive, Global and Functional Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Schizophrenia - Protocol Specified Other Endpoints - Assessment of sociodemographic outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Subjects with Neurocognitive Impairment</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - BDNF_HUMAN_rs6265(A)</PatientSegment><PatientSegment>Schizophrenia - Subjects with gene variants - BDNF_HUMAN_rs6265(G)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Brain-derived neurotrophic factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Rafael Penadés, Ph.D.</Name></ContactNames></Trial><Trial Id="295871"><Indications><Indication>Keratitis</Indication></Indications><CompaniesSponsor><Company>Banc De Sang I Teixits</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-04-07T00:00:00Z</DateEnd><DateStart>2017-02-24T00:00:00Z</DateStart><Identifiers><Identifier>2016-001841-23</Identifier><Identifier>I.2016.010</Identifier><Identifier>NCT03084861</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Air Optix Night and Day contact lens alone</Intervention><Intervention>Lubristil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cord Blood Eye Drops alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> This is a multicenter, randomized, open-label, two-arms phase &lt;b&gt;I&lt;/b&gt;/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to evaluate the safety and efficacy through corneal sensibility, corneal opacity, visual acuity</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Laboratory/Diagnostic Measures - Assessment of corneal opacity</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other ocular disease - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Other ocular disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-17T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Antonio Sabala, MD</Name><Name>Daniela Ortiz, MD</Name><Name>Dinara Samarkanova, MD</Name><Name>Javier Puig Galy, MD PHD</Name><Name>Josep Torras, MD</Name><Name>Marta Calatayud, MD</Name><Name>Miriam Barbany, MD</Name><Name>Pablo Martí, MD</Name><Name>Ruth Coll Bonet, MD</Name><Name>Sergi Querol Giner, MD PHD</Name><Name>Teresa Torrent, MD</Name><Name>Zoraida Del Campo Carrasco, MD</Name></ContactNames></Trial><Trial Id="104381"><Indications><Indication>Obesity</Indication></Indications><CompaniesCollaborator><Company>Fundacio Clinic Per A La Recerca Biomedica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-09T00:00:00Z</DateChangeLast><DateEnd>2009-05-31T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2006-000567-28</Identifier><Identifier>NCT00555074</Identifier><Identifier>TROTA-1</Identifier><Identifier>TROTA-1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sodium tungstate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>44</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this study was to compare the efficacy and safety of sodium tungstate versus placebo in patients with obesity (grade &lt;b&gt;I&lt;/b&gt; and II).</Teaser><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of body composition</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of weight loss</EndpointIndex><EndpointIndex>Obesity - Assessment of Dietary Intake - Assessment of caloric intake</EndpointIndex><EndpointIndex>Obesity - Assessment of Metabolic Parameters - Assessment of basal metabolic rate</EndpointIndex><EndpointIndex>Obesity - Assessment of adverse events</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Obesity - Hematological Assessments - Changes in hormonal parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TROTA-1: Sodium Tungstate in Obesity</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Vidal, MD</Name></ContactNames></Trial><Trial Id="373389"><Indications><Indication>Hyperalgesia</Indication></Indications><CompaniesCollaborator><Company>Fundacio Clinic Per A La Recerca Biomedica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-20T00:00:00Z</DateChangeLast><DateEnd>2019-07-15T00:00:00Z</DateEnd><DateStart>2019-04-01T00:00:00Z</DateStart><Identifiers><Identifier>2018-004378-92</Identifier><Identifier>EdomTHC</Identifier><Identifier>NCT03875261</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cannabinoid (THC/CBD 50%) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the treatment of the symptoms of deep endometriosis such as hyperalgesia with a cannabinoid derivate, cannabinoid (THC/CBD 50%).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Endometriosis - Assessment of Pain</EndpointIndex><EndpointIndex>Endometriosis - Assessment of Safety and Tolerability - Anthropometry/vital signs</EndpointIndex><EndpointIndex>Endometriosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Endometriosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Endometriosis - Patient Reported Outcomes/Quality of Life Assessments - Generic health related quality of life(EQ-5D)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>EdomTHC: Effect of Cannabinoid (THC/CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Endometriosis - Subjects with Symptomatic Disease - Women with dysmenorrhea</PatientSegment><PatientSegment>Endometriosis - Subjects with Symptomatic Disease - Women with dyspareunia</PatientSegment><PatientSegment>Endometriosis - Subjects with Symptomatic Disease - Women with pelvic pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-07-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christian Dursteler, MD</Name><Name>David Garcia Cinca</Name></ContactNames></Trial><Trial Id="348394"><Indications><Indication>Pneumonia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA gyrase inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacion Clinic per a la Recerca Biomédica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-05T00:00:00Z</DateChangeLast><DateEnd>2021-05-15T00:00:00Z</DateEnd><DateStart>2019-02-15T00:00:00Z</DateStart><Identifiers><Identifier>2017-001406-15</Identifier><Identifier>NAC-ATB</Identifier><Identifier>NCT03609099</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>moxifloxacin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>424</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>be evaluated during 5 days compared to the usual antibiotic treatment for more than 7 days in patients with community-acquired pneumonia with a Pneumonia Severity Index IV to V severity score who present an adequate response in the first 4 days of &lt;b&gt;hospital&lt;/b&gt; antibiotic treatment. Patients will receive either 400 mg/day of moxifloxacin or placebio qd po treatment during 3 days.</Teaser><TrialCategories><Category>Pathophysiology</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Response - Clinical failure</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pneumonia - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Pneumonia - Protocol Specified Other Endpoints - Antimicrobial usage</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects with Community Acquired Pneumonia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-11-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Adrian Ceccato, MD</Name><Name>Adrian Ceccato, MSD</Name><Name>David Garcia Cinca, Study Applicant</Name><Name>Inmaculada Alfageme, MD</Name><Name>Jordi Almirall, MD</Name><Name>Miquel Ferrer, MD</Name><Name>Pedro España, MD</Name><Name>Rosario Menéndez, MD</Name></ContactNames></Trial><Trial Id="328277"><Indications><Indication>Diabetic retinopathy</Indication><Indication>Insulin dependent diabetes</Indication></Indications><CompaniesCollaborator><Company>Fundació Marató de TV3</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2017-05-08T00:00:00Z</DateStart><Identifiers><Identifier>NCT03422965</Identifier><Identifier>OCTAMaratoTV3ICOF</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>optical coherence tomography angiography alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1000</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the role of optical coherence tomography angiography (OCT-A) in the evaluation of the perifoveal vascular network in type 1 diabetic patients, and to investigate the relationship between OCT-A-derived parameters and demographic and clinical factors, as metabolic control and duration of the disease.</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Non-Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of ocular function</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Clinical Assessments</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Imaging/Radiological Assessments - Assessment by optical coherence tomography (OCT)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Protocol Specified Other Endpoints - Duration of diabetes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin dependent diabetes - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Fovea centralis</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-05-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Alfredo Adan, MD PhD</Name><Name>Anibal Alé-Chilet, MD</Name><Name>Anna Sala-Puigdollers, MD</Name><Name>Cristian Oliva-Parra, OD</Name><Name>Emilio Ortega, MD PhD</Name><Name>Enric Esmatjes, MD PhD</Name><Name>Irene Vinagre, MD PhD</Name><Name>Javier Zarranz-Ventura, MD PhD FEBO</Name><Name>Jesus Gascón, OD</Name><Name>Marc Figueras-Roca, MD</Name><Name>Marina Barraso-Rodrigo, MD</Name><Name>Teresa Hernandez, OD</Name></ContactNames></Trial><Trial Id="106379"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Non-nucleoside reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Hospital Clinic of Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundació Clínic Per A La Recerca Biomèdica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2013-05-31T00:00:00Z</DateStart><Identifiers><Identifier>A-TRI-WEEK</Identifier><Identifier>A-TRI-WEEK</Identifier><Identifier>EudraCT 2012-004970-24</Identifier><Identifier>NCT01778413</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to determine the feasibility of maintaining virological suppression on standard plasma viral load (limit of detection 37 copies/ml) of a dose reduction strategy of Atripla once a day to three tablets per week in patients infected with HIV-1 with sustained suppression of plasma viral load standard for more than two years. Secondary objectives were: Virological study including: ultrasensitive viral load in plasma (limit of detection 1 copy/ml), and HIV-1 reservoir</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of T-cell apoptosis</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of Renal Function</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A-TRI-WEEK: Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz/Tenofovir/Emtricitabine</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>ADP-ribosyl cyclase 1 </BiomarkerName><BiomarkerName> Annexin A5 </BiomarkerName><BiomarkerName> Beta-2-microglobulin </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Bone mineral density </BiomarkerName><BiomarkerName> C-C chemokine receptor type 7 </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 </BiomarkerName><BiomarkerName> HLA-DR Antigens </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Mononuclear leukocytes </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> T-cell-specific surface glycoprotein CD28 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Urinary albumin to creatinine ratio </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio </BiomarkerName><BiomarkerName> Vitamin D</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>CTU</Name><Name>Esteban Martinez, MD</Name></ContactNames></Trial><Trial Id="168163"><Indications><Indication>Hepatorenal syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vasopressin V1 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Vasoconstrictor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Instituto de Salud Carlos III</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundació Clínic Per A La Recerca Biomèdica</Company><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-08T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2012-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-002166-20</Identifier><Identifier>AMELIORATE</Identifier><Identifier>AMELIORATE</Identifier><Identifier>NCT01530711</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>human albumin Grifols 20% solution plus terlipressin acetate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> The purpose of this trial is to observe the effect of terlipressin acetate on renal function in patients with hepatorenal syndrome (SHR) type &lt;b&gt;I&lt;/b&gt; adjusting the dose based on hemodynamic response. The secondary objective of this trial are: To determine the predictors of response to treatment. To evaluate the safety and adverse effects.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal failure - Assessment of Fluid Balance</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Cardiac assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Hepatic assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AMELIORATE: Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal failure - Subjects with Prerenal Causes for Acute Renal Failure(ARF) - Subjects with liver disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Aldosterone </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>56 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Fundació clínic per a la Recerca biomèdica</Name><Name>German Soriano Pastor, MD</Name><Name>Isabel Cirera Lorenzo, MD</Name><Name>Jordi Sánchez Delgado, MD</Name><Name>Juan Cordoba, MD</Name><Name>Marta Martín Llahí, MD</Name></ContactNames></Trial><Trial Id="373565"><Indications><Indication>Stroke</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Fibrinolysis stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesCollaborator><Company>Fundacion Clinic per a la Recerca Biomédica</Company><Company>Fundació Marató de TV3</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-20T00:00:00Z</DateChangeLast><DateEnd>2021-03-31T00:00:00Z</DateEnd><DateStart>2018-12-05T00:00:00Z</DateStart><Identifiers><Identifier>CHOICE</Identifier><Identifier>CHOICE</Identifier><Identifier>NCT03876119</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>alteplase alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 2b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a multicenter, randomized, placebo-controlled, double-blind, phase IIb trial of acute stroke subjects treated with mechanical thrombectomy (MT), in which two therapies are compared: alteplase (Actilyse, recombinant tissue plasminogen activator, rt-PA) or placebo. The study objective is to evaluate whether rt-PA is safe and efficient as an add-on to MT in subjects with acute ischemic stroke and complete or near-complete recanalization of a proximal vessel occlusion but partial brain</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stroke - Assessment of Cerebrovascular Events - Assessment of infarct size</EndpointIndex><EndpointIndex>Stroke - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Stroke - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Stroke - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Stroke - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Stroke - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Stroke - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Stroke - Assessment of Vascular Endothelial Function - Assessment of blood flow</EndpointIndex><EndpointIndex>Stroke - Clinical Assessments</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments - Assessment by Magnetic Resonance Imaging (MRI)</EndpointIndex><EndpointIndex>Stroke - Imaging/Radiological Assessments - Assessment by angiography</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Barthel Activities of Daily Living Index</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Modified Rankin Scale (MRS) Score</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by National Institute of Health Stroke Scale (NIHSS)</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CHOICE: Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy</TitleDisplay><PatientSegmentTerms><PatientSegment>Stroke - Post-stroke Subjects</PatientSegment><PatientSegment>Stroke - Subjects with Acute Stroke</PatientSegment><PatientSegment>Stroke - Subjects with Ischemic Stroke</PatientSegment><PatientSegment>Stroke - Subjects with history/scheduled for surgery</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Angel Chamorro</Name><Name>Angel Chamorro, MD</Name><Name>Anna Ramos, MD</Name><Name>Arturo Renú, MD</Name><Name>Elisa Cuadrado, MD</Name><Name>Joan M Fábregas, MD</Name><Name>Marian Muchada, MD</Name><Name>Marián Muchada, MD</Name><Name>Martha Vargas, PhD</Name><Name>Pere Cardona, MD</Name><Name>Pol Camps, MD</Name><Name>Sergi Amaro, MD</Name></ContactNames></Trial><Trial Id="64395"><Indications><Indication>Bipolar I disorder</Indication><Indication>Major depressive disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action><Action>Dopamine transporter inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Psychostimulant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Teva Pharmaceutical Industries Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cephalon Inc</Company></CompaniesSponsor><Countries><Country>Bulgaria</Country><Country>France</Country><Country>Poland</Country><Country>Canada</Country><Country>Serbia</Country><Country>Spain</Country><Country>Australia</Country><Country>Argentina</Country><Country>US</Country><Country>Ukraine</Country><Country>Romania</Country></Countries><DateChangeLast>2018-11-19T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-016667-11</Identifier><Identifier>C10953/3071</Identifier><Identifier>NCT01072929</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Suicidal ideation</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>armodafinil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>433</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Axis &lt;b&gt;I&lt;/b&gt; disorder apart from bipolar &lt;b&gt;I&lt;/b&gt; disorder that was the primary focus of treatment within 6 months of the screening visit or during the screening period The patient... The patient has a diagnosis of bipolar &lt;b&gt;I&lt;/b&gt; disorder according to the DSM-IV-TR criteria as determined by the SCID-CT and is currently experiencing a major depressive...years of age The patient is in good health (except for diagnosis of bipolar &lt;b&gt;I&lt;/b&gt; disorder) as judged by the investigator, on the basis of medical and psychiatric history</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Subjects with Bipolar I Disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>105</NumberOfSites><ContactNames><Name>Sponsor's Medical Expert</Name></ContactNames></Trial><Trial Id="180880"><Indications><Indication>Atrial fibrillation</Indication><Indication>Cardiac failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel inhibitor</Action><Action>Potassium channel inhibitor</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Class I antiarrhythmic agent</Action><Action>Class III antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacion Incliva</Company><Company>Fundacion Para La Investigacion Hospital La Fe</Company><Company>Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla</Company><Company>Hospital Puerta de Hierro Majadahonda</Company><Company>Hospital Universitario Ramon y Cajal</Company><Company>La Paz University Hospital (Madrid)</Company><Company>University of Navarra</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-15T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2010-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-020106-15</Identifier><Identifier>NCT01181414</Identifier><Identifier>SPARE III - 2010</Identifier><Identifier>SPAREIII</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Atrio ventricular junction ablation with radio-frequency alone</Intervention><Intervention>amiodarone alone</Intervention><Intervention>digoxine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Study consists of two arms: Arm &lt;b&gt;I&lt;/b&gt;: patients would receive atrioventricular junction ablation by using radiofrequency energy. Arm II: patients would receive beta blocker/digoxine/ amiodarone for control of ventricular rate.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Cardiac Function - Assessment of cardiac remodeling</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Ventricular Structure/Dimension/Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function - Left ventricular end-systolic volume (LVESV)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Cardiovascular intervention/surgery</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Clinical Symptoms - Assessment of arrhythmia</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Ventricular Structure/Dimension/Function</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Cardiac Function - Assessment of cardiac remodeling</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Ventricular Structure/Dimension/Function</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiac Function - Assessment of left ventricular ejection fraction (LVEF)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SPAREIII: Spanish Atrial Fibrillation And Resynchronization Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Atrial fibrillation - Subjects with Other Cardiac Rhythm Disorders - Subjects with ventricular tachycardia</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with disease related complications - Subjects with congestive heart failure as a complication</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with Chronic Atrial Fibrillation</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with Permanent Atrial Fibrillation</PatientSegment><PatientSegment>Cardiac failure - Chronic Heart Failure Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with History of Treatment - Subjects with history of device therapy</PatientSegment><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Moderate/NYHA Functional Class III Heart Failure Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Severe/NYHA Functional Class IV Heart Failure Subjects</PatientSegment><PatientSegment>Cardiac failure - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Cardiac failure - Subjects with comorbid conditions</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with Additional Risk Factor for Thromboembolic Events - Subjects with congestive heart failure</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with Ventricular Arrhythmias</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with specific disease - Subjects with chronic atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with specific disease - Subjects with permanent atrial fibrillation</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jose M Tolosana, M.D.</Name></ContactNames></Trial><Trial Id="102876"><Indications><Indication>Nephrocalcinosis</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-19T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-000298-22</Identifier><Identifier>NCT01756547</Identifier><Identifier>PRENECAL</Identifier><Identifier>PRENECAL</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>potassium citrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>74</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> Premature infants of both sexes born at the &lt;b&gt;Hospital&lt;/b&gt; Clinic of &lt;b&gt;Barcelona&lt;/b&gt; Corrected gestational age&amp;lt; 32 weeks and lower birth weight 1500 g Survivors at 7 days old Clinically stable, in the opinion of the investigator, at the time of inclusion That, properly informed, parents and / or legal guardians give </Teaser><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>PRENECAL: Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature</TitleDisplay><BiomarkerNames><BiomarkerName>Calcium </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Oxalic acid </BiomarkerName><BiomarkerName> Phosphorus </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Francisco Botet Mussons, MD</Name><Name>Judit Pich Martínez, Pharmacist</Name></ContactNames></Trial><Trial Id="301019"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2005-11-30T00:00:00Z</DateStart><Identifiers><Identifier>HCB/2016/0883</Identifier><Identifier>MUSCLE-COPD</Identifier><Identifier>NCT03169270</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Exercise training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>26</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>training. Arm 2 (healthy training group) : healthy sedentary age-matched controls would recruited from the outpatients' clinics of &lt;b&gt;hospital&lt;/b&gt;. The intervention would consist in an 8-week program of exercise training. All patients and controls would perform...of the &lt;b&gt;Hospital&lt;/b&gt; Clinic &lt;b&gt;de&lt;/b&gt; &lt;b&gt;Barcelona&lt;/b&gt; (HCB/2016/0883). The project was partly supported by the Smart Innovation Strategies promoted by the EU Commission (COMRDI15-1-0016). Specifically,</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Cardiopulmonary exercise testing parameters</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Muscular Training-induced Changes in COPD</TitleDisplay><BiomarkerNames><BiomarkerName>Maximal oxygen uptake </BiomarkerName><BiomarkerName> Oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Roca</Name></ContactNames></Trial><Trial Id="250785"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>DNA polymerase inhibitor</Action><Action>HIV GAG POL polyprotein inhibitor</Action><Action>HIV GAG protein inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Bristol-Myers Squibb Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundació Clínic Per A La Recerca Biomèdica</Company><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-12-21T00:00:00Z</DateChangeLast><DateStart>2015-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-002720-27</Identifier><Identifier>NCT02652793</Identifier><Identifier>Osteosimply014</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including atazanavir , lamivudine , ritonavir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>A 48-week, open-label, non-comparative, prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for &gt; 24 weeks (human immunodeficiency virus-1 RNA &amp;lt; 50 c/ml) switching from an antiretroviral regimen containing tenofovir and lamivudine or emtricitabine and boosted protease inhibitor to boosted atazanavir (Reyataz) and lamivudine. Study visits will take place at screening, baseline, weeks 4, 12, 24, and 48. The Main</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>HIV infection - Assessment of Markers of Bone/Cartilage/Collagen Turnover</EndpointIndex><EndpointIndex>HIV infection - Assessment of Renal Function</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response - Assessment of virological failure</EndpointIndex><EndpointIndex>HIV infection - Imaging/Radiological Assessments - Assessment by imaging/radiology</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone Resorption Markers - Serum and urinary collagen type I cross-linked N-telopeptide</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Laboratory/Diagnostic Measures - Assessments using imaging modalities</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Markers of Bone/Cartilage/Collagen Turnover - Assessment of bone specific alkaline phosphatase</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Renal Function</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Osteosimply014: Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIV Infected Adults With Osteopenia</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>Osteoporosis - Subjects at risk of developing disease - Subjects with osteopenia as a risk factor</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Acetylglucosaminidase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Beta-2-microglobulin </BiomarkerName><BiomarkerName> Bone mineral density </BiomarkerName><BiomarkerName> Collagen type I trimeric cross-linked peptide </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Phosphorus</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Garcia Cinca</Name><Name>Jaime Camacho</Name><Name>Jose Luis Blanco, MD</Name><Name>Jose Luís Blanco, MD</Name></ContactNames></Trial><Trial Id="244194"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CCR5 chemokine antagonist</Action><Action>CD4 agonist</Action><Action>Cytochrome P450 3A4 inhibitor</Action><Action>DNA polymerase inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 gp120 protein inhibitor</Action><Action>HIV-1 integrase inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>HIV fusion inhibitor</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundació Clínic Per A La Recerca Biomèdica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-06-01T00:00:00Z</DateChangeLast><DateEnd>2018-11-30T00:00:00Z</DateEnd><DateStart>2016-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2015-000251-24</Identifier><Identifier>NCT02588820</Identifier><Identifier>VIRECURE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Antiretroviral therapy alone</Intervention><Intervention>Variable regimens including abacavir , darunavir , dolutegravir , emtricitabine , lamivudine , maraviroc , ritonavir , tenofovir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Men who have sex with men Male's between18 and 65 years old A&amp;lt; 100 days of infection Patient stage Fiebig &lt;b&gt;I&lt;/b&gt; to V Negative or Incomplete western blot with negative p31 band...the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of &amp;lt; 20 days (Fiebig stages &lt;b&gt;I&lt;/b&gt; to II) compared to patients with infection of 20 to 100 days (Fiebig stages III to V), to induce HIV functional</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>VIRECURE: Impact of Extremely Early Antiretroviral Therapy to Reduce Viral Reservoir and Induce Functional cure of HIV-1 Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-Helper Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Maria Miró, MD</Name></ContactNames></Trial><Trial Id="250061"><Indications><Indication>Portal hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor Xa antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiarrhythmic agent</Action><Action>Coagulation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Institut d'Investigacions Biomediques August Pi I Sunyer</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2016-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-005523-27</Identifier><Identifier>CIRROXABAN</Identifier><Identifier>NCT02643212</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>rivaroxaban alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>160</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this double-blind, multicenter clinical trial is to determine efficacy and safety of rivaroxaban (anticoagulation free survival) in patients with liver cirrhosis, to improve hypertension decompensation portal and/or transplantation without serious side effects also analyze and develop secondary endpoint portal vein thrombosis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Hepatic Disease Activity - Hepatic encephalopathy</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Liver Functions</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Hematological Assessments - Assessment of hematocrit</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CIRROXABAN: Multicenter, Prospective, Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gastrointestinal disease - Subjects with specific disease - Nonalcoholic steatohepatitis (NASH) subjects</PatientSegment><PatientSegment>Other gastrointestinal disease - Subjects with specific disease - Subjects with Liver Cirrhosis</PatientSegment><PatientSegment>Other gastrointestinal disease - Subjects with specific disease - Subjects with Portal Hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-factor Xa antibodies </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Fatty acid-binding protein, intestinal </BiomarkerName><BiomarkerName> Hepatic venous pressure gradient </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Lipopolysaccharide binding protein </BiomarkerName><BiomarkerName> Monocyte differentiation antigen CD14</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>14</NumberOfSites><ContactNames><Name>Agustin Albillos</Name><Name>Angela Puente</Name><Name>Betty Paola Morales</Name><Name>Carles Aracil</Name><Name>Carmen Alvarez-Navascués</Name><Name>Càndid Villanueva</Name><Name>David Garcia Cinca</Name><Name>Joan Genescà</Name><Name>José Castellote</Name><Name>José Luis Calleja</Name><Name>Juan Carlos Garcia-Pagan, MD</Name><Name>Juan Carlos García Pagan, MD</Name><Name>Juan Turnes</Name><Name>Manuel Hernández-Guerra de Aguilar</Name><Name>María Berenguer</Name><Name>Rafael Bañares</Name></ContactNames></Trial><Trial Id="357075"><Indications><Indication>Autoimmune hepatitis</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-25T00:00:00Z</DateChangeLast><DateEnd>2021-04-30T00:00:00Z</DateEnd><DateStart>2018-01-10T00:00:00Z</DateStart><Identifiers><Identifier>NCT03711669</Identifier><Identifier>PI17/00955</Identifier></Identifiers><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>10% of losses, the final sample size will be 96 patients. Patients: investigators will select 96 patients diagnosed with type 1 AIH with biochemical remission of at least three years that are under immunosuppressive treatment followed in &lt;b&gt;Hospital&lt;/b&gt; Clinic &lt;b&gt;Barcelona&lt;/b&gt;. Patients with type 2 AIH will excluded because of their proved high risk of recurrence.ata collection: Demographic variables: age, sex, time from diagnosis to treatment withdrawal, laboratory information such as aminotransferases, gamma-</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Liver Functions - Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Liver Functions - Serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gastrointestinal disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-liver-kidney microsome type 1 antibodies </BiomarkerName><BiomarkerName> Anti-smooth muscle antibodies </BiomarkerName><BiomarkerName> C-X-C motif chemokine 10 </BiomarkerName><BiomarkerName> C-X-C motif chemokine 9 </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Cytotoxic T-lymphocyte protein 4 </BiomarkerName><BiomarkerName> Forkhead box protein P3 </BiomarkerName><BiomarkerName> HLA class II histocompatibility antigen gamma chain </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> Interleukin-7 receptor subunit alpha </BiomarkerName><BiomarkerName> Matrix metalloproteinase-9 </BiomarkerName><BiomarkerName> O-Phosphoseryl-tRNA(Sec) selenium transferase </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> STAT5 Transcription Factor </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Thymidine kinase, cytosolic</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Laura P Llovet, MD</Name><Name>Maria C Londoño, MD, PhD</Name><Name>Maria C Londoño, MD,PhD</Name><Name>Montserrat Garcia-Retortillo</Name></ContactNames></Trial><Trial Id="203241"><Indications><Indication>Bleeding</Indication><Indication>Esophageal varices</Indication></Indications><CompaniesCollaborator><Company>Germans Trias i Pujol Hospital</Company><Company>Hospital General Universitario Gregorio Marañon</Company><Company>Hospital Puerta de Hierro Majadahonda</Company><Company>Hospital Universitario Central de Asturias</Company><Company>Hospital Universitario Ramon y Cajal</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-02-09T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01242280</Identifier><Identifier>PE08001</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Self-expandable esophageal stent, SX-Ella-Danis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>28</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The study will include all patients with cirrhosis admitted to the &lt;b&gt;hospital&lt;/b&gt; because an acute esophageal variceal bleeding defined according to Baveno II criteria (5) and who will achieve the following criteria: Failure to control bleeding despite pharmacological (somatostatin 3 or 6 mg/12h iv or terlipressin, 2 mg/4h iv)</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding</TitleDisplay><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Angels Escorsell, MD</Name></ContactNames></Trial><Trial Id="150631"><Indications><Indication>HIV infection</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-16T00:00:00Z</DateChangeLast><DateEnd>2014-09-30T00:00:00Z</DateEnd><DateStart>2013-09-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01923610</Identifier><Identifier>RISVAC02 BOOST</Identifier><Identifier>RisVac02 boost</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MVA-B alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>collected, and receive one immunisation. They would be counselled prior to and following a HIV test, and given health education on prevention of sexually transmitted infections including HIV. T. The two centres which participate were &lt;b&gt;Hospital&lt;/b&gt; Clinic, &lt;b&gt;Barcelona&lt;/b&gt; and &lt;b&gt;Hospital&lt;/b&gt; Gregorio Maranon, Madrid.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Antibody Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV Vaccine - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of anti-body titers/antibody responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>RisVac02 boost: Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After Four Years of Receiving MVA-B</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CD8/CD4 ratio </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> T-lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Felipe Garcia, MD</Name></ContactNames></Trial><Trial Id="102519"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-13T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2008-09-30T00:00:00Z</DateStart><Identifiers><Identifier>BTB-10</Identifier><Identifier>NCT01243801</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ketamine alone</Intervention><Intervention>fentanyl plus ropivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>104</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>7 day, 3 and 6 months after surgery.The investigators would consider 30 patients per group in order to obtain three points of difference of the ratio between the hyperalgesia area and the incision length, considering a SD of differences of 3.5, type &lt;b&gt;I&lt;/b&gt; error of 0.05 and statistical power of 0.9.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Prevention of Persistent Post-surgical Pain After Thoracotomy</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>End-tidal carbon dioxide </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Mean arterial pressure </BiomarkerName><BiomarkerName> Oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Beatriz Tena, MD</Name><Name>Carmen Gomar, PhD</Name><Name>Daniel Poggio, MD</Name><Name>Guillermina Fita, PhD</Name><Name>Irene Rovira, PhD</Name><Name>Jordi Perez, PhD</Name><Name>Jose Rios</Name><Name>Maria J Jimenez, PhD</Name><Name>Samuel Garcia, MD</Name></ContactNames></Trial><Trial Id="100781"><Indications><Indication>Renal failure</Indication></Indications><CompaniesCollaborator><Company>Fondo de Investigacion Sanitaria</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-06T00:00:00Z</DateChangeLast><DateEnd>2008-10-31T00:00:00Z</DateEnd><DateStart>2004-11-30T00:00:00Z</DateStart><Identifiers><Identifier>FIS</Identifier><Identifier>FIS05/0273</Identifier><Identifier>Infecir</Identifier><Identifier>NCT00124228</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>albumin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The parameters to be investigated include: In-&lt;b&gt;hospital&lt;/b&gt; mortality. Evaluation of the treatment effects over the renal vascular territory, estimated by Doppler ultrasonography of the intrarenal arteries. Evaluation of the relationship between the...following &lt;b&gt;hospital&lt;/b&gt; protocols according to the cause of the infection. Arm 2: patients would receive antibiotics following &lt;b&gt;hospital&lt;/b&gt; protocols according to the cause of the infection plus albumin 1.5 g/kg body weight the first day</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Biomarkers - Assessment of other inflammatory/oxidative stress markers</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Disease Progression</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Intra-abdominal Infections - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Intra-abdominal Infections - Assessment of Immune Response</EndpointIndex><EndpointIndex>Intra-abdominal Infections - Assessment of Mortality/Death Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Infecir: Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects at risk of developing disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Infections/Associated Nephropathy</PatientSegment><PatientSegment>End stage renal disease - Subjects with Liver Disorder/Associated Nephropathy</PatientSegment><PatientSegment>Intra-abdominal Infections - Subjects with Peritonitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Aldosterone </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Interleukin 1 </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Natriuretic peptides A </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pere Ginès, Dr</Name></ContactNames></Trial><Trial Id="358713"><Indications><Indication>Bipolar disorder</Indication><Indication>Schizophrenia</Indication></Indications><CompaniesCollaborator><Company>CIBER (Consorcio Centro de Investigación Biomédica en Red, MP)</Company><Company>Institut d'Investigacions Biomediques August Pi I Sunyer</Company><Company>Instituto de Salud Carlos III</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2021-10-31T00:00:00Z</DateEnd><DateStart>2018-10-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03722082</Identifier><Identifier>PI/1700741</Identifier><Identifier>PI17/01066</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Enhancing Cognitive Reserve alone</Intervention><Intervention>Support intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>173</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the &lt;b&gt;hospital&lt;/b&gt; and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. Group 2: support group will schedule meetings with the participants in order to talk</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Hamilton Depression Rating Scale (HDRS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Bipolar disorder - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Schizophrenia - Clinical Assessments - Physical/anthropometric assessments</EndpointIndex><EndpointIndex>Schizophrenia - Cognitive, Global and Functional Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of mood states</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Enhancing Cognitive Reserve of the Offsprings of Bipolar and Schizophrenic Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Others - Healthy Subjects</PatientSegment><PatientSegment>Schizophrenia - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Grey matter </BiomarkerName><BiomarkerName> White matter</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carla Torrent</Name><Name>Carla Torrent, Dr</Name><Name>Elena De la Serna, Dr</Name><Name>Elena de la Serna, Dr</Name></ContactNames></Trial><Trial Id="318745"><Indications><Indication>Hematopoietic stem cell transplantation</Indication><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-09-15T00:00:00Z</DateEnd><DateStart>2012-05-12T00:00:00Z</DateStart><Identifiers><Identifier>2012-7705</Identifier><Identifier>NCT03324620</Identifier><Identifier>ovERsHOT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>functional and respiratory rehabilitation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>190</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>50% according to the studies. The patients would be treated in the &lt;b&gt;hospital&lt;/b&gt; setting in airtight rooms with HEPA filters. Patients would be collected correlatively...muscular atrophy, onset of sleep disorders, days of stay in different &lt;b&gt;hospital&lt;/b&gt; units, cost of interventions: physiotherapy, treatment of complications, and program...the patients in the intervention group at baseline, at discharge from &lt;b&gt;hospital&lt;/b&gt; for transplantation, at the month of discharge, and at 3, 6 and 12 months, in</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hematological neoplasm - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Hematological neoplasm - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hematological neoplasm - Clinical Assessments</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Anxiety by Protocol Specified Scales</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Depression Severity by Specific Criteria</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Physical Examination - Assessment of anthropometric measures</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of infections</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Sleep - Assessment by Pittsburgh Sleep Quality Index (PSQI)</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Systemic Function - Assessment of musculo-skeletal function</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of hospitalization</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of pain</EndpointIndex><EndpointIndex>Stem cell transplantation - Clinical Assessments</EndpointIndex><EndpointIndex>Stem cell transplantation - Health Economic Assessments</EndpointIndex><EndpointIndex>Stem cell transplantation - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Stem cell transplantation - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Stem cell transplantation - Patient Reported Outcomes/Quality of Life Assessments - Assessment by functional assessment of cancer therapy(FACT-BMT, FACT-G)</EndpointIndex><EndpointIndex>Stem cell transplantation - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Quality of life Measures</EndpointIndex><EndpointIndex>Stem cell transplantation - Protocol Specified Other Endpoints - Assessment of symptoms</EndpointIndex><EndpointIndex>Stem cell transplantation - Protocol Specified Other Endpoints - Assessment of use of other medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ovERsHOT: Effectiveness Rehabilitation Hematopoietic Transplantation (ovERsHOT)</TitleDisplay><PatientSegmentTerms><PatientSegment>Hematological neoplasm - Subjects with specific disease</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Allogenic Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Lean body mass </BiomarkerName><BiomarkerName> Muscle </BiomarkerName><BiomarkerName> Muscle strength </BiomarkerName><BiomarkerName> Six-minute walk distance </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-05-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>64 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Yolanda Torralba García, RN</Name></ContactNames></Trial><Trial Id="357391"><Indications><Indication>Hypoglycemia</Indication></Indications><CompaniesCollaborator><Company>Universitat de Girona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-26T00:00:00Z</DateChangeLast><DateEnd>2019-04-30T00:00:00Z</DateEnd><DateStart>2018-10-10T00:00:00Z</DateStart><Identifiers><Identifier>NCT03711656</Identifier><Identifier>NOCTURNAL HYPOGLYCEMIA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>insulin alone</Intervention><Intervention>intermittently scanned continuous glucose monitoring (isCGM) alone</Intervention><Intervention>physical exercise tracking alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The objective is to develop a novel system to predict and prevent nocturnal hypoglycemia in type 1 diabetic (T1D) patients, focused in patients with multiple daily injections (MDI) therapy. The general idea is to make use of previous-day information in the moment when patients go to sleep, and then predict if in the next following hours any hypoglycemic event will occur. If the system will have predicted any hypoglycemic event in that moment, it is expected that it will be able to warn the patient</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of continuous glucose monitoring system (CGMS)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of high blood glucose index (HBGI) score</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of low blood glucose index (LBGI) score</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Change in mean glucose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Hypoglycemic Episodes</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Mean and standard deviation blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin dependent diabetes - Subjects on Treatment of Insulin - Subjects on basal-bolus insulin regimen</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects on Treatment of Insulin - Subjects on multiple daily injections (MDI) therapy</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with History of Hypoglycemia - Subjects with reduced awareness/unawareness of hypoglycemia</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Specified Duration of Disease - Subjects with more than 5 years of diabetes mellitus</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Arthur Bertachi, Msc</Name><Name>Clara Viñals Domenech</Name><Name>Clara Viñals Domenech, MD</Name><Name>Clara Viñals, MD</Name><Name>Ignacio Conget Donlo, MD</Name><Name>Ignacio Conget Donlo, MD, PhD</Name><Name>Ignacio Conget, MD, PhD</Name><Name>Josep Vehí, PhD</Name><Name>Marga Giménez Álvarez, MD, PhD</Name></ContactNames></Trial><Trial Id="65945"><Indications><Indication>Cardiac failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ACE inhibitor</Action><Action>Alpha adrenoceptor antagonist</Action><Action>Beta adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Antioxidant agent</Action><Action>Cardiac agent</Action><Action>Class II antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Instituto de Salud Carlos III</Company><Company>The European Union</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-07-03T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2008-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2007-006604-38</Identifier><Identifier>FIS EC07/90211</Identifier><Identifier>NCT01110824</Identifier><Identifier>OVERCOME</Identifier><Identifier>OVERCOME</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>carvedilol plus enalapril</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>failure Need to be treated with ACEI, ARBs or beta-blockers Prior allergy to ACEI or ARBs Blood systolic pressure&amp;lt; 90 mmHg Asthma AV block or sinus bradycardia (HR&amp;lt; 50 beats per min [bpm]) Persistent atrial fibrillation Need to be treated with class &lt;b&gt;I&lt;/b&gt; antiarrhythmic drugs Pregnancy Inability or unwillingness to give unformed consent</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of cardiac toxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Imaging/Radiological Assessments - Assessment by Magnetic Resonance Imaging (MRI)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Function - Assessment of left ventricular ejection fraction (LVEF)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Markers - Cardiac isoform of TnI (cTnI)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiac Markers - Plasma B-type natriuretic peptide (BNP)</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Assessment of left ventricular dysfunction</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Cardiovascular Events - Heart failure symptoms / Clinical signs of heart failure</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Ventricular Structure/Dimension/Function</EndpointIndex><EndpointIndex>Cardiac failure - Protocol Specified Other Endpoints - Pharmacogenomic/Pharmacogenetic Study</EndpointIndex><EndpointIndex>Leukemia - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures - Echo-doppler assessment</EndpointIndex><EndpointIndex>Leukemia - Assessment of Markers of Tumor Growth and Progression - Assessment of prognostic markers</EndpointIndex><EndpointIndex>Leukemia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Leukemia - Assessment of enzyme levels</EndpointIndex><EndpointIndex>Leukemia - Pharmacogenetic/Pharmacogenomics Analysis - Assessment of genetic polymorphisms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>OVERCOME: Prevention of Ventricular Dysfunction During Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Leukemia - Subjects with Acute Leukemia Unspecified Type</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Bone Marrow Transplantation(BMT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Troponin I, cardiac muscle</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Xavier Bosch, M.D., PhD.</Name></ContactNames></Trial><Trial Id="318532"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV-1 integrase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundació Clínic Per A La Recerca Biomèdica</Company><Company>Merck &amp; Co Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2020-03-30T00:00:00Z</DateEnd><DateStart>2018-05-03T00:00:00Z</DateStart><Identifiers><Identifier>2017-000985-31</Identifier><Identifier>NCT03333083</Identifier><Identifier>RALAM-II</Identifier><Identifier>RALAM-II</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lamivudine plus raltegravir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a phase IIIb, single-arm, simplification study with dual therapy including lamivudine (300 mg, qd) plus raltegravir (1200 mg, qd) in virologically suppressed HIV-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current regimen. Main objective of the trial: Efficacy assessed with standard plasma HIV-1 RNA detection (limit of detection 5037 copies/ml) at 48 weeks. Secondary objectives of the trial: Change</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Biomarkers</EndpointIndex><EndpointIndex>HIV infection - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures - Assessment of insulin resistance/sensitivity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Morbidity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of cardiovascular toxicity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex><EndpointIndex>HIV infection - Assessment of body fat distribution</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response - Assessment of virological failure</EndpointIndex><EndpointIndex>HIV infection - Clinical Assessments</EndpointIndex><EndpointIndex>HIV infection - Imaging/Radiological Assessments - Assessment by imaging/radiology</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>HIV infection - Protocol Specified Other Endpoints - Assessment of changes in antiretroviral treatment</EndpointIndex><EndpointIndex>HIV infection - Protocol Specified Other Endpoints - Assessment of treatment success/failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RALAM-II: Study With Dual Therapy Including Lamivudine (300 mg, qd) Plus Raltegravir (1200 mg, qd) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>ADP-ribosyl cyclase 1 </BiomarkerName><BiomarkerName> Body fat percentage </BiomarkerName><BiomarkerName> Bone mineral density </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> HLA-DR Antigens </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin resistance </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-03-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Esteban Martinez, MD</Name><Name>Esteban Martínez, MD</Name></ContactNames></Trial><Trial Id="268920"><Indications><Indication>Renal insufficiency</Indication></Indications><CompaniesCollaborator><Company>Fundacion Clinic per a la Recerca Biomédica</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-09-09T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2016-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2016-002032-33</Identifier><Identifier>NCT02872155</Identifier><Identifier>NICIR</Identifier><Identifier>NICIR</Identifier></Identifiers><InterventionsControlDisplay><Intervention>sodium bicarbonate alone</Intervention><Intervention>sodium chloride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>oral hydratation (water) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>264</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate if oral hydratation is as effective as endovenous hydratation in the prophylaxis of contrast-induced nephropathy in patients renal insufficiency grade III under study conducting contrasted computed tomography. Main objective of the trial is to check if oral hydration is at least as effective as intravenous hydration in reducing the appearance of contrast-induced nephropathy after performing a computed tomography with intravenous contrast in patients with renal</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal failure - Assessment of Acute Renal Failure - Assessment of contrast induced nephropathy(CIN)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex><EndpointIndex>Renal failure - Assessment of dialysis</EndpointIndex><EndpointIndex>Renal failure - Protocol Specified Other Endpoints - Imaging assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>NICIR: Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephropathy (CIN) in Patients With Renal Insufficiency (RI) Grade III Under Study Conducting Computed Tomography (CT)</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal failure - Subjects with Intrarenal Causes for Acute Renal Failure(ARF) - Subjects with contrast induced nephropathy(CIN)/exposed to contrast agent</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Garcia Cinca, Bch</Name><Name>Maria Carmen Sebastià, PhD</Name></ContactNames></Trial><Trial Id="315092"><Indications><Indication>Interstitial cystitis</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company><Company>Universitat de Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-10-09T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>triamcinolone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Patients with bladder pain syndrome (BPS) with Hunner's ulcers (HU) Patients treated at the &lt;b&gt;Hospital&lt;/b&gt; Clinic of &lt;b&gt;Barcelona&lt;/b&gt;</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Retrospective</Term></TermsDesign><TitleDisplay>A Retrospective Study to Assess Pain Relief after Triamcinolone Injection in Patients with Bladder pain syndrome (BPS) with Hunner's ulcers (HU)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="345298"><Indications><Indication>Insulin dependent diabetes</Indication></Indications><CompaniesCollaborator><Company>UNIVERSIDAD POLITECNICA DE VALENCIA</Company><Company>Universitat de Girona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-05-31T00:00:00Z</DateEnd><DateStart>2018-06-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03577158</Identifier><Identifier>SAFE-AP3</Identifier><Identifier>SAFE-AP3</Identifier></Identifiers><InterventionsControlDisplay><Intervention>commercial insulin infusion systems alone</Intervention><Intervention>insulin alone</Intervention><Intervention>open-loop insulin infusion system alone</Intervention><Intervention>subcutaneous continuous glucose monitoring device alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>commercial insulin infusion systems alone</Intervention><Intervention>cycloergometer alone</Intervention><Intervention>exercise alone</Intervention><Intervention>insulin alone</Intervention><Intervention>novel closed-loop controller alone</Intervention><Intervention>subcutaneous continuous glucose monitoring device alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>In this project, a rigorous clinical testing of a novel closed-loop controller ('artificial pancreas') will be carried out in type 1 diabetes (T1D) patients treated with continuous subcutaneous insulin infusion (CSII). The hypothesis is that closed loop control will provide better glycemic control, with less hypoglycemia episodes.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of continuous glucose monitoring system (CGMS)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Hypoglycemic Episodes</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Area under concentration curve (AUC)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>SAFE-AP3: Automatic Control of Blood Glucose Under Announced and Unannounced Exercise</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin dependent diabetes - Subjects on Treatment of Insulin - Subjects on continuous subcutaneous insulin Infusion (CSII) therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Clara Viñals Domenech, MD</Name><Name>Ignacio Conget Donlo, MD</Name><Name>Jorge Bondia, PhD</Name><Name>Josep Vehi, PhD</Name><Name>Marga Gimenez Alvarez, MD</Name><Name>Marga Giménez Álvarez, MD</Name></ContactNames></Trial><Trial Id="316264"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV-1 integrase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundació Clínic Per A La Recerca Biomèdica</Company><Company>Merck &amp; Co Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2020-03-30T00:00:00Z</DateEnd><DateStart>2018-05-03T00:00:00Z</DateStart><Identifiers><Identifier>2017-000986-60</Identifier><Identifier>NCT03311945</Identifier><Identifier>RALAM-Roll-Over</Identifier><Identifier>RALAM-RollOver</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>raltegravir + lamivudine (HIV infection), Merck &amp; Co alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>49</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is a phase IIIb, single-arm, single-site simplification study of HIV-1 infected patients with virological suppression under the combination of lamivudine (150 mg bid) plus raltegravir (400 mg bid) ( Dutrebis ) switching to lamivudine (300 mg qd) plus raltegravir (1200 mg qd): Roll-over study of the RALAM clinical trial ( NCT02284035 ). Main objective of the trial: Efficacy assessed with standard plasma HIV-1 RNA detection (limit of detection 50 copies/ml) at 48 weeks. Secondary objectives of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Biomarkers</EndpointIndex><EndpointIndex>HIV infection - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of peripheral blood mononuclear cells (PBMC)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of cytokines</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures - Assessment of insulin resistance/sensitivity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>HIV infection - Assessment of Renal Function</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response - Assessment of virological failure</EndpointIndex><EndpointIndex>HIV infection - Glycemic Control Analysis</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>HIV infection - Protocol Specified Other Endpoints - Assessment of changes in antiretroviral treatment</EndpointIndex><EndpointIndex>HIV infection - Protocol Specified Other Endpoints - Assessment of treatment success/failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RALAM-RollOver: Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg bid) Plus Raltegravir (400 mg bid) Switching to Lamivudine (300 mg qd) Plus Raltegravir (1200 mg qd)</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Beta-2-microglobulin </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Calcifediol </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Femoral neck bone mineral density </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin resistance </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Lumbar spine bone mineral density </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-03-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Esteban Martinez, MD</Name><Name>Esteban Martínez, MD</Name></ContactNames></Trial><Trial Id="68423"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Sociedad Andaluza de Enfermedades Infecciosas</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01166477</Identifier><Identifier>QoLKAMON</Identifier><Identifier>SAI-CDV-2009-01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lopinavir + ritonavir alone</Intervention><Intervention>ritonavir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>228</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study would help to compare the quality of life for those HIV patients that were on monotherapy with Kaletra (lopinavir 200 mg/ritonavir 50 mg) versus triple therapy with a boosted protease inhibitor.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - Medication adherence questionnaires</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>QoLKAMON: Clinical Trial, Open-Label, Randomized, in Order to Compare the Quality of Life for Those HIV+ Patients That Start With Monotherapy on LPV/r Tablets Versus Triple Therapy With a Boosted Protease Inhibitor</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>30</NumberOfSites><ContactNames><Name>Carmen Farinas</Name><Name>Carmen Galvez</Name><Name>Isabel Garcia</Name><Name>Jose Cuadrado</Name><Name>Jose Giron</Name><Name>Jose Hernandez</Name><Name>Juan Flores</Name><Name>Juan Pasquau</Name><Name>Kodo Aguirrebengoa</Name><Name>Manuel Milla</Name><Name>Naiara Carretero</Name></ContactNames></Trial><Trial Id="211417"><Indications><Indication>Acute coronary syndrome</Indication></Indications><CompaniesCollaborator><Company>Instituto de Salud Carlos III</Company><Company>Ministerio de Economia y Competitividad</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-23T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01682096</Identifier><Identifier>PI09/90513</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Computed coronary angiography alone</Intervention><Intervention>Exercise stress echocardiography alone</Intervention><Intervention>Somatom Sensation 64 or128-Flash Definition (Siemens) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Estimated pre-test probability of significant coronary artery disease &gt; 15% Absence of ECG changes suggestive of myocardial ischemia (ST-segment deviation&gt; 1 mm or T Wave inversion &gt; 4 mm in at least two contiguous leads) Negative initial troponins &lt;b&gt;I&lt;/b&gt; at admission (&amp;lt; 0.05 ng/ml)</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Acute coronary syndrome</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Major adverse cardiovascular events (MACE)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - New /Acute myocardial infarction</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Reperfusion/Revascularization - Time from arrival to the reperfusion</EndpointIndex><EndpointIndex>Acute coronary syndrome - Health Economic Assessments - Cost of therapy/other medical costs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pilot Safety Study of Coronary CTA for the Diagnosis of Acute Coronary Syndrome in the Emergency Room</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Subjects at risk of developing disease</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Abnormal Echo/ECG findings - ST segment changes (elevation /depression)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Abnormal Echo/ECG findings - T wave abnormalities</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carlos Pare</Name><Name>José T Ortiz-Perez, MD, PhD</Name><Name>Marta Sitges</Name><Name>Monica Masotti</Name><Name>Rosario Perea</Name><Name>Teresa Caralt</Name><Name>Xavier Bosch</Name></ContactNames></Trial><Trial Id="326319"><Indications><Indication>Obesity</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2018-01-28T00:00:00Z</DateStart><Identifiers><Identifier>HCB/2017/0730</Identifier><Identifier>NCT03395067</Identifier><Identifier>PRO-FIV</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Lifestyle counseling alone</Intervention><Intervention>Psychotherapeutical intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>104</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Pathological conditions: diabetes type &lt;b&gt;I&lt;/b&gt;, Cushing syndrome, premature ovarian failure, uncontrolled thyroidal dysfunction, hepatic and/or renal dysfunction, antiphospholipid syndrome, medical condition that contraindicate ovarian stimulation and/or pregnancy Simultaneous practice of another</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Cycle Cancellation Rate</EndpointIndex><EndpointIndex>Infertility - Assessment of Embryo - Assessment of number of embryos transferred</EndpointIndex><EndpointIndex>Infertility - Assessment of Fertility Outcomes - Assessment of embryo quality</EndpointIndex><EndpointIndex>Infertility - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Infertility - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Infertility - Assessment of Oocytes</EndpointIndex><EndpointIndex>Infertility - Assessment of Perinatal/Neonatal Outcomes</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy - Assessment of live birth</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy - Assessment of pregnancy loss</EndpointIndex><EndpointIndex>Infertility - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Infertility - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Infertility - Uterine Assessments</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of Body Weight</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of waist circumference</EndpointIndex><EndpointIndex>Obesity - Assessment of Cardiovascular Events - Hypertension analysis</EndpointIndex><EndpointIndex>Obesity - Assessment of Cardiovascular Risk Factors</EndpointIndex><EndpointIndex>Obesity - Assessment of Co-morbidity - Development of gestational diabetes</EndpointIndex><EndpointIndex>Obesity - Assessment of Fertility Outcomes</EndpointIndex><EndpointIndex>Obesity - Assessment of Fertility Outcomes - Assessment of live birth rate</EndpointIndex><EndpointIndex>Obesity - Assessment of Hormone Levels - Assessment of ghrelin levels</EndpointIndex><EndpointIndex>Obesity - Assessment of Hormone Levels - Assessment of leptin</EndpointIndex><EndpointIndex>Obesity - Assessment of Inflammatory &amp; Oxidative Stress Markers - Adiponectin</EndpointIndex><EndpointIndex>Obesity - Assessment of Insulin Levels</EndpointIndex><EndpointIndex>Obesity - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Obesity - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Obesity - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Obesity - Assessment of Physical Examination - Assessment of growth</EndpointIndex><EndpointIndex>Obesity - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Obesity - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Obesity - Assessment of complications - Assessment of pregnancy complications</EndpointIndex><EndpointIndex>Obesity - Assessment of neonatal outcomes</EndpointIndex><EndpointIndex>Obesity - Clinical Assessments</EndpointIndex><EndpointIndex>Obesity - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Obesity - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>PRO-FIV: Multidisciplinary Treatment of Obesity Prior to in Vitro Fertilization: Impact on Global Reproductive Outcomes</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Histroy of Infertility - Women with infertility</PatientSegment><PatientSegment>Obesity - Morbid Obesity(Class III) Subjects</PatientSegment><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adiponectin </BiomarkerName><BiomarkerName> Appetite regulating hormone </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Leptin </BiomarkerName><BiomarkerName> Muellerian-inhibiting factor </BiomarkerName><BiomarkerName> Oocytes </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gemma Casals</Name></ContactNames></Trial><Trial Id="96522"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS3 protease inhibitor</Action><Action>Hepatitis C virus protease inhibitor</Action><Action>Hepatitis C virus protein NS4B inhibitor</Action><Action>Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Hepatitis C virus replication inhibitor</Action><Action>RNA synthesis inhibitor</Action><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Prodrug</Technology><Technology>Protein conjugation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Fundació Clínic Per A La Recerca Biomèdica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-21T00:00:00Z</DateChangeLast><DateEnd>2015-06-30T00:00:00Z</DateEnd><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-003984-23</Identifier><Identifier>BOC-HIV</Identifier><Identifier>NCT01718301</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including boceprevir , peginterferon alfa-2a , peginterferon alfa-2b , ribavirin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>128</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed (tid po) in combination with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in HIV/HCV genotype 1 infected patients that failed to previous HCV therapy.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Markers of Co-infection - Assessment of HCV RNA levels</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Analysis of Hepatitis C Virus Variants - Emergence of resistant/mutant variants</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Treatment-emergent adverse events</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon/Ribavirin</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy</PatientSegment><PatientSegment>HIV infection - Subjects with comorbid conditions - Subjects with opportunistic/other infections</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with HIV infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with cirrhosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>CTU Clinic</Name><Name>Josep Mallolas, MD</Name></ContactNames></Trial><Trial Id="240262"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-09-21T00:00:00Z</DateChangeLast><DateEnd>2015-11-30T00:00:00Z</DateEnd><DateStart>2015-10-31T00:00:00Z</DateStart><Identifiers><Identifier>INDAEPOC</Identifier><Identifier>NCT02547558</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>indacaterol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>previously described. Cardiac output will be directly measured by bio-impedance. Spirometry values will be recorded from the history records of each patient. All measurements will be performed in the Center &lt;b&gt;de&lt;/b&gt; Diagnostic Respiratori (CDR), Servei &lt;b&gt;de&lt;/b&gt; Pneumologia, Institut del Torax, &lt;b&gt;Hospital&lt;/b&gt; Clinic, &lt;b&gt;Barcelona&lt;/b&gt;. The primary outcome will be the PaO2 change after indacaterol at each analysis time. Based on a previous study in stable severe COPD patients using nebulized salbutamol during convalescence of exacerbation</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of partial pressure of O2(PaO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Carbon dioxide elimination (VCO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Nocturnal oxygen saturation (SaO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Partial pressure of carbon dioxide (PaCO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - pH analysis</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Assessment of peak oxygen consumption (VO2 max)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Vital Signs - Blood pressure assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pulmonary Gas Exchange Response to Indacaterol in COPD</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 1/Mild COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alveolar-arterial oxygen gradient </BiomarkerName><BiomarkerName> Arterial oxygen saturation </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Carbon dioxide output </BiomarkerName><BiomarkerName> Cardiac Output </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Maximal oxygen uptake </BiomarkerName><BiomarkerName> Partial pressure of carbon dioxide </BiomarkerName><BiomarkerName> Partial pressure of oxygen </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Isabel Blanco, MD, PhD</Name></ContactNames></Trial><Trial Id="146002"><Indications><Indication>Ischemic stroke</Indication></Indications><CompaniesCollaborator><Company>Instituto de Salud Carlos III</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-08-24T00:00:00Z</DateChangeLast><DateEnd>2013-05-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01894529</Identifier><Identifier>PI09/1313</Identifier></Identifiers><PatientCountEnrollment>132</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this prospective study was to validate in acute stroke patients the prognostic usefulness of a panel of immune biomarkers that have previously been associated with various clinical outcomes.</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Stroke - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Stroke - Assessment of Cerebrovascular Events - Assessment of infarct lesion volume</EndpointIndex><EndpointIndex>Stroke - Assessment of Immune Function</EndpointIndex><EndpointIndex>Stroke - Assessment of Other Functional outcomes</EndpointIndex><EndpointIndex>Stroke - Disease Severity Assessment by Other Scales</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Modified Rankin Scale (MRS) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Immunological Biomarkers in Patients With Acute Ischemic Stroke</TitleDisplay><PatientSegmentTerms><PatientSegment>Stroke - Post-stroke Subjects</PatientSegment><PatientSegment>Stroke - Subjects with History of Treatment</PatientSegment><PatientSegment>Stroke - Subjects with Ischemic Stroke</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HLA-DR Antigens </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> T-lymphocyte activation antigen CD86 </BiomarkerName><BiomarkerName> Toll-like receptor 4 </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>40 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Angel Chamorro, MD, PhD</Name></ContactNames></Trial><Trial Id="189364"><Indications><Indication>Vitamin D deficiency</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-01-19T00:00:00Z</DateChangeLast><DateStart>2012-05-01T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2011-006163-22</Identifier><Identifier>NCT01637155</Identifier><Identifier>PK-VIT-D</Identifier><Identifier>PK-VIT-D</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cholecalciferol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>44</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the pharmacokinetics of vitamin D (cholecalciferol) in patients undergoing obesity surgery in a deficit situation and after standardization.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Obesity - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Area under concentration curve (AUC)</EndpointIndex><EndpointIndex>Obesity - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum concentration of drug (Cmax)</EndpointIndex><EndpointIndex>Obesity - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of t½ (terminal half-life)</EndpointIndex><EndpointIndex>Obesity - Assessment of Renal Function - Assessment of creatinine</EndpointIndex><EndpointIndex>Obesity - Assessment of Urinary Metabolomic Profile - Urinary calcium and sodium excretion</EndpointIndex><EndpointIndex>Obesity - Assessment of adverse events</EndpointIndex><EndpointIndex>Obesity - Assessment of fat</EndpointIndex><EndpointIndex>Obesity - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PK-VIT-D: Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment><PatientSegment>Obesity - Subjects Scheduled for Bariatric Surgery</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Body fat percentage </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Phosphorus </BiomarkerName><BiomarkerName> Total protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Violeta Moize, MD</Name></ContactNames></Trial><Trial Id="176525"><Indications><Indication>Joint disease</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-15T00:00:00Z</DateChangeLast><DateEnd>2013-04-30T00:00:00Z</DateEnd><DateStart>2011-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01233739</Identifier><Identifier>RIZACONDRO</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>chondroitin sulfate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this trial is to study the efficacy and safety of chondroitin sulfate compared to placebo in patients with rhizarthrosis along with objective and subjective indicators of pain and sensibility.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Laboratory/Diagnostic Measures - Assessment of blood biochemistry</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Osteoarthritis - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Knee injury and Osteoarthritis Outcome Score (KOOS)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Musculoskeletal Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain During Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of hematological function</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects with Symptomatic Disease - Subjects with pain&amp; stiffness</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2013-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Joaquim Forés, MD</Name><Name>Joaquím Forés, MD</Name><Name>Judit Pich, Pharmacist</Name></ContactNames></Trial><Trial Id="207016"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>Parc de Salut Mar</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2018-03-31T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2012/4025</Identifier><Identifier>NCT01871025</Identifier><Identifier>TIME</Identifier></Identifiers><InterventionsControlDisplay><Intervention>respiratory physiotherapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Hospital and home exercise training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This trial was to study the effects of early exercise training in hospitalized subjects for chronic obstructive pulmonary disease (COPD).</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough - Assessment of cough intensity/frequency</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - COPD Assessment Test(CAT)Score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Shortness of breath questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TIME: Early Incentive and Mobilization During COPD Exacerbation</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Almudena Garcia</Name><Name>Daniel Fernandez</Name><Name>Diego Rodriguez, MD</Name><Name>Esther Marco, MD</Name><Name>Juan Galdiz</Name><Name>Maria Cejudo</Name><Name>Teodoro Montemayor</Name></ContactNames></Trial><Trial Id="207863"><Indications><Indication>Vascular occlusive disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>P2Y12 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>AstraZeneca plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-14T00:00:00Z</DateChangeLast><DateEnd>2019-11-30T00:00:00Z</DateEnd><DateStart>2014-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2013-002675-17</Identifier><Identifier>NCT02211066</Identifier><Identifier>TIGER-BVS</Identifier><Identifier>TIGER-BVS</Identifier></Identifiers><InterventionsControlDisplay><Intervention>clopidogrel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ABSORB BVS alone</Intervention><Intervention>ticagrelor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The study was a single-center, randomized, active-controlled, open-label clinical trial. The primary hypothesis was that ticagrelor will show superiority over clopidogrel immediately after CTO-PCI (chronic total occlusion - percutaneous coronary intervention). The hypothesis would be tested in the first randomization. Both antiplatelet therapy would be used in both arms at the approved doses and for the approved duration therapy of one year. The secondary hypothesis would test the role of ticagrelor</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TIGER-BVS: TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization</TitleDisplay><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Carotid artery intima-media </BiomarkerName><BiomarkerName> Coronary artery lumen </BiomarkerName><BiomarkerName> Coronary flow reserve </BiomarkerName><BiomarkerName> Vessel lumen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>61 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Salvatore Brugaletta, MD</Name></ContactNames></Trial><Trial Id="188633"><Indications><Indication>Hypertrophic cardiomyopathy</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-12-12T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CARDIO-HCM</Identifier><Identifier>CRT-01-2011-HCPB</Identifier><Identifier>NCT01332162</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>biventricular pacing alone</Intervention><Intervention>cardiac resynchronization therapy-defibrillation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to evaluate the benefit of the optimal pacing configuration, including the possibility of biventricular or left ventricular pacing, in hypertrophic obstructive cardiomyopathy patients.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiac Function - Assessment of left ventricular volume or function</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Cardiovascular Events - Change in NYHA functional class</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Myocardial disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CARDIO-HCM: Cardiac Desynchronization In Obstructive HCM</TitleDisplay><PatientSegmentTerms><PatientSegment>Myocardial disease - Subjects with Hypertrophic Cardiomyopathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interventricular septum </BiomarkerName><BiomarkerName> Left ventricle </BiomarkerName><BiomarkerName> Left ventricular posterior wall </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>90 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>ANTONIO BERRUEZO, MD</Name><Name>Dr. Josep Brugada, MD. PhD.</Name><Name>Dr.Antonio Berruezo, MD. PhD.</Name><Name>JOSEP BRUGADA, MD, PhD</Name></ContactNames></Trial><Trial Id="104877"><Indications><Indication>HIV-1 infection</Indication></Indications><CompaniesCollaborator><Company>Hospital Clinic of Barcelona</Company><Company>Hospital General Universitario Gregorio Marañon</Company><Company>Instituto de Salud Carlos III</Company></CompaniesCollaborator><CompaniesSponsor><Company>Germans Trias i Pujol Hospital</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-17T00:00:00Z</DateChangeLast><DateEnd>2009-07-31T00:00:00Z</DateEnd><DateStart>2006-01-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2004-001413-34</Identifier><Identifier>NCT00287677</Identifier><Identifier>VIHCREC01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HAART alone</Intervention><Intervention>Hepatitis A + B + tetanus toxoid vaccine alone</Intervention><Intervention>recombinant human growth hormone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>33</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a pilot, randomized, clinical open-label study aimed to investigate thymic functionality and the HIV-specific responses after administration of rhGH in HIV-1 infected patients in highly active antiretroviral therapy (HAART) regimen.</Teaser><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-hepatitis A antibody concentration</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-tetanus antibody concentration</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response - Assessment of anti-body titers/antibody responses</EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Assessment of Immune Response - Assessment of anti-HAV antibodies</EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Assessment of Immune Response - Immunogenic response to other vaccine/infectious agent</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>DTP Vaccine - Subjects Received/Scheduled for Other Therapies</PatientSegment><PatientSegment>DTP Vaccine - Subjects Received/Scheduled for Other Therapies - Subjects received/scheduled for anti-HIV therapy</PatientSegment><PatientSegment>DTP Vaccine - Subjects with History of/Suspected Infectious Disorders - Subjects with history of/suspected HIV infection</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior tetanus vaccination</PatientSegment><PatientSegment>HIV Vaccine - Subjects with HIV Infection</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with Acute/Asymptomatic HIV infection</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>Hepatitis A Vaccine - Subjects with comorbid conditions</PatientSegment><PatientSegment>Hepatitis A virus infection - Subjects with comorbid conditions</PatientSegment><PatientSegment>Hepatitis B Vaccine - Subjects with comorbid conditions - Subjects with HIV infection</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with Prior Other Vaccination - Non-responders to previous hepatitis B vaccination</PatientSegment><PatientSegment>Hepatitis B virus infection - Subjects with comorbid conditions - Subjects with HIV infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Bonaventura Clotet, PhD</Name><Name>Jose Mª Gatell, PhD</Name><Name>Lidia Ruiz, PhD</Name><Name>Margarita Bofill, PhD</Name></ContactNames></Trial><Trial Id="153779"><Indications><Indication>Hypercholesterolemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiarteriosclerotic</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action><Action>Antihypertriglyceridemic agent</Action><Action>Cardioprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-03T00:00:00Z</DateChangeLast><DateEnd>2014-09-30T00:00:00Z</DateEnd><DateStart>2013-09-30T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612000732886</Identifier><Identifier>NCT01935674</Identifier><Identifier>SOS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>rosuvastatin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this study was to compare the effect of rosuvastatin to protease inhibitor switching on: Fasting total cholesterol up to week 12. Safety parameters (HIV viral load, clinical adverse events, serious adverse events, laboratory adverse events, modifications to antiretroviral therapy). Quality of life (SF-12). Fasting LDL cholesterol (estimated with Friedewald equation unless triglycerides &gt; 400 mg/dl, in which case LDL-C would be measured directly), HDL cholesterol, total : HDL</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures - Assessment of insulin resistance/sensitivity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex><EndpointIndex>HIV infection - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>HIV infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of Cardiovascular Risk Factors</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of High Density Lipoprotein (HDL)</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of Insulin Levels</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of lipid profiles - Assessment of Triglycerides</EndpointIndex><EndpointIndex>Hypercholesterolemia - Glycemic Control Analysis - Assessment of glucose level</EndpointIndex><EndpointIndex>Hypercholesterolemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Cardiovascular Risk Factors</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of High Density Lipoprotein (HDL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles - Assessment of Triglycerides</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Glycemic Control Analysis - Assessment of glucose level</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-12)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Increased Total Cholesterol Levels</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease - Subjects with diabetes mellitus as a risk factor for coronary heart disease</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease - Subjects with family history of premature CHD</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Increased Total Cholesterol Levels</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD) - Subjects with diabetes mellitus</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD) - Subjects with family history of premature CHD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Total cholesterol/HDL-C ratio </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Esteban Martinez, MD</Name></ContactNames></Trial><Trial Id="14924"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>HIV-1 integrase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-11T00:00:00Z</DateChangeLast><DateEnd>2010-03-31T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2007-003401-27</Identifier><Identifier>NCT00528892</Identifier><Identifier>SPIRAL</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ritonavir alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>raltegravir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>282</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The hypothesis of this study was that switching from a ritonavir boosted protease inhibitors (PI) to raltegravir (400 mg bid) might be associated with an at least non-inferior effectiveness, virological response and safety, and even a better tolerability profile with regard to lipid metabolism, insulin resistance, body fat distribution as compared with continuation of the baseline regimen in HIV-1 seropositive males or females at least 18 years of age and older on ritonavir -boosted PI plus at</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Biomarkers</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response - Assessment of virological failure</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SPIRAL: Switching From PI to Raltegravir in HIV Stable Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Flow-mediated dilation </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Total cholesterol/HDL-C ratio </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jose Gatell</Name></ContactNames></Trial><Trial Id="180443"><Indications><Indication>Parturition</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2018-04-30T00:00:00Z</DateEnd><DateStart>2014-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2013-001921-19</Identifier><Identifier>NCT02103166</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>hyoscine bromide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Suspended</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to determine whether hyoscine bromide decreases the duration of the active phase of labor.</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Role of Hyoscine Bromide in Latent and Active Labor</TitleDisplay><PrimaryCompletionDate type="Anticipated">2018-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ana Sandra Hernandez, MD</Name><Name>Irene Teixido, MD</Name><Name>Irene Vives, MD</Name><Name>Mariona Rius, MD</Name><Name>Midwives Collaborative Group HCP</Name><Name>Montse Palacio, MD, PhD</Name></ContactNames></Trial><Trial Id="289532"><Indications><Indication>Premature labor</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-08-20T00:00:00Z</DateChangeLast><DateEnd>2021-06-30T00:00:00Z</DateEnd><DateStart>2016-11-16T00:00:00Z</DateStart><Identifiers><Identifier>HCB/2016/0552</Identifier><Identifier>NCT03062020</Identifier></Identifiers><InterventionsControlDisplay><Intervention>clinical management alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>QUIPP alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>258</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate the QUIPP tool in the investigators setting in order to optimize the management of women at high risk for spontaneous preterm births (sPTB) and to validate in a randomized clinical trial, whether the use of QUIPP improves efficiently the management of our asymptomatic high-risk women when it is compared with the current clinical management. The main outcome of the study: sPTB &amp;lt; 34.0 and &amp;lt; 37.0 weeks of gestation. Secondary outcomes: pregnancy outcomes</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other gynecological disorder - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other gynecological disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women</TitleDisplay><PatientSegmentTerms><PatientSegment>Other gynecological disorder - Others - Healthy Subjects</PatientSegment><PatientSegment>Other gynecological disorder - Women giving birth/Obstetrics</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cervix </BiomarkerName><BiomarkerName> Fibronectin </BiomarkerName><BiomarkerName> Leukocyte count</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>55 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Federico Migliorelli, M.D</Name><Name>Montse Palacio, M.D, Ph.D</Name><Name>Núria Baños, M.D</Name><Name>Núria Lorente, M.D</Name><Name>Rosalia Pascal, Resident</Name><Name>Sílvia Ferrero, M.D, Ph.D</Name><Name>Teresa Cobo, M.D, Ph. D</Name></ContactNames></Trial><Trial Id="73749"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV GAG POL polyprotein inhibitor</Action><Action>HIV GAG protein inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-09-17T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-021002-38</Identifier><Identifier>ATADAR</Identifier><Identifier>ATADAR</Identifier><Identifier>NCT01274780</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including atazanavir , darunavir , ritonavir , tenofovir/emtricitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> increase in total cholesterol and HDL-cholesterol, however, only in the darunavir/ritonavir arm, LDL cholesterol increased and only in the atazanavir/ritonavir arm, triglycerides increased. Only in the atazanavir/ritonavir arm, the apolipoprotein A-&lt;b&gt;I&lt;/b&gt;/apolipoprotein B ratio increased. In the darunavir/ritonavir arm, at week 48, the LDL subfraction phenotype improved (increase in LDL particle size and in large LDL particles), however, it worsened in the atazanavir/ritonavir arm (increase in small and</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of lipodystrophy</EndpointIndex><EndpointIndex>HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex><EndpointIndex>HIV infection - Assessment of body fat distribution</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex><EndpointIndex>HIV infection - Clinical Assessments - Assessment of liver function</EndpointIndex><EndpointIndex>HIV infection - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ATADAR: Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in Naive HIV-1 Infected Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Abdominal fat </BiomarkerName><BiomarkerName> Adiponectin </BiomarkerName><BiomarkerName> Arterial stiffness </BiomarkerName><BiomarkerName> Body fat percentage </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Carotid artery </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Homeostasis model assessment insulin resistance </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Limb fat </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Platelet-activating factor acetylhydrolase </BiomarkerName><BiomarkerName> Subcutaneous fat </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Total cholesterol/HDL-C ratio </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Esteban Martinez</Name><Name>Jose Gatell</Name></ContactNames></Trial><Trial Id="60476"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>HIV protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>HIV replication inhibitor</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-24T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2005-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00979706</Identifier><Identifier>PHI-INMUNOMEDIADO</Identifier></Identifiers><InterventionsControlDisplay><Intervention>lamivudine + abacavir + zidovudine, GSK plus lopinavir + ritonavir</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including GM-CSF , ciclosporin, Novartis , emtricitabine , lamivudine + abacavir + zidovudine, GSK , lopinavir + ritonavir , pegylated-interferon-alpha , tenofovir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>22</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>drugs Patients with a history of psychiatric disorder, thyroid illness, dislipidemia requiring treatment, cardiovascular disease, arterial hypertension, or diabetes mellitus In treatment with drugs interacting with study drugs Acute infection for HTLV-&lt;b&gt;I&lt;/b&gt; or EBV</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response - Assessment of virological control</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD)</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>116 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Maria Miró, MDPhD</Name></ContactNames></Trial><Trial Id="103292"><Indications><Indication>Colorectal tumor</Indication></Indications><CompaniesCollaborator><Company>Abbott Laboratories</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2005-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EPA-05</Identifier><Identifier>EPA-05/ ACA-SPAI-05-05</Identifier><Identifier>NCT00398333</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Prosure alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>13</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser> Patients diagnosed of metastatic colon adenocarcinoma that are going to receive first line chemotherapy treatment in the oncology day &lt;b&gt;hospital&lt;/b&gt; Aged &gt;/= 18 years</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints - Assessment of Diet/Nutritional Intake</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pere Leyes, MD</Name></ContactNames></Trial><Trial Id="84963"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>HIV protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>CCR5 chemokine antagonist</Action><Action>CD4 agonist</Action><Action>HIV-1 gp120 protein inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>HIV fusion inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Fundació Clínic Per A La Recerca Biomèdica</Company><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-12-06T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2011-002069-39</Identifier><Identifier>MARAVI-PEP</Identifier><Identifier>MARAVI-PEP</Identifier><Identifier>NCT01533272</Identifier></Identifiers><InterventionsControlDisplay><Intervention>lopinavir + ritonavir plus tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>maraviroc plus tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to compare two alternatives of anti-retroviral therapy ( tenofovir + emtricitabine plus lopinavir + ritonavir [400 mg bid] versus tenofovir + emtricitabine plus maraviroc ) as post-exposure prophylaxis (PEP) to HIV-1. The primary objective of this study would be to compare the dropout rate of a new pattern of post-exposure prophylaxis (PEP) for HIV with a classic pattern before 28 days of treatment. The secondary objective of this study would be : To compare the tolerability</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MARAVI-PEP: Study Comparing Two Alternatives of Antiretroviral Therapy as Post-Exposure Prophylaxis to HIV-1: Fovir + Emcitrabine + Lopinavir/Ritonavir versus Tenofovir + Emcitrabine + Maraviroc</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Felipe Garcia, PhD</Name></ContactNames></Trial><Trial Id="39325"><Indications><Indication>Metabolic bone disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Bone resorption inhibitor</Action><Action>Calcium metabolism inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2003-12-31T00:00:00Z</DateEnd><DateStart>2000-12-31T00:00:00Z</DateStart><Identifiers><Identifier>99-NV001</Identifier><Identifier>NCT00657852</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pamidronate disodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>79</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aims of this study were to prospectively evaluate the efficacy of two iv infusions of pamidronate 90 mg, associated with calcium and calcidiol, in the early post-transplant period, on bone loss in liver transplant recipients, and to asses the safety of this treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Fractures - Assessment of non-vertebral fractures</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Fractures - Assessment of vertebral fractures</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Laboratory/Diagnostic Measures - Assessments using imaging modalities</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of adverse events</EndpointIndex><EndpointIndex>Osteoporosis - Protocol Specified Other Endpoints - Assessment of incidence of fractures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Subjects Awaiting Liver Transplantation</PatientSegment><PatientSegment>Osteoporosis - Subjects at risk of developing disease - Subjects with osteopenia as a risk factor</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Miquel Navasa</Name></ContactNames></Trial><Trial Id="170291"><Indications><Indication>Pneumonia</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-03-09T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2004-01-31T00:00:00Z</DateStart><Identifiers><Identifier>FIS 2003-CA</Identifier><Identifier>NCT00908713</Identifier></Identifiers><IndicationsAdverse><Indication>Hyperglycemia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>methylprednisolone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study was that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Response - Clinical failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Corticoids in Severe Community-Acquired Pneumonia (CAP)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects with Community Acquired Pneumonia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>98 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Carlos Agusti, MD</Name></ContactNames></Trial><Trial Id="166084"><Indications><Indication>Anemia</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Iron uptake stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-10-26T00:00:00Z</DateChangeLast><DateEnd>2007-09-30T00:00:00Z</DateEnd><DateStart>2005-09-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00660933</Identifier><Identifier>POSTPARTFEEV</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>iron sucrose injection (iron deficiency anemia), Vifor/American Regent/Galenica alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to compare the effect of intravenous versus oral iron sucrose in women with severe postpartum anemia.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Transfusions</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hematocrit</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Other Forms of Anemia - Subjects with pregnancy related anemia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Montse Palacio, MD, PhD</Name></ContactNames></Trial><Trial Id="228333"><Indications><Indication>Atrial fibrillation</Indication></Indications><CompaniesCollaborator><Company>FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU</Company><Company>Fundacion Incliva</Company><Company>Germans Trias i Pujol Hospital</Company><Company>Hospital Clinico San Carlos</Company><Company>Hospital Puerta de Hierro Majadahonda</Company><Company>Hospital Virgen de la Salud</Company><Company>Hospital del Mar</Company><Company>Universidad de Vigo</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-05-02T00:00:00Z</DateChangeLast><DateEnd>2017-04-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>LAGO-FA</Identifier><Identifier>LAGO-FA</Identifier><Identifier>NCT02373982</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pulmonary vein ablation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>417</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this was a multicenter, observational, one-year, retrospective, cohort study was to evaluate the predictive value of the left atrial sphericity on the recurrence rate of atrial fibrillation after pulmonary vein ablation procedure.</Teaser><TrialCategories><Category>Surgical procedure</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Atrial Fibrillation Recurrence</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LAGO-FA: Left Atrial Geometry and Outcomes After Atrial Fibrillation Ablation</TitleDisplay><PatientSegmentTerms><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with Recurrent Atrial Fibrillation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Left atrium</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Felipe Bisbal, MD</Name><Name>Lluís Mont, MD PhD</Name></ContactNames></Trial><Trial Id="338518"><Indications><Indication>Bleeding</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2018-05-10T00:00:00Z</DateEnd><DateStart>2018-01-01T00:00:00Z</DateStart><Identifiers><Identifier>2016/0906</Identifier><Identifier>NCT03516552</Identifier></Identifiers><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of this study is to estimate the hemoglobin content on blood loss and to assess hemoglobin/volume ratio.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other hematological disease - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Other hematological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison and Analysis of Blood Loss Formulas</TitleDisplay><PatientSegmentTerms><PatientSegment>Other hematological disease - Subjects with History of/Undergoing Procedures/Surgery</PatientSegment><PatientSegment>Other hematological disease - Subjects with specific disease - Subjects with bleeding/clotting disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-05-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sebastian Jaramillo, MD</Name></ContactNames></Trial><Trial Id="14773"><ActionsPrimaryInterventionsPrimary><Action>HIV gp41 protein modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>HIV fusion inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>F Hoffmann-La Roche AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-09-13T00:00:00Z</DateChangeLast><DateEnd>2006-03-31T00:00:00Z</DateEnd><DateStart>2005-09-30T00:00:00Z</DateStart><Identifiers><Identifier>ENF/01FD-05/UF1</Identifier><Identifier>EudraCT #: 2005-002018-39</Identifier><Identifier>NCT00657761</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>enfuvirtide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>A short-term study in healthy volunteers, with a double-blind crossover design versus placebo was to assess the effect of enfuvirtide on lipid and glucose metabolism and mitochondrial function in healthy volunteers.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Metabolic Effects of Enfuvirtide in Healthy Volunteers</TitleDisplay><PrimaryCompletionDate/><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Neus Riba</Name></ContactNames></Trial><Trial Id="62747"><Indications><Indication>Liver transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-12-19T00:00:00Z</DateChangeLast><DateEnd>2011-11-30T00:00:00Z</DateEnd><DateStart>2009-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2008-007177-20</Identifier><Identifier>NCT01034345</Identifier><Identifier>Sirolimus_Liver_Tolerance</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sirolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>52</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The goal of this study is to evaluate the effects of sirolimus on previously identified tolerogenic pathways in humans and, indirectly, to assess the capacity of this drug to enhance the proportion of liver recipients undergoing successful immunosuppression weaning.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Liver Transplant Recipients</PatientSegment><PatientSegment>Liver transplantation - Subjects with History of/Currently on/Scheduled for Liver Transplant Therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alberto Sanchez Fueyo, MD</Name><Name>Alberto Sanchez-Fueyo, MD</Name></ContactNames></Trial><Trial Id="220123"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>DNA polymerase inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 integrase inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2015-03-31T00:00:00Z</DateStart><Identifiers><Identifier>Advanz-4</Identifier><Identifier>Advanz-4</Identifier><Identifier>NCT02337322</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including abacavir , darunavir , dolutegravir , lamivudine , ritonavir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>104</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This is a multicenter, randomized, open clinical trial, comparing two parallel groups, to compare the immunological reconstitution and the virological efficacy and safety of two different combinations of antiretroviral therapy given once-daily: abacavir plus lamivudine plus either dolutegravir , or darunavir - ritonavir during 96 weeks in advanced antiretroviral naive HIV-1 infected patients with &amp;lt; 100 CD4+ T-cells/mm3. The primary endpoint is the median increase in CD4+ T-cell count at 48</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of virological response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Advanz-4: Immune Recovery in Advanced, ARV-naive, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Subjects with Low CD4 Cell Count</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>57 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Juan A. Arnaiz</Name></ContactNames></Trial><Trial Id="14974"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>DNA polymerase inhibitor</Action><Action>HIV GAG POL polyprotein inhibitor</Action><Action>HIV GAG protein inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Non-nucleoside reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>HIV replication inhibitor</Action><Action>Hepatitis B virus replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Peptidomimetic</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Suspension</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2007-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2006-006268-42</Identifier><Identifier>ADVANZ-3</Identifier><Identifier>EC07/90642</Identifier><Identifier>NCT00532168</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including atazanavir , efavirenz , emtricitabine , lopinavir + ritonavir , ritonavir , tenofovir disoproxil fumarate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Chronic HIV-1 infection Age 18 years or more Antiretroviral-naive Baseline CD4+ count&amp;lt; 100 cells/microl No mutations of drug resistance at baseline (M184V/&lt;b&gt;I&lt;/b&gt;, K65R, resistance to efavirenz or two or more PRAMs (protease-associated mutations [L33I/F/V, V82A/F/L/T, I84V, L90M]) Written informed consent</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Morbidity</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ADVANZ-3: Once-Daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/microl</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Subjects with Low CD4 Cell Count</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C chemokine receptor type 5 </BiomarkerName><BiomarkerName> C-X-C chemokine receptor type 4 </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>63 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jose M Miró, MD</Name></ContactNames></Trial><Trial Id="129790"><Indications><Indication>Bone injury</Indication></Indications><CompaniesCollaborator><Company>AbbVie Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01850251</Identifier><Identifier>ORTOHMB-13</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Ensure Plus High Protein alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>hydroxymethylbutyrate alone</Intervention><Intervention>vitamin D alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>This study would consist of two treatment arms: Arm &lt;b&gt;I&lt;/b&gt;: patients would receive 440 ml (two bottles) of nutritional supplement with HMB and vitamin D (Ensure Plus Advance) po each day during 8 weeks. Arm II: patients would receive 440 ml (two bottles) of standard nutritional supplement (Ensure Plus High Protein) po each day during 8 weeks.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture</TitleDisplay><BiomarkerNames><BiomarkerName>Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Joan Trabal, RD, MS</Name><Name>Margarita Navarro, MD</Name><Name>Maria T Forga, MD</Name><Name>Pere Leyes, MD</Name><Name>Salvi Prat, MD, PhD</Name></ContactNames></Trial><Trial Id="73027"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 integrase inhibitor</Action><Action>HIV-1 protease inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-09-07T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01258374</Identifier><Identifier>RALDAR</Identifier><Identifier>RALDAR-HCB</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including darunavir , raltegravir , ritonavir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In this study, investigators hypothesized that raltegravir / darunavir would be well tolerated and effective regimen for those patients who were failing nucleoside reversre transcriptase inhibitors based regimens, due to poor tolerability or resistance. The investigators would also aim to explore the plasma pharmacokinetics of raltegravir combined with darunavir in a sub-group of 12 HIV-infected patients.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>RALDAR: Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects Refractory/Intolerant to Anti Retroviral Therapy</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Mallolas, MD, PhD</Name></ContactNames></Trial><Trial Id="63786"><Indications><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Pulmonary hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HETE modulator</Action><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-29T00:00:00Z</DateChangeLast><DateEnd>2012-01-31T00:00:00Z</DateEnd><DateStart>2008-08-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT: 2007-006040-21</Identifier><Identifier>JA Barbera</Identifier><Identifier>NCT01055405</Identifier><Identifier>SIL-COPD-02</Identifier><Identifier>SIL-COPD-02</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sildenafil citrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study hypothesis was that sildenafil might improve pulmonary hemodynamics and increase exercise tolerance in patients with chronic obstructive pulmonary disease (COPD).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters - Assessment of oxygen saturation (SaO2/SpO2)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Assessment of endurance/endurance time</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Constant-load exercise</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Performance in incremental exercise test</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Assessment of Exercise Capacity/Tolerance - Assessment of endurance time</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Assessment of Six Minute Walk Test</EndpointIndex><EndpointIndex>Pulmonary artery hypertension - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SIL-COPD-02: Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with pulmonary hypertension</PatientSegment><PatientSegment>Pulmonary artery hypertension - Subjects with Pulmonary Hypertension Owing to Lung Diseases and/or Hypoxia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Joan Albert Barbera</Name><Name>Joan Albert Barbera, MD</Name></ContactNames></Trial><Trial Id="152965"><Indications><Indication>Hepatorenal syndrome</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>GIN-TER-2010-01</Identifier><Identifier>NCT01932151</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>albumin plus terlipressin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate whether treatment with terlipressin and albumin in the course of an infection associated with type-1 hepatorenal syndrome (HRS) was effective and safe.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of renin-angiotensin aldosterone system(RAAS)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of vascular structure/function</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>End stage renal disease - Hematological Assessments</EndpointIndex><EndpointIndex>Sepsis - Assessment of Laboratory/Diagnostic Measures - Liver function tests</EndpointIndex><EndpointIndex>Sepsis - Assessment of Laboratory/Diagnostic Measures - Renal function tests</EndpointIndex><EndpointIndex>Sepsis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Treatment of Type-1 Hepatorenal Syndrome Associated With Active Infections</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects with Liver Disorder/Associated Nephropathy</PatientSegment><PatientSegment>Sepsis - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pere Ginès, MD</Name></ContactNames></Trial><Trial Id="360187"><Indications><Indication>Blood transfusion</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-11-20T00:00:00Z</DateChangeLast><DateEnd>2018-12-01T00:00:00Z</DateEnd><DateStart>2018-09-01T00:00:00Z</DateStart><Identifiers><Identifier>HCB/2016/0906/2</Identifier><Identifier>NCT03740438</Identifier></Identifiers><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of the study is to observe the hemoglobin drop in the uncomplicated postoperative course.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Other genitourinary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other gynecological disorder - Hematological Assessments - Assessment of hemoglobin levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Modeling of the Hemoglobin Drop in the Uncomplicated Postoperative Course</TitleDisplay><BiomarkerNames><BiomarkerName>Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-12-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sebastian Jaramillo</Name><Name>Sebastian Jaramillo, MD</Name></ContactNames></Trial><Trial Id="166441"><Indications><Indication>Liver transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Inc</Company><Company>Fresenius SE &amp; Co KGaA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2009-07-31T00:00:00Z</DateEnd><DateStart>2006-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ATEGE-LIVER</Identifier><Identifier>EUDRACT 2005-005635-10</Identifier><Identifier>NCT00436722</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>anti-thymocyte globulin (ATG) alone</Intervention><Intervention>tacrolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>This was a randomized, controlled trial in liver transplantation in which conventional immunosuppressive treatment was compared with a therapeutic strategy consisting in pre-transplant antibody-mediated T cell depletion followed by reduced calcineurin inhibitor usage. The working hypothesis was that antibody induction followed by calcineurin inhibitor minimization may promote development of tolerogenic mechanisms allowing the eventual withdrawal of all immunosuppressive therapy. Aim of the study</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Chronic Graft Rejection (CGR) - Incidence of CGR</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Graft Survival - Graft survival rate at 1 year</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Morbidity - Diabetes related events</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Morbidity - Hypertension related events</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Renal Function - Assessment of renal events</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Survival - Patient survival at 1 year</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of use of Rescue Medication - Change in immunosuppressive therapy</EndpointIndex><EndpointIndex>Liver transplantation - Infections/Opportunistic Infections</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ATEGE-LIVER: Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Liver Transplant Recipients</PatientSegment><PatientSegment>Liver transplantation - Liver Transplant Recipients - Primary (first) liver transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2009-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alberto Sanchez-Fueyo</Name></ContactNames></Trial><Trial Id="195326"><Indications><Indication>Insulin dependent diabetes</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-04-08T00:00:00Z</DateChangeLast><DateEnd>2010-05-31T00:00:00Z</DateEnd><DateStart>2009-01-31T00:00:00Z</DateStart><Identifiers><Identifier>BMATXDM1</Identifier><Identifier>NCT00821899</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>autologous bone marrow blood alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This project would evaluate the effectiveness of the administration of autologous bone marrow blood in patients with brittle type 1 diabetes mellitus to restore insulin secretion.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Hypoglycemic Episodes</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Insulin Dose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Glycemic Control Analysis - Assessment of glucose tolerance</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Bone Marrow Autotransplantation in Type 1 Diabetes</TitleDisplay><BiomarkerNames><BiomarkerName>Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Insulin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Esmatjes Enric, MD</Name></ContactNames></Trial><Trial Id="66879"><Indications><Indication>Liver cirrhosis</Indication><Indication>Renal disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-06-30T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2010-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2009-011437-27</Identifier><Identifier>MAFRI</Identifier><Identifier>NCT01133795</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>albumin plus midodrine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>7</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to evaluate the effect of administration of midodrine and albumin on renal function in patients with cirrhosis and creatinine &gt; 1.2 mg/dl.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of renin-angiotensin aldosterone system(RAAS)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MAFRI: Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>End stage renal disease - Subjects with Liver Disorder/Associated Nephropathy</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 2 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 4 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Other Chronic Disorders/Associated Nephropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Aldosterone </BiomarkerName><BiomarkerName> Arginine vasopressin </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Endothelins </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Natriuretic peptides A </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renal plasma flow </BiomarkerName><BiomarkerName> Renin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>76 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gustavo Pereira</Name><Name>Monica Guevara</Name><Name>Pere Ginès, MD</Name><Name>Pere Gines</Name></ContactNames></Trial><Trial Id="20341"><Indications><Indication>Hepatorenal syndrome</Indication><Indication>Liver cirrhosis</Indication><Indication>Peritonitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA gyrase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bacterial nucleic acid synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2005-03-31T00:00:00Z</DateEnd><DateStart>2000-09-30T00:00:00Z</DateStart><Identifiers><Identifier>00-pbe-mnjf-2</Identifier><Identifier>NCT00359853</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>norfloxacin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main aim of the study would be to investigate if oral administration of norfloxacin prevents the first episode of spontaneous bacterial peritonitis (SBP), hepatorenal syndrome and improves survival in cirrhotic patients with ascites and low protein concentration in ascitic fluid (&amp;lt; 15 g/l). This would be a prospective, multicenter, randomized, double-blind placebo controlled trial comparing oral norfloxacin (400 mg/d; n = 35) with placebo (n = 35).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hyponatremia - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Hyponatremia - Assessment of Survival</EndpointIndex><EndpointIndex>Intra-abdominal Infections - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Intra-abdominal Infections - Assessment of Morbidity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Hyponatremia - Subjects with comorbid conditions</PatientSegment><PatientSegment>Intra-abdominal Infections - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>54 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Miquel Navasa, MD</Name></ContactNames></Trial><Trial Id="373516"><Indications><Indication>Respiratory failure</Indication></Indications><CompaniesCollaborator><Company>Getinge AB</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-19T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2019-04-30T00:00:00Z</DateStart><Identifiers><Identifier>HCB/2019/0049</Identifier><Identifier>NCT03877172</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Airvo 2 alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Face-mask oxygen therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The goal of this single-center, physiological crossover study is to evaluate the role that high-flow nasal cannulas (HFNC) have on respiratory drive, work of breathing and neuromuscular efficiency after lung resection surgery. The main question the investigators aim to answer is whether HFNC decrease respiratory drive by &gt;/= 15% in these patients, assessed by a special diaphragmatic electromyography (EMG) device (NAVA catheter). In order, to perform this study, the investigators will perform a</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>High Flow Nasal Cannula in Thoracic Surgery: a Physiologic Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects Undergoing Surgery</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen tension/inspiratory oxygen fraction ratio </BiomarkerName><BiomarkerName> Partial pressure of carbon dioxide </BiomarkerName><BiomarkerName> Thoracic diaphragm</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ricard Mellado Artigas, MD</Name></ContactNames></Trial><Trial Id="34958"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV-1 integrase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2013-09-13T00:00:00Z</DateChangeLast><DateStart>2008-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00787774</Identifier><Identifier>RAL-dyn</Identifier><Identifier>RAL-dyn</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>raltegravir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This was a prospective study to evaluate the potential persistent viral effect of raltegravir in 20 treatment-experienced HIV patients with incomplete viral suppression.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex></EndpointIndex><TitleDisplay>RAL-dyn: Integrase resistance analysis in HIV patients who interrupted raltegravir due to incomplete viral suppression</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects Refractory/Intolerant to Anti Retroviral Therapy</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2010-01-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jose Gatell</Name><Name>Jose Luis Blanco, MD</Name></ContactNames></Trial><Trial Id="176263"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Non-nucleoside reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU</Company><Company>Germans Trias i Pujol Hospital</Company><Company>Hospital Universitari Joan XXIII de Tarragona</Company><Company>Hospitales Universitarios Virgen del Rocío</Company></CompaniesCollaborator><CompaniesSponsor><Company>Abbott Laboratories</Company><Company>Fondo de Investigacion Sanitaria</Company><Company>Gilead Sciences Inc</Company><Company>Hospital Clinic of Barcelona</Company><Company>Instituto de Salud Carlos III</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-07-30T00:00:00Z</DateChangeLast><DateEnd>2013-07-31T00:00:00Z</DateEnd><DateStart>2008-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2007-002698-29</Identifier><Identifier>LIPOTAR-07</Identifier><Identifier>NCT00759070</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including efavirenz , lopinavir + ritonavir , tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study was an open-label, randomized, pilot comparison of the effects of either lopinavir/ritonavir ( Kaletra ) or efavirenz ( Sustiva ) in combination with tenofovir plus emtricitabine ( Truvada ) on cholesterol metabolism, mitochondrial functioning and immune response in 50 naive HIV patients after 48 weeks.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of lipid profiles</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LIPOTAR-07: Effects of Two Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Adiponectin </BiomarkerName><BiomarkerName> Cytochrome c oxidase subunit 4 isoform 1, mitochondrial </BiomarkerName><BiomarkerName> Cytoplasmic polyadenylation element-binding protein 1 </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Interleukin-7 </BiomarkerName><BiomarkerName> Interleukin-7 receptor subunit alpha </BiomarkerName><BiomarkerName> Lipoprotein lipase </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Non-high density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> Soluble carrier family 2, facilitated glucose transporter member 4 </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2013-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>58 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Juan A. Arnaiz</Name></ContactNames></Trial><Trial Id="14693"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Non-nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Hepatitis B virus replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Nucleoside synthesis</Technology><Technology>Nucleotide and derivatives</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Suspension</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2006-10-10T00:00:00Z</DateStart><Identifiers><Identifier>ADVAN-Z-2</Identifier><Identifier>ADVAN-Z-2</Identifier><Identifier>NCT00386659</Identifier></Identifiers><InterventionsControlDisplay><Intervention>efavirenz alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including abacavir , lopinavir + ritonavir , tenofovir disoproxil fumarate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this pilot, randomized, parallel, open-label, controlled, clinical study was to evaluate virological response in plasma and extra-plasmatic compartments, together with the degree and kinetics of immune reconstitution in treatment-naive patients with CD4 count below 100 cells/ml, when treated with tenofovir and abacavir together with lopinavir/ritonavir or efavirenz .</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of AIDS Defining Events(CDC Criteria)</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ADVAN-Z-2: Immune Reconstitution in naive HIV Patients With CD4 &lt; 100 Cells/ml When Treated With Lopinavir or Efavirenz</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>4</NumberOfSites><ContactNames><Name>Josep M Gatell, MD</Name></ContactNames></Trial><Trial Id="269291"><Indications><Indication>Ischemic stroke</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA A receptor alpha-5 subunit inhibitor</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>ADIR Association</Company><Company>Servier</Company></CompaniesCollaborator><CompaniesSponsor><Company>Institut de Recherches Internationales Servier (France)</Company><Company>Laboratorios Servier</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>Spain</Country><Country>Italy</Country><Country>Canada</Country><Country>Sweden</Country><Country>Belgium</Country><Country>Netherlands</Country><Country>South Korea</Country><Country>France</Country><Country>Slovenia</Country><Country>UK</Country><Country>Brazil</Country><Country>Hungary</Country><Country>Australia</Country></Countries><DateChangeLast>2019-06-08T00:00:00Z</DateChangeLast><DateEnd>2019-03-10T00:00:00Z</DateEnd><DateStart>2016-12-19T00:00:00Z</DateStart><Identifiers><Identifier>2016-001005-16</Identifier><Identifier>CL2-44819-004</Identifier><Identifier>NCT02877615</Identifier><Identifier>RESTORE BRAIN</Identifier><Identifier>U1111-1180-8991</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>afizagabar (ischemic stroke), Institut de Recherches Internationales Servier alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>585</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the efficacy and safety of S-44819 in enhancing functional recovery after an ischemic stroke. The primary objective was to demonstrate the superiority of at least one of the two doses of S-44819 versus placebo on functional recovery from ischemic stroke measured with the modified Rankin Scale (mRS) after 90 days of treatment. The secondary objectives: To assess the efficacy of the two doses of S-44819 versus placebo in stroke recovery using neurological</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stroke - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Stroke - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>Stroke - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Stroke - Assessment of Neuropsychological Function - Assessment by Montreal Cognitive Assessment (MoCA)</EndpointIndex><EndpointIndex>Stroke - Assessment of Neuropsychological Function - Assessment by Trail Making Test (TMT)</EndpointIndex><EndpointIndex>Stroke - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Stroke - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Stroke - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Stroke - Assessment of adverse events</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Modified Rankin Scale (MRS) Score</EndpointIndex><EndpointIndex>Stroke - Patient Reported Outcomes/Quality of Life Assessments - Assessment by National Institute of Health Stroke Scale (NIHSS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RESTORE BRAIN: Efficacy and Safety Trial With S-44819 After Recent Ischemic Cerebral Event</TitleDisplay><PatientSegmentTerms><PatientSegment>Stroke - Post-stroke Subjects</PatientSegment><PatientSegment>Stroke - Subjects with Acute Stroke</PatientSegment><PatientSegment>Stroke - Subjects with Ischemic Stroke</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2019-03-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>128</NumberOfSites><ContactNames><Name>Clinical Studies Department</Name><Name>Kristy Tailford</Name><Name>Maria de Quintana Barajas</Name></ContactNames></Trial><Trial Id="349473"><Indications><Indication>Metastatic non small cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Erbb3 tyrosine kinase receptor inhibitor</Action><Action>Erbb4 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein conjugated</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Bioven Europe Ltd</Company><Company>MFAR Clinical Research</Company></CompaniesCollaborator><CompaniesSponsor><Company>Instituto Oncologico Rosell, Barcelona, Spain</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-01T00:00:00Z</DateChangeLast><DateEnd>2020-06-30T00:00:00Z</DateEnd><DateStart>2018-07-06T00:00:00Z</DateStart><Identifiers><Identifier>2017-003237-28</Identifier><Identifier>EPICAL</Identifier><Identifier>MEDOPP137</Identifier><Identifier>NCT03623750</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including CimaVax EGF , afatinib , cyclophosphamide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this study is to assess safety and efficacy of an EGFR tyrosine kinase inhibitor in combination with EGF pathway targeting immunization ( EGF-PTI ) in treatment-naive patients with EGFR mutant NSCLC.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Lung tumor - Assessment of compliance/adherence</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EPICAL: EGFR TKI and EGF-PTI COmbination in EGFR mutant NSCL C</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with EGFR Positive Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_Mutation(GOF)</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_Mutation(codon719)</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_delex19</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_rs121434568(G)</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_rs121434569(T)</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_rs121913444(A)</PatientSegment><PatientSegment>Lung tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Delvys Rodríguez</Name><Name>Delvys Rodríguez, M.D.</Name><Name>Federico Nepote</Name><Name>Manuel Cobo</Name><Name>Manuel Cobo, M.D.</Name><Name>Niki Karachaliou, M.D., Ph.D.</Name><Name>Niki Karachaliou, M.D., PhD.</Name><Name>Noemi Reguart, M.D.</Name><Name>Rafael Rosell, M.D., PhD.</Name><Name>Verónica Roca</Name></ContactNames></Trial><Trial Id="363416"><Indications><Indication>Surgical procedure</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2019-10-01T00:00:00Z</DateEnd><DateStart>2018-11-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03767387</Identifier><Identifier>NEXTCARE-PREHAB</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>standard care alone</Intervention><Intervention>trimodal prehabilitation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>750</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The current study protocol will aim to assess cost-effectiveness of prehabilitation as mainstream service in the ongoing deployment at &lt;b&gt;Hospital&lt;/b&gt; Clinic, as well as to generate a roadmap for regional scalability of the service. It will be planned...activity, nutritional balance and psychological support. The intervention will be currently deployed as mainstream service at &lt;b&gt;Hospital&lt;/b&gt; Clinic in several types of major surgeries. Trimodal prehabilitation will consist of a short-term (approximately 4</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other cardiovascular disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Other cardiovascular disease - Health Economic Assessments</EndpointIndex><EndpointIndex>Other cardiovascular disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other cardiovascular disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of hospitalization - Assessment of days in intensive care unit admission</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Health Economic Assessments</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other gastrointestinal disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other genitourinary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genitourinary disease - Health Economic Assessments</EndpointIndex><EndpointIndex>Other genitourinary disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Health Economic Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints - Length of hospital stay (LOS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Protocol for Prehabilitation Service Implementation in Catalonia</TitleDisplay><PatientSegmentTerms><PatientSegment>Other cardiovascular disease - Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment><PatientSegment>Other gastrointestinal disease - Subjects Undergoing Surgery</PatientSegment><PatientSegment>Other respiratory disease - Subjects Undergoing Surgery</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-08-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Josep Roca, MD</Name></ContactNames></Trial><Trial Id="382641"><Indications><Indication>Ulcerative colitis</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-05-31T00:00:00Z</DateChangeLast><DateEnd>2020-06-15T00:00:00Z</DateEnd><DateStart>2019-06-15T00:00:00Z</DateStart><Identifiers><Identifier>HCB/2017/0842</Identifier><Identifier>NCT03955328</Identifier><Identifier>PRODUC</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>magnetic resonance imaging alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The hypothesis of the study is that in ulcerative colitis repeated flares of inflammatory activity, as well as mechanisms involved in resolution of the inflammatory response, contributes to accumulation of damage in the colon leading to functional disturbances and symptoms that affect patient's functioning. The primary objective is to determine whether ulcerative colitis induces permanent anatomical damage, by means of magnetic resonance imaging.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of hospitalization</EndpointIndex><EndpointIndex>Ulcerative colitis - Assessment of use of Rescue Medication - Assessment by steroid/immunosuppressant use</EndpointIndex><EndpointIndex>Ulcerative colitis - Clinical Assessments</EndpointIndex><EndpointIndex>Ulcerative colitis - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Ulcerative colitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Inflammatory Bowel Disease Questionnaire (IBDQ)</EndpointIndex><EndpointIndex>Ulcerative colitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by euroqol(EQ-5D) questionnaire</EndpointIndex><EndpointIndex>Ulcerative colitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex><EndpointIndex>Ulcerative colitis - Patient Reported Outcomes/Quality of Life Assessments - Work Productivity and Activity Impairment Questionnaire</EndpointIndex><EndpointIndex>Ulcerative colitis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PRODUC: Progression of Damage in Ulcerative Colitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ulcerative colitis - Ulcerative Colitis Subjects in Remission</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Colon</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Eva Iglesias, MD</Name><Name>Isabel Vera, MD</Name><Name>Jose Arevalo, MD</Name><Name>Julia Panes, MD</Name></ContactNames></Trial><Trial Id="187373"><Indications><Indication>Breast tumor</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-05-20T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00647075</Identifier><Identifier>YUNZHI-BC</Identifier><Identifier>YUNZHI-BC</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Yunzhi extract alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study is to assess the effects of a dietary supplement, the traditional Asian mushroom Yunzhi, as adjuvant in the treatment of patients with breast cancer.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Breast tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Disease/Symptom Assesment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>YUNZHI-BC: Yunzhi as Dietary Supplement in Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Leukocyte count</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2010-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Miquel A Segui, MD</Name><Name>Miquel Segui</Name><Name>Montse Munoz</Name><Name>Montse Muñoz, MD</Name><Name>Pere Gascon, MD</Name></ContactNames></Trial><Trial Id="307209"><Indications><Indication>Myocardial infarction</Indication></Indications><CompaniesCollaborator><Company>Spanish Society of Cardiology</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-04-22T00:00:00Z</DateChangeLast><DateEnd>2023-07-31T00:00:00Z</DateEnd><DateStart>2017-07-01T00:00:00Z</DateStart><Identifiers><Identifier>MAG-01</Identifier><Identifier>MAGSTEMI</Identifier><Identifier>NCT03234348</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Orsiro sirolimus-eluting stent alone</Intervention><Intervention>percutaneous coronary intervention alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Magmaris sirolimus eluting bioresorbable vascular scaffold system alone</Intervention><Intervention>percutaneous coronary intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>151</PatientCountEnrollment><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Infarction documented in an ambulance or in a Cathlab, with &gt;/= 2 mm ST segment elevation in at least two contiguous leads, presenting in the Cathlab&amp;lt; 12 h after the onset of symptoms lasting &gt;/= 20 min requiring primary PCI Target lesion must be a &lt;b&gt;de&lt;/b&gt;-novo lesion located in a native vessel The patient accepts informed consent The patient understands and accepts clinical follow-up and angiographic control Angiographic: Vessel size should match available M-BRS scaffold sizes (&gt;/= 2.75 mm, and&amp;lt;/=</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Artery Plaque /Atheroma - Vessel Lumen Patency/Change in lumen area and volume</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Procedure and Procedure Related Events - Procedural success</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization - Device success/Lesion success</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Stenosis/Restenosis - Binary restenosis rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Stenosis/Restenosis - Stent strut coverage/Malapposition /Incomplete stent apposition</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis (Definite /Probable /Possible)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization - Assessment of in-hospital complications</EndpointIndex><EndpointIndex>Coronary artery disease - Imaging/Radiological Assessments - Assessment by optical coherence tomography (OCT)</EndpointIndex><EndpointIndex>Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Protocol Specified Other Endpoints - TIMI frame count</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MAGSTEMI: Magnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Vessel lumen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Ander Regueiro, MD</Name><Name>Andrés Iñiguez</Name><Name>Angel Cequier</Name><Name>Antonio Serra, MD</Name><Name>Bruno García del Blanco, MD</Name><Name>Fernando Alfonso, MD, PhD</Name><Name>Gema Céspedes</Name><Name>Javier Goicolea</Name><Name>Manel Sabate, MD</Name><Name>Manel Sabaté, MD</Name><Name>Mónica Masotti, MD</Name><Name>Pablo Salinas, MD</Name><Name>Pascual Bordes</Name><Name>Rosana Hernandez-Antolín, MD</Name><Name>Salvatore Brugaletta, MD</Name><Name>Sebastian Romani, MD</Name><Name>Victoria Martín-Yuste, MD</Name><Name>Xavier Freixa, MD</Name></ContactNames></Trial><Trial Id="222429"><Indications><Indication>Gastrointestinal bleeding</Indication><Indication>Portal hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha adrenoceptor antagonist</Action><Action>Beta adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Antioxidant agent</Action><Action>Cardiac agent</Action><Action>Class II antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU</Company><Company>Germans Trias i Pujol Hospital</Company><Company>Hospital Clinic of Barcelona</Company><Company>Hospital Universitario Ramon y Cajal</Company><Company>Hospital del Mar</Company></CompaniesCollaborator><CompaniesSponsor><Company>Institut d'Investigacions Biomediques August Pi I Sunyer</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-11-24T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>ET_GV15</Identifier><Identifier>NCT02364297</Identifier><Identifier>PI 14/00392</Identifier><Identifier>TFB</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Transjugular intrahepatic portosystemic shunt (TIPS) alone</Intervention><Intervention>carvedilol alone</Intervention><Intervention>somatostatin alone</Intervention><Intervention>terlipressin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Patients developing acute variceal bleeding from GOV2 and/or IGV1 defined according to Baveno II criteria, admitted in the &lt;b&gt;hospital&lt;/b&gt; and receiving standard combined medical therapy (somatostatin 3 mg/12 h continuous iv infusion or terlipressin, 2 mg/4 h iv + endoscopic injection of tissue adhesives as per center protocol)</Teaser><TrialCategories><Category>Biological</Category><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>TFB: TIPS in Fundal Variceal Bleeding</TitleDisplay><BiomarkerNames><BiomarkerName>Erythrocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Angels Escorsell, MD</Name><Name>Càndid Villanueva, MD</Name><Name>José Carrión, MD</Name><Name>Rosa Morillas, MD</Name></ContactNames></Trial><Trial Id="14585"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 3A4 inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>Non-nucleoside reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-04-02T00:00:00Z</DateChangeLast><DateStart>2001-11-30T00:00:00Z</DateStart><Identifiers><Identifier>ADVAN-Z</Identifier><Identifier>Advanz</Identifier><Identifier>NCT00385957</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including efavirenz , indinavir , lamivudine + zidovudine, GlaxoSmithKline , ritonavir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to analyze the virological response in plasma and non-plasma compartments, as well as the degree and kinetics of immune reconstitution in 70 treatment-naive patients with CD4 &amp;lt; 100/mm3, when they receive treatment with two nucleoside analogs (NRTI) Combivir plus one protease inhibitor (PI), ritonavir or indinavir compared with two NRTIs, Combivir plus one non-nucleoside reverse transcriptase inhibitor, efavirenz (NNRTI).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Advanz: Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment><PatientSegment>HIV infection - Subjects with Low CD4 Cell Count</PatientSegment><PatientSegment>HIV infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>ADP-ribosyl cyclase 1 </BiomarkerName><BiomarkerName> C-C chemokine receptor type 5 </BiomarkerName><BiomarkerName> C-X-C chemokine receptor type 4 </BiomarkerName><BiomarkerName> CD4/CD8 ratio </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Human immunodeficiency virus RNA </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> T-cell-specific surface glycoprotein CD28 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>6</NumberOfSites><ContactNames><Name>Jose Gatell</Name><Name>Jose M Gatell, MD</Name></ContactNames></Trial><Trial Id="200471"><Indications><Indication>Premature labor</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-06-22T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00646802</Identifier><Identifier>PROMISE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>progesterone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>265</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Eligible patients would be informed and asked to enroll in the study at &lt;b&gt;hospital&lt;/b&gt; admission. A transvaginal ultrasound examination would be performed to determine cervical length. If an eligible woman accepts to participate, patient would be randomized...suspected infection, premature rupture of membranes or any other pathological gravid maternal or fetal condition coexisting at &lt;b&gt;hospital&lt;/b&gt; admission (Pre-eclampsia, RCIU) which may induce iatrogenic labor Present or previous liver disease, present or previous</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>PROMISE: Vaginal Progesterone as Maintenance Treatment After an episode of preterm Labor</TitleDisplay><BiomarkerNames><BiomarkerName>Cervix</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Montse Palacio, MD</Name></ContactNames></Trial><Trial Id="13230"><Indications><Indication>HIV infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>HIV GAG POL polyprotein inhibitor</Action><Action>HIV GAG protein inhibitor</Action><Action>HIV protease inhibitor</Action><Action>HIV-1 protease inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Pellet</Technology><Technology>Peptidomimetic</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-03-26T00:00:00Z</DateChangeLast><DateEnd>2009-08-31T00:00:00Z</DateEnd><DateStart>2006-05-31T00:00:00Z</DateStart><Identifiers><Identifier>DATEM-PEP</Identifier><Identifier>DATEM-PEP</Identifier><Identifier>NCT00385645</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including atazanavir , lamivudine + zidovudine, GlaxoSmithKline , lopinavir + ritonavir</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>255</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This phase IV study compares the adherence of 240 HIV-negative subjects randomly assigned to two different antiretroviral therapies ( Combivir + Kaletra versus Combivir + Reyataz ) for 28 days after accidental exposure to HIV.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of Incidence/Prevalence of HIV</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Time to Event Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DATEM-PEP: Atazanavir or Lopinavir in HIV Post-Exposure Prophylaxis</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Felipe Garcia, MD</Name></ContactNames></Trial><Trial Id="57633"><Indications><Indication>Endocarditis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Peptidoglycan recognition protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>RNA synthesis modulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Glycoprotein</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-08-04T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2009-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT number: 2008-008683-28</Identifier><Identifier>FOSIMI</Identifier><Identifier>NCT00871104</Identifier></Identifiers><InterventionsControlDisplay><Intervention>vancomycin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fosfomycin trometamol plus imipenem</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin , the standard therapy.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis</TitleDisplay><PrimaryCompletionDate type="Anticipated">2013-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Ana Cruceta, MD</Name><Name>Arístides de Alarcón González, MD</Name><Name>Asunción Moreno Camacho, MD</Name><Name>Carmen Peña Miralles, MD</Name><Name>Enrique Navas Elorza, MD</Name><Name>José R Paño Pardo, MD</Name><Name>Juan E Losa García, MD</Name><Name>Juan Gálvez Acebal, MD</Name><Name>Mercè Gurguí Ferrer, MD</Name><Name>Miguel Montejo Baranda, MD</Name><Name>Patricia Muñoz García, MD</Name></ContactNames></Trial><Trial Id="183052"><Indications><Indication>Atelectasis</Indication><Indication>Lung tumor</Indication></Indications><CompaniesCollaborator><Company>Ministerio de Economia y Competitividad</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundació Clínic Per A La Recerca Biomèdica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-02-21T00:00:00Z</DateEnd><DateStart>2014-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CPAP-RFP</Identifier><Identifier>CPAP-RFP</Identifier><Identifier>NCT02117908</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ResMed S9 Autoset CPAP device alone</Intervention><Intervention>pulmonary radiofrequency ablation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>47</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The project aimed to study whether the application of a continuous positive airway pressure (CPAP) of 4 cm water vapor was a safe method in pulmonary radiofrequency intervention (PRF) for lung cancer under conscious sedation compared with placebo. And, assessed whether CPAP prevents atelectasis formation and consequently reduces the potential complications of PRF and improves procedural success.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of Other Treatment Related Outcomes</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of hospitalization/re-admissions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CPAP-RFP: Study of the Application of CPAP to Reduce Complications and Improve Lung Cancer Ablation Radiofrequency Treatment</TitleDisplay><BiomarkerNames><BiomarkerName>Mean arterial pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-02-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Enrique J Carrero Cardenal</Name></ContactNames></Trial><Trial Id="71983"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CCR5 chemokine antagonist</Action><Action>CD4 agonist</Action><Action>HIV-1 gp120 protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>HIV fusion inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-04-08T00:00:00Z</DateChangeLast><DateStart>2010-11-04T00:00:00Z</DateStart><Identifiers><Identifier>DIS-MVC</Identifier><Identifier>NCT01235013</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>maraviroc alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The study hypothesizes that adding maraviroc to the antiretroviral treatment of discordant patients, defined as those having CD4 lymphocyte counts &amp;lt; 200 cells/mm3 during the last year, could lead to its immunological recovery.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage</EndpointIndex><EndpointIndex>HIV infection - Assessment of Disease Progression</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients with CD4 Lymphocyte Counts Below 200 Cells/mm3</TitleDisplay><PatientSegmentTerms><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>José Luis Blanco, MD</Name><Name>José María Gatell, MD</Name><Name>Judit Pich, Pharmacist</Name></ContactNames></Trial><Trial Id="70145"><Indications><Indication>Bipolar I disorder</Indication><Indication>Bipolar II disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 2 receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Centro de Investigación Biomédica en Red de Salud Mental</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-05-25T00:00:00Z</DateChangeLast><DateEnd>2012-07-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-018195-33</Identifier><Identifier>D1443L00079</Identifier><Identifier>NCT01197846</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>quetiapine fumarate (once-daily sustained release tablet), AstraZeneca alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>28</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>axis &lt;b&gt;I&lt;/b&gt; or II DSM-IV-TR diagnoses different from bipolar disorder &lt;b&gt;I&lt;/b&gt; or II. This doesn't apply to nicotine nor caffeine abuse-dependence. Punctual alcohol and/or substances use not constitutive of a diagnoses of abuse or dependence following DSM-IV-TR criteria wouldn't... Informed consent signature At least 18 years old Diagnoses of bipolar disorder &lt;b&gt;I&lt;/b&gt; or II (as DSM-IV-TR 4a Ed codes) Previous treatment with a mood stabilizer (lithium, valproate or lamotrigine) at stable and optimum doses for at least 6 weeks</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Bipolar Disorder Symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Subjects with Bipolar I Disorder</PatientSegment><PatientSegment>Bipolar disorder - Subjects with Bipolar II Disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Ana Gonzalez Pinto</Name><Name>Belen Arranz</Name><Name>Benedikt Amann</Name><Name>Celso Arango</Name><Name>Eduard Vieta, PhD</Name><Name>Gabriel Selva</Name><Name>Jeronimo Saiz</Name><Name>Jose Manuel Crespo</Name><Name>Josefina Perez</Name><Name>Julio Bobes</Name></ContactNames></Trial><Trial Id="305701"><Indications><Indication>Osteoarthritis</Indication><Indication>Pain</Indication></Indications><CompaniesCollaborator><Company>Hospital Clinic of Barcelona</Company><Company>Universitat de Barcelona</Company></CompaniesCollaborator><CompaniesSponsor><Company>Centro Universitario de Ciencias de la Salud</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateStart>2017-11-23T00:00:00Z</DateStart><Identifiers><Identifier>NCT03198247</Identifier><Identifier>TKA-01</Identifier></Identifiers><InterventionsControlDisplay><Intervention>physiotherapy alone</Intervention><Intervention>usual care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>coping skills training alone</Intervention><Intervention>pain neuroscience education alone</Intervention><Intervention>physiotherapy alone</Intervention><Intervention>usual care alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><Teaser>arms: Arm 1 (control: usual care): the biomedical education session would be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It would have a duration of 2 h and it would be designed for a group of five subjects. The &lt;b&gt;hospital&lt;/b&gt; rehabilitation starts 6 h after surgery, and it would based in early wandering stimulation, articular mobility exercises and isometric exercises. Arm 2 (experimental : usual care + PNE and CST): the PNE and CST program would be divided in three individual</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function - Assessment of physical function by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Implant/Prosthesis Function - Assessment of range of motion post treatment</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EuroQol EQ-5D</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Pain Catastrophizing Scale(PCS)</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Tampa Scale of Kinesiophobia (TSK)</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Coping strategies questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Physiotherapy and Therapeutic Education After Total Knee Arthroplasty</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects With History of /Scheduled For Surgical Procedures - Subjects with history of/scheduled for total knee arthroplasty</PatientSegment><PatientSegment>Osteoarthritis - Subjects with Symptomatic Disease - Subjects with pain&amp; stiffness</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Knee motion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-01-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hector Beltran-Alacreu</Name><Name>Hector Beltran-Alacreu, PhD</Name></ContactNames></Trial><Trial Id="230548"><Indications><Indication>Bronchiectasis</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-01-04T00:00:00Z</DateChangeLast><DateEnd>2016-01-31T00:00:00Z</DateEnd><DateStart>2015-03-31T00:00:00Z</DateStart><Identifiers><Identifier>Hyperosmolar_NCFB</Identifier><Identifier>NCT02392663</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Hyaneb alone</Intervention><Intervention>Hypertonic saline solution alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to analyze whether the hypertonic saline nebulization enhances sputum clearance effects, reduces the impact on cough severity and their level of safety and tolerability in a population with non-cystic fibrosis bronchiectasis (NCFBE). In addition, this trial aimed to compare these health outcomes among three nebulized solutions: hypertonic saline (7%); hyaluronic acid + hypertonic saline (7%); isotonic saline (0.9%).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bronchiectasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bronchiectasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Bronchiectasis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Bronchiectasis - Subjects with specific disease - Subjects with non-cystic fibrosis bronchiectasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Eva Polverino, Dr.</Name></ContactNames></Trial><Trial Id="186257"><Indications><Indication>Heart arrhythmia</Indication></Indications><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-05-13T00:00:00Z</DateChangeLast><DateEnd>2010-01-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>AJUAR</Identifier><Identifier>AJUAR</Identifier><Identifier>EUDRACT NUMBER:2007-006334-33</Identifier><Identifier>NCT00702117</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ajmaline alone</Intervention><Intervention>flecainide alone</Intervention><Intervention>procainamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>123</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study evaluates three different populations. The purpose of this open, randomized, parallel-group study was to compared the effectiveness of iv ajmaline with currently used antiarrhythmic drugs in the acute treatment of recent-onset atrial fibrillation versus iv flecainide, sustained monomorphous ventricular tachycardia versus iv procainamide. The study also evaluates in an open, randomized, crossover study, the use of iv ajmaline versus iv flecainide in the diagnosis of Brugada syndrome</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Atrial Fibrillation Recurrence</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Incidence of Other Arrhythmic Events</EndpointIndex><EndpointIndex>Atrial fibrillation - Assessment of Incidence of Other Arrhythmic Events - Assessment of ventricular arrhythmias</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Atrial Fibrillation Recurrence</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Incidence of Other Arrhythmic Events</EndpointIndex><EndpointIndex>Heart arrhythmia - Assessment of Incidence of Other Arrhythmic Events - Assessment of ventricular arrhythmias</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AJUAR: Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias</TitleDisplay><PatientSegmentTerms><PatientSegment>Atrial fibrillation - Subjects with First Detected Atrial Fibrillation - Subjects with new-onset atrial fibrillation</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with Other Cardiac Rhythm Disorders - Subjects with ventricular tachycardia</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with Chronic Atrial Fibrillation</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with Lone Atrial Fibrillation</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with Permanent Atrial Fibrillation</PatientSegment><PatientSegment>Atrial fibrillation - Subjects with specific disease - Subjects with idiopathic atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with Atrial Fibrillation - Subjects with symptomatic atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with Ventricular Arrhythmias</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with first detected atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with specific disease - Subjects with chronic atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with specific disease - Subjects with lone atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with specific disease - Subjects with other forms of atrial fibrillation</PatientSegment><PatientSegment>Heart arrhythmia - Subjects with specific disease - Subjects with permanent atrial fibrillation</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Ignacio Fernandez-Lozano</Name><Name>Jose Brugada</Name><Name>Jose Porres</Name></ContactNames></Trial><Trial Id="64675"><Indications><Indication>Anorexia nervosa</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1a receptor partial agonist</Action><Action>5-HT 2a receptor antagonist</Action><Action>Dopamine D2 receptor partial agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2010-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-010082-23</Identifier><Identifier>ARIANE</Identifier><Identifier>ARIANE</Identifier><Identifier>NCT01082848</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aripiprazole alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>DSM-IV-TR] [includes BMI below 17.5 kg/m2 and above 14 kg/m2] confirmed by a psychiatrist and validated by Kiddie-Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version [K-SADS-PL] interview) Severity criteria requiring &lt;b&gt;hospital&lt;/b&gt; admission Consent given by parents and patients</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>ARIANE: Aripiprazole in Anorexia Nervosa</TitleDisplay><PrimaryCompletionDate type="Anticipated">2013-03-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jaime Moyá, MD</Name></ContactNames></Trial><Trial Id="173190"><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2014-03-25T00:00:00Z</DateChangeLast><DateEnd>2011-09-30T00:00:00Z</DateEnd><DateStart>2011-01-31T00:00:00Z</DateStart><Identifiers><Identifier>FIV-01</Identifier><Identifier>NCT01291212</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Follicle stimulating hormone (FSH) , Luteinizing hormone (LH) , testosterone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>104</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>In this study, the investigators want to evaluate the efficacy of luteinizing hormone (LH) activity added to recombinant follicular stimulating hormone (FSHr) during ovarian stimulation in these patients.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Infertility - Assessment of Ovarian Function</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy</EndpointIndex><EndpointIndex>Infertility - Assessment of Pregnancy - Assessment of live birth</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone</TitleDisplay><PatientSegmentTerms><PatientSegment>Infertility - Subjects with Assisted Reproductive Technique(ART) Failure</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2011-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="15221"><Indications><Indication>Bone and joint infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Cephalosporin</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-03-10T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00497341</Identifier><Identifier>PTR2007</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cefuroxime (antibacterial), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1332</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a randomized, double-blind, placebo-controlled study of cefuroxime to evaluate the best moment to infuse the prophylactic antibiotic in knee arthroplasty performed under ischemia.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Antibiotic Prophylaxis in Total Knee Prosthesis</TitleDisplay><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="84781"><Indications><Indication>HIV-1 infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II AT-1 receptor antagonist</Action><Action>Angiotensin II receptor antagonist</Action><Action>HIV-1 integrase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Non-nucleoside reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antihypertensive</Action><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Granule</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-05-13T00:00:00Z</DateChangeLast><DateEnd>2015-01-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2011-002071-42</Identifier><Identifier>HIV-IMMUNESARTAN</Identifier><Identifier>NCT01529749</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co alone</Intervention><Intervention>Variable regimens including losartan , raltegravir , tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences , tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>randomized to one of four groups in equal proportion between arms (1 : 1). The four arms are as follows: Arm &lt;b&gt;I&lt;/b&gt;: 12 patients would receive po tenofovir disoproxil fumarate/emtricitabine/efavirenz (245/200/600 mg, qd). Arm II: 12 patients would...h in week 12) and po MK-0518 (400 mg). The allocation would take place in two phases: Phase &lt;b&gt;I&lt;/b&gt;: 24 patients would be randomized in 1 : 1 ratio to receive tenofovir disoproxil fumarate/emtricitabine/efavirenz versus tenofovir disoproxil fumarate</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dementia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Dementia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Dementia - Assessment of adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD4 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of CD8 Cell Responses</EndpointIndex><EndpointIndex>HIV infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>HIV infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>HIV infection - Assessment of Viral Load</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Losartan and Anti-retroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated</TitleDisplay><PatientSegmentTerms><PatientSegment>Dementia - Subjects with AIDS Dementia Complex</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent non-nucleoside reverse transcriptase inhibitors</PatientSegment><PatientSegment>HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors</PatientSegment><PatientSegment>HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Beta-2-microglobulin </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> CD4/CD8 ratio </BiomarkerName><BiomarkerName> Cerebrospinal fluid </BiomarkerName><BiomarkerName> D-dimer </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Metalloproteases </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial></SearchResults></trialResultsOutput>